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Prologue | On elderly chaps and ferocious Orcs
This chapter has been published as: Elderly: a term to avoid or to embrace? 
Petra E. Spies, Jurgen A.H.R. Claassen, J Am Geriatr Soc 2011;59:1986-7
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With the surge in articles that report research on aging, the question has risen whether 
the commonly used ‘elderly’ is an appropriate term to describe old people.1,2 A strong 
plea was even launched to ban this term from medical journals, and replace it by ‘older 
persons’.3 Three main arguments were put forward: 1) old people reject being called 
‘elderly’; 2) ‘elderly’ may be confused with ‘frail’; 3) the term ‘elderly’ is pejorative, and its 
use thus reflects negatively on older patients as well as on health care for the old.2,3 
We question the validity of these arguments.  
Old people reject being called ‘elderly’
This argument was based on a European survey on preferential terminology for older 
citizens, conducted in 12 countries.4 The multi-linguistic setting was a surprising choice 
for an investigation of semantic preferences. Noteworthy, only preference, and not 
rejection, was measured. It remains unclear how linguistic and cultural differences were 
taken into account. Were participants addressed in their own language? Were the 
intuitive subtleties of the English language correctly brought across? The Danish for 
example quite liked being called ‘elderly’ – maybe their translation carries with it a 
different meaning than the English ‘elderly’. In the English-speaking countries, ‘elderly’ 
was indeed not a preferred term, but remarkably, neither was ‘older people’. ‘Senior 
(citizen)’ received most votes. In contrast, the American media guide issued by The 
International Longevity Center advised against the use of senior. Apparently, semantic 
preferences cannot easily be generalized.  
‘Elderly’ is easily confused with ‘frail’
We find this hard to believe. For example, in the 2001 cinema hit ‘Lord of the Rings’, the 
character Gandalf was described as an ‘elderly chap’. Gandalf, who in this film 
subsequently slays a dragon-like creature as well as several ferocious Orcs, can hardly be 
considered frail. If the large audience can distinguish elderly from frail, so can and 
should people who work in the field of aging research. And they do: even though the 
concept of frailty remains ill-defined and disputed, old age in itself is not considered a 
criterion by most researchers. Underlining this is the fact that those who work in the 
field do not shy from the term. When a number of medical journals were scanned for 
the use of ‘elderly people’ and ‘older people’, it was found that most authors and editors, 
even in geriatrics, had continued to use ‘elderly’ in spite of the proposed ban.1  
On elderly chaps and ferOciOus Orcs
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 One may argue that the term ‘elderly’ has insufficient categorical validity. Obviously, 
the inherent heterogeneity in the older age group is tremendous, making the use of a 
single term as a group denominator an easy target for criticism. However, we argue that 
‘elderly’ is as unambiguous a term as ‘child’ or ‘adult’, terms that also cover a wide 
spectrum and that must be further specified by descriptives such as ‘prepubertal’ or 
‘healthy’.
‘Elderly’ is a pejorative term
Is it the term elderly that is responsible for the negative image of older people and of 
the health services and professionals devoted to their care? Will frenetic avoidance of 
this term remove this stigma? Naturally, it can be defended that people do not want to 
be seen as old. Most adults, if told that they look much younger than their date of birth 
suggests, glow with happiness. When geriatric patients are asked how they get along at 
day care, they complain that it is full of old people. The unpleasantness of being 
confronted with one’s advanced age may transpire to how any term describing old age 
is perceived, including ‘elderly’. But does that make these terms inappropriate? Calling 
an 80-year-old ‘elderly’, ‘senior’ or ‘in later life’ will not change his actual age. Even if one 
preferred word were found, it would be a matter of time before this new term would 
carry the stigma of the old one. It would be better to change the stigma and not the 
word. We should remember that elderly is not the same as frail, that old is not the same 
as worthless. This message is far more important than the discussion whether elderly or 
older people feel insulted by either term, or whether health care for the elderly will rise 
in status if it changes its name to health care for later life. Clinicians and researchers 
could therefore embrace ‘elderly’ as the preferred term to describe the old people they 
care for and investigate. Stemming from the Old English ‘aeld’ it means ‘somewhat 
older’, a clear and gentle way to describe an old person. Let’s stop debating semantics, 
and start changing a stigma. 
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Dementia 
Dementia is a cognitive disorder that, by definition, interferes with activities of daily 
living.1,2 Different types of dementia exist. Alzheimer disease (AD) is the most prevalent 
and therefore the best known cause of dementia. This disease will be described in more 
detail below. Both vascular dementia (VaD) and dementia with Lewy bodies (DLB) are 
reported to be the second most prevalent types of dementia.3,4 Patients with vascular 
dementia present with impairments in multiple cognitive domains, slowness in executive 
functioning, bradyphrenia, and sometimes focal neurological deficits. Neuro imaging 
shows vascular lesions such as cerebral infarcts or extensive white matter disease.5 DLB 
patients have fluctuating functioning and attention, together with visuospatial dysfunction 
on neuropsychological examination. They often suffer from visual hallucinations and 
parkinsonism. Neuropathologically, this disorder is characterized by intraneuronal 
inclusions composed of α-synuclein, the so-called Lewy bodies.6 A less common cause 
of dementia is frontotemporal dementia (FTD). Features are early decline in social 
interpersonal conduct, emotional blunting, loss of insight, behavioural disorders and 
impairments in speech and language.7 The neuropathological substrate of FTD is 
heterogeneous. Most cases display cellular inclusions of tau or TAR DNA-binding 
protein-43 (TDP-43), but in some cases, the pathologic protein is unknown.7-11
Alzheimer disease
AD is a progressive disorder that generally affects memory first, but other cognitive 
domains such as language, perception and praxis are usually affected as well.2,12 Aloïs 
Alzheimer was the first to describe the amyloid β (Aβ) plaques and neurofibrillary 
tangles that are seen upon neuropathological examination.13 In addition, severe loss of 
neurons is found, and often at least a mild degree of cerebral amyloid angiopathy (CAA): 
Aβ deposits in the walls of blood vessels. The Aβ content of amyloid plaques and of 
these vascular deposits was discovered in the 1980s, the same decade that tau protein 
and its hyperphosphorylated form were identified in neurofibrillary tangles.14-18 
 Aβ is a small protein derived from sequential cleaving of the Aβ precursor protein 
(APP) by β- and γ-secretase. Several isoforms of Aβ have been identified, but Aβ42 and 
Aβ40 have received most attention. Aβ40, 40 amino acids long, is the most abundant Aβ 
peptide, and makes up about 60% of the cerebrospinal fluid (CSF) Aβ concentration. 
Aβ42 accounts for approximately 10% of the CSF Aβ concentration in healthy people.19-21 
IntroductIon and outlIne
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Two types of Aβ plaques are found in AD patients: diffuse plaques without an amyloid 
core that contain only Aβ42, and classic plaques that have an amyloid core and consist 
of both Aβ42 and Aβ40.22,23 In contrast, the vascular deposits in the walls of leptomeningeal 
and cortical arteries – and less frequently, in capillaries24 – contain mostly Aβ40.25 
 Tau is a protein that stabilizes the microtubules of the neuronal cytoskeleton. In AD, 
abnormal phosphorylation of tau leads to destabilizing of microtubules and is suggested 
to obstruct axonal transport, resulting in synaptic dysfunction.26 Hyperphosphorylated 
tau accumulates intracellularly and forms neurofibrillary tangles. After deterioration of 
the neuron, the tangles remain visible as extraneuronal ghost tangles.26,27 
Diagnosing dementia
Several criteria sets have been developed that summarize the core features of AD, VaD, 
FTD and DLB.2,5-7,12 The Dutch dementia guideline28 states that a diagnosis of dementia 
can be made clinically using these criteria. History taking with the patient and a proxy 
should focus on gaining the information that is confined in the criteria sets. Neuropsy-
chological assessment can aid in determining whether or not a cognitive disorder is 
present that may indicate dementia. When more diagnostic certainty is desired, for 
example to differentiate between the different types of dementia, additional 
examinations are advised such as structural magnetic resonance imaging (MRI) of the 
brain and CSF analysis. 
 One may wonder whether differentiating between the dementia types (in other 
words, to establish an etiological diagnosis) really adds important information that 
extends beyond the knowledge that a dementia is present. As there are no cures 
available for any of these causes of dementia, what is the point of knowing the 
underlying cause? There are several reasons that make it important to clarify the cause 
of dementia. First, AD, VaD, DLB and FTD differ importantly in the types of deficits they 
induce in cognition and behaviour. Therefore, an adequate etiological diagnosis allows 
appropriate and specific education, guidance and care for patients and their informal 
caregivers.29,30 Second, knowledge on the type of dementia can provide information on 
a patient’s prognosis. For example, DLB patients deteriorate faster than AD patients, 
with shorter time between onset of cognitive symptoms and death,31,32 and in FTD 
patients, behavioural problems are far more dominant than in AD patients. Third, 
accurately diagnosing the cause of dementia is important for pharmacological 
management. Cholinesterase inhibitors may not cure the disease, but they can offer 
Chapter ONe
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functional improvement in AD. DLB patients also respond well to cholinesterase 
inhibitors, but these patients are extremely sensitive to the side effects of neuroleptic 
drugs.4,33 Knowing the cause of the dementia therefore helps in deciding which drugs 
may be beneficial, and which ones should be avoided. A fourth reason to clarify the 
cause of the dementia is to advance research in this area. For example, an accurate 
diagnosis is essential to select patients for trials. If a drug is aimed at treating AD, but the 
patient group is contaminated by patients with other types of dementia, the drug under 
study may show no overall effect, despite an effect in patients with true AD. Recognizing 
AD in the very early stages of the disease may help in selecting patients for trials aimed 
at prevention of the disease. 
 Underlined by the ongoing efforts to redefine them,2,34,35 the criteria sets that were 
laid out so many years ago are insufficient to reliably differentiate between dementia 
types. A comparison of the clinical diagnoses made with these criteria to the neuro-
pathological diagnoses made post-mortem showed that their sensitivity or their 
specificity is low, depending on the criteria set used and the comparison made.36-38 
Especially mixed pathologies are often not recognized clinically.36,37,39
 One strategy to improve the accuracy of clinical diagnosis is by introducing 
biomarkers in addition to the clinical criteria. A biomarker, as defined by the National 
Institute of Health, is ‘a characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention’.40 The Dutch dementia  guideline already 
suggested the use of biomarkers such as atrophy on MRI or decreased CSF Aβ42 and 
increased CSF total tau (t-tau) to gain more certainty about the cause of dementia. This 
reasoning was explicated in the research criteria for AD as published in 2007, in which 
positive biomarkers are considered a supportive feature of Alzheimer disease, regardless 
of whether or not dementia is clinically present.41,42
Biomarkers for AD
The ideal biomarker for AD should have the following properties: it should be able to 
detect a fundamental feature of AD’s neuropathology, it should be validated against 
neuropathologically confirmed AD cases, it should be precise, reliable, non-invasive, 
simple to perform and inexpensive.43 AD biomarkers discovered thus far can be divided 
into biomarkers of Aβ plaque deposition (CSF Aβ42, Aβ imaging with positron emission 
tomography (PET)) and biomarkers of neurodegeneration (structural MRI of the 
IntroductIon and outlIne
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hippocampus, CSF t-tau and hyperphosphorylated tau (p-tau), fluorodeoxyglucose 
(FDG)-PET).44 
 Hippocampal atrophy, seen on computed tomography (CT), was the first AD 
biomarker to be established.45 The involvement of the hippocampus in AD had been 
recognized a few years earlier, when severe neuronal loss in this region in AD cases was 
described in a neuropathology study.46 A visual rating scale was developed for use with 
CT or MRI that is still in use today.47 Hippocampal volume on MRI correlates well with AD 
pathology at neuropathological examination, although hippocampal atrophy can also 
be found with increasing age and in other diseases such as FTD and hippocampal 
sclerosis.48,49 
 FGD-PET gives a measure of synaptic activity based on glucose metabolism in the 
brain. In AD, bilateral temporo-parietal hypometabolism is observed that cannot only 
be explained by brain atrophy.50 A positive scan correlates with the presence of AD 
pathology on post-mortem examination.51,52
 CSF biomarkers are derived from the fluid that circulates around the brain and 
spinal cord and thus can provide information from close to the brain. Measuring Aβ42, 
t-tau and p-tau in the CSF succeeded a few years after their discovery53-57 and it was 
shown that CSF Aβ42 is decreased and CSF t-tau and p-tau are increased in AD.56,58-62 
These three biomarkers provide excellent discrimination between AD patients and 
healthy controls.63,64 The specificity for discrimination with other dementias is lower,65,66 
but the combination of biomarkers may still help in the discrimination between AD and 
VaD,67 DLB68 and FTD.69 
 As with all biochemical analyses, the concentrations of CSF biomarkers vary 
between different laboratories.70 This variation makes it difficult to compare the results 
between laboratories and makes it impossible to provide generally applicable reference 
values for use in clinical practice. The variation is probably a result of variations in 
analytical procedures and batch-to-batch variation in the biomarker assays. Laboratories 
therefore establish their own reference values.64,71 The Alzheimer’s Association is 
currently executing a quality control programme that aims to standardize CSF biomarker 
measurements in both research and clinical laboratories.72
 Aβ imaging is thus far only advocated for research purposes.2 11C-Pittsburgh 
compound B (PiB) binds to fibrillar Aβ in the brain and can be visualized using nuclear 
imaging. Because this technique is relatively new, cases with post-mortem confirmation 
of the PiB-PET findings are still limited. Some cases have shown a positive correlation 
between PiB-binding and fibrillar Aβ deposition, others showed clear Aβ deposition 
upon neuropathological examination but a negative PiB-PET scan during life.73-77 
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Furthermore, it has been shown that 33% of control subjects had positive PiB-PET scans 
and that PiB-retention increased in elderly without dementia that were followed 
longitudinally.78,79 The clinical relevance of these findings is as yet unclear and longer 
follow up is needed to determine whether these are preclinical cases of AD or whether 
these cases should be considered as false positive scans in truly healthy controls.
 Despite the availability of this variety of biomarkers, differentiating between dementia 
disorders in clinical practice can still be a challenge, as is shown in the following case report.
Case report
A 63-year-old woman was referred to our memory clinic for a second opinion. The past 
two years she had become increasingly anxious in new situations. She had difficulty 
finding words and engaging in conversations. In 2007, a neurologist identified no 
cognitive disorder. At that time, she was diagnosed by a psychiatrist as having dysthymic 
disorder and post-traumatic stress disorder. She was treated with venlafaxine 75 mg 
once a day. When she presented to our memory clinic nine months later, her complaints 
had not disappeared. The difficulty in engaging in conversations was still present and 
she did not manage to finish daily chores because she kept forgetting what she was 
doing. The anxiety had made her give up driving, internet banking and using the phone 
and video recorder. There was severe loss of initiative. Her Mini Mental State Examination 
(MMSE) score was 21 out of 30.80 The score on the Revised Cambridge Cognitive 
Examination (CAMCOG-R), a multiple-domain cognitive assessment, was 68 out of 104 
(cut-off adjusted for age and education 83).81,82 She scored 2 out of 15 on the geriatric 
depression scale (GDS) (a score above 7 indicates depression).83 These results suggested 
cognitive decline, possibly AD, since no other underlying disease was apparent, and 
history taking and GDS score indicated that her depressive mood was in remission. An 
MRI, made in 2007, was re-evaluated and showed asymmetrical frontotemporal atrophy 
without medial temporal lobe atrophy (Figure 1). A lumbar puncture was performed, 
because the screening neuropsychological assessment and the MRI were not fully 
conclusive and left the possibility of a diagnosis of AD as well as FTD. CSF analysis 
showed normal concentrations of all biomarkers [reference values]64: Aβ42 560 pg/ml 
[>500 pg/ml]; t-tau 335 pg/ml [<350 pg/ml]; p-tau 77 pg/ml [<85 pg/ml]. These results 
made AD less likely. Specific neuropsychological testing was performed, which showed 
below-average memory learning curves with unimpaired delayed recall and recognition, 
and a decline in attention and executive functions with reduced information processing 
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speed and apathy. Apart from below-average word fluency, there were no language 
disorders. The combination of MRI, CSF biomarker results and neuropsychological 
examination at that moment resulted in the diagnosis FTD. Fifteen months later the 
patient had deteriorated mildly. Her MMSE was 18 out of 30. No behavioural problems 
had occurred and her mood was stable. This clinical follow up is atypical for FTD and AD 
cannot be ruled out.
CSF biomarkers in clinical practice
As illustrated by this case report, additional examinations to collect biomarkers do not 
always result in a clear-cut diagnosis. CSF analysis showed that biomarker concentrations 
were all within the pre-determined normal range, but clinical follow up still left room for 
AD. It is worth noticing that all CSF biomarker concentrations were close to the cut-off 
values. It has been suggested that in patients with a naturally occurring high Aβ load, a 
decrease in Aβ42 with AD may not be as clear.84 Relating Aβ42 to Aβ40, the latter as a 
measure of the total Aβ load, was suggested to provide a more precise reflection of the 
decrease in Aβ42. This ratio could be a means to improve the accuracy of the existing 
biomarker CSF Aβ42. Questions like these fuelled us to start this clinical diagnostic 
Chapter ONe
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research. Whether this Aβ42/Aβ40 ratio can help us to differentiate between dementia 
disorders, alone and in combination with p-tau and t-tau, was addressed in Chapter Two. 
 Besides improving the accuracy of existing biomarkers, differentiating between 
dementia disorders may also be improved if new, specific biomarkers are found. Most 
research has focused on biomarkers for AD, however, if hallmarks of other dementias 
could be measured, these could serve as biomarkers for that type of dementia. An 
example of such a hallmark is α-synuclein, the protein found to accumulate in DLB. It 
was isolated from brain tissue in 199385 and was identified in CSF ten years later.86 
Chapter Three and Four describe the properties of CSF α-synuclein as a possible 
biomarker for DLB. However, finding new CSF biomarkers is only useful if clinicians are 
willing to use lumbar puncture as a diagnostic tool. Therefore, the current use of CSF 
analysis in the diagnostic work up of memory clinic patients, both in the Netherlands 
and in Europe, was investigated in chapter Five. Finally, in order to facilitate the 
interpretation of CSF biomarkers in clinical practice, we developed a prediction model 
based on CSF biomarkers which estimates the probability that dementia in a memory 
clinic patient is due to AD (Chapter Six).
Hypotheses for the pathophysiological cascade of AD
Although the involvement of plaques and tangles in AD has been known for over a 
century, many questions around the pathophysiological cascade of AD remain 
unresolved. Several hypotheses have been formulated, the amyloid cascade hypothesis 
being the oldest one that still finds support (Figure 2).87-89 It postulated that the critical 
event in AD is the deposition of Aβ as a result of APP mismetabolism. Aβ, or APP 
cleavage products that contain Aβ, were suggested to be neurotoxic and to lead to 
 phosphorylation of tau, possible by increasing the intraneuronal calcium concentration. 
Hyperphosphorylated tau polymerized into neurofibrillary tangles which further led to 
neuronal death. The temporal sequence of the hypothesis (Aβ plaques precede tau 
tangles) was based on cases of familial AD who displayed both Aβ plaques and neuro-
fibrillary tangles and in whom a mutation in APP was discovered. Further support was 
found in reports of persons with Down syndrome, in whom it was shown that diffuse 
plaques were the first detectable lesion, followed by senile plaques, neurofibrillary 
tangles, and eventually severe loss of neurons and atrophy. 
 A critical reappraisal almost 20 years later concluded that research findings thus far 
are compatible with this theory, even though the pathway between Aβ and tau is still 
IntroductIon and outlIne
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Figure 2    The amyloid cascade hypothesis as defined in 1991 
Figure 3    Hypothetical model of the AD pathological cascade 
Reprinted from Trends Pharmacol Sci, Volume 12, Hardy J, Allsop D, Amyloid deposition as the central event 
in the aetiology of Alzheimer's disease, Page 387, Copyright (1991), with permission from Elsevier. 
Reprinted from Lancet Neurology, Volume 9, Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, 
Weiner MW, Petersen RC, Trojanowski JQ, Hypothetical model of dynamic biomarkers of the Alzheimer's 
pathological cascade, Page 122, Copyright (2010), with permission from Elsevier.
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unclear, and Aβ toxicity has not sufficiently been demonstrated in vivo to explain the 
massive cell loss as seen in AD.90 Correlations between Aβ plaque load and cognitive 
impairment or dementia severity have both been described and disputed91-95 and it has 
been suggested that not the Aβ plaques, but the still soluble oligomeric Aβ species are 
in fact the culprit.96 
 Recently, a hypothetical model of the AD pathological cascade was described that 
incorporated information from studies on several AD biomarkers.44 In line with the 
amyloid cascade hypothesis, it was suggested that the initiating event in AD is related 
to abnormal processing of Aβ, resulting in Aβ deposition. Aβ biomarkers (decreased CSF 
Aβ42 concentration and increased uptake of PiB) were hypothesized to reach a plateau 
before clinical symptoms are apparent (Figure 3). Biomarkers of neuronal injury and neu-
rodegeneration, such as increased CSF t-tau and p-tau and cerebral atrophy on MRI, 
were suggested to become abnormal in a later stage of the disease and to correlate 
with clinical symptom severity.
IntroductIon and outlIne
Figure 4    The vascular hypothesis 
With kind permission from Springer Science+Business Media: Acta Neuropathologica, The overlap between 
neurodegenerative and vascular factors in the pathogenesis of dementia, Volume 120, 2010, Page 292, 
Iadecola C, Figure 3.
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 The vascular hypothesis of AD can be regarded as an extension of the amyloid 
hypothesis (Figure 4). It proposes a bidirectional relationship between cerebrovascular 
disease and AD pathology.97 Cerebrovascular disease, through chronic or intermittent 
hypoperfusion and oxidative stress, is suggested to lead to APP upregulation and 
perhaps to Aβ deposition, thus initiating or aggravating AD.98-100 Vice versa, AD may lead 
to vascular disease since Aβ exerts detrimental effects on cerebrovascular function.101 
The influence of vascular factors on tau pathology is less well understood, although 
ischemia might induce hyperphosphorylation of tau.97
 Hypotheses serve no purpose if they are not tested and challenged. They often 
incorporate information from a multitude of sources, such as animal models, 
post-mortem research and explorative studies in selected patients groups with strict 
in- and exclusion criteria. It cannot simply be assumed that these data can be 
extrapolated to clinical practice. For example, previous studies showed that results from 
animal models cannot always be replicated in humans102,103 and neuropathological 
studies generally suffer from selection bias. For example, one of the largest and most 
influential series of neuropathological studies on AD (the Nun study) consisted fully of 
members of a religious order.104 These participants may not be representative for the 
general population. Even for other neuropathological studies it is important to realize 
that the subset of persons who agree to autopsy may not be representative. Testing 
hypotheses in the population of interest is therefore an essential part of research. In 
Chapter Seven the proposed separation between the timing of Aβ and tau pathology 
was investigated in an AD patient with several years of follow up. Chapter Eight takes a 
closer look at the suggestion that Aβ biomarkers reach a plateau before clinical 
symptoms are apparent, while tau biomarkers supposedly continue to increase during 
the clinical stages and thus correlate with clinical symptom severity. The vascular 
hypothesis is subject of Chapter Nine, in which the relation between cerebrovascular 
disease and AD pathology was investigated in a sample of the memory clinic population. 
 Once it is established how pathological factors such as Aβ, tau and vascular factors 
interact and how this is reflected in their biomarkers, these biomarkers may be used as 
intermediate outcomes in trials that aim to influence the pathology of the disease. Since 
AD is a disease that develops over several years or even decades, an intervention that 
slows or halts this development cannot be expected to yield obvious clinical results in 
a short period of time. A major advantage of biomarkers is that they may provide early 
evidence that an intervention is successful in changing a pathological process. With the 
search for disease-modifying treatments, CSF biomarkers, and especially Aβ42, have 
been advocated as markers to detect and monitor the biochemical effects of newly 
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developed drugs for AD.105,106 To be able to interpret changes in biomarker concentrations 
that occur during a pharmacological intervention, it is important to understand the 
reason why these biomarker concentrations were abnormal in the first place. In Chapter 
Ten, (theoretical) reasons why the CSF Aβ42 concentration is decreased in AD have been 
systematically examined. 
Aims of this thesis
This thesis has two aims: 
One, to explore the potential use of CSF biomarkers as diagnostic tools in the differential 
diagnosis of dementia.  
Two, to investigate whether CSF biomarkers, derived from a sample of memory clinic 
patients, support the current hypotheses on the pathophysiological cascade of AD.  
Outline of this thesis
This thesis is divided in two parts that address the aims outlined above by means of 
several investigations. This is followed by a summary and general discussion of the findings.
Part One | CSF biomarkers in the differential diagnosis of dementia
Chapter Two investigates the diagnostic value of the CSF Aβ42/Aβ40 ratio in differenti-
ating patients with AD from controls and from patients with either VaD, DLB or FTD. It is 
hypothesized that this ratio provides a more valid measure for reflecting changes in Aβ 
levels in dementia patients than CSF Aβ42 alone. The Aβ42/Aβ40 ratio combined with 
p-tau and t-tau is also compared to the combination of Aβ42, p-tau and t-tau.  
Chapter Three examines the value of CSF α-synuclein as biomarker for DLB, by 
comparing its concentration between groups of DLB, AD, VaD and FTD patients. In 
addition, a comparison to the CSF α-synuclein concentration in controls is made.
Chapter Four further explores the properties of the CSF α-synuclein concentration in 
two ways: the presence of a circadian rhythm in CSF α-synuclein concentrations is 
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investigated, and the correlation between CSF α-synuclein and Aβ concentrations in 
healthy elderly, AD and DLB patients is investigated. 
Chapter Five assesses the current use of CSF analysis in memory clinics in Europe and 
in the Netherlands. 
Chapter Six describes the development and validation of a prediction model for AD 
based on CSF biomarkers, meant to facilitate the use of CSF biomarkers in clinical 
practice. A few models have been described previously, but they do not offer a formula 
that can be applied in clinical practice for the differentiation between dementia due to 
AD and dementia due to another cause.107,108 The prediction model in this chapter 
translates the results of CSF analysis into the probability that dementia in a memory 
clinic patient is due to AD.
Part Two | CSF biomarkers in pathophysiological hypotheses
Chapter Seven challenges the hypothetical model of the AD pathophysiological 
cascade (Figure 3) with empirical data. Especially the separation in the moments at 
which Aβ and tau become abnormal is questioned. This will be illustrated by a case of 
early-onset AD with the longest follow-up of CSF biomarkers reported in the literature.
Chapter Eight explores the correlation between CSF biomarkers and cognitive 
performance in a heterogeneous group of memory clinic patients. It is hypothesized 
that changes in the CSF biomarkers reflect neuronal damage and directly underlie 
cognitive impairment. According to the suggested pathophysiological cascade of AD, 
the strongest correlation should be expected with tau, and only a weak or absent 
correlation with Aβ. 
Chapter Nine investigates the hypothesis that AD patients have an increased 
susceptibility to develop cerebrovascular disease. In addition, possible mechanisms for 
this relationship are investigated, using CSF Aβ42, CSF Aβ40 and APOE-ε4 status.
Chapter Ten reviews the evidence for several proposed reasons why the CSF Aβ42 
concentration is decreased in AD, in order to create a better understanding of the 
underlying mechanisms that lead to its recognition as an AD biomarker.
Chapter Eleven provides a summary and discussion of the findings presented in this thesis.
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CSF biomarkers in the differential
diagnosis of dementia
Part One
Part One
Part  One

The CSF Aβ42/Aβ40 ratio
This chapter has been published as: The cerebrospinal fluid amyloid β42/40 ratio in the differentiation of  
Alzheimer’s disease from non-Alzheimer’s dementia. Petra E. Spies, Diane Slats, Magnus J.C. Sjögren,  
Berry P.H. Kremer, Frans R.J. Verhey, Marcel G.M. Olde Rikkert, Marcel M. Verbeek, Curr Alzheimer Res 2010;7:470-6
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Abstract
Background: Amyloid β40 (Aβ40) is the most abundant Aβ peptide in the brain. The 
cerebrospinal fluid (CSF) level of Aβ40 might therefore be considered to most closely 
reflect the total Aβ load in the brain. Both in Alzheimer disease (AD) and in normal aging 
the Aβ load in the brain has a large inter-individual variability. Relating Aβ42 to Aβ40 
levels might consequently provide a more valid measure for reflecting the change in Aβ 
metabolism in dementia patients than the CSF Aβ42 concentrations alone. This measure 
may also improve differential diagnosis between AD and other dementia syndromes, 
such as vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal 
dementia (FTD).
Objective: To investigate the diagnostic value of the CSF Aβ42/Aβ40 ratio in differentiat-
ing AD from controls, VaD, DLB and FTD.
Methods: We analysed the CSF Aβ42/Aβ40 ratio, phosphorylated tau181 and total tau in 
69 patients with AD, 26 patients with VaD, 16 patients with DLB, 27 patients with FTD, 
and 47 controls.
Results: Mean Aβ40 levels were 2850 pg/ml in VaD and 2830 pg/ml in DLB patients, 
both significantly lower than in AD patients (3698 pg/ml; p<0.01). Aβ40 levels in AD 
patients were not significantly different from those in controls (4035 pg/ml; p=0.384). 
The Aβ42/Aβ40 ratio was significantly lower in AD patients than in all other groups (p 
<0.001, ANCOVA). Differentiating AD from VaD, DLB and non-AD dementia improved 
when the Aβ42/Aβ40 ratio was used instead of Aβ42 concentrations alone (p<0.01) The 
Aβ42/Aβ40 ratio performed equally well as the combination of Aβ42, phosphorylated 
tau181 and total tau in differentiating AD from FTD and non-AD dementia. The diagnostic 
performance of the latter combination was not improved when the Aβ42/Aβ40 ratio was 
used instead of Aβ42 alone.
Conclusion: The CSF Aβ42/Aβ40 ratio improves differentiation of AD patients from VaD, 
DLB and non-AD dementia patients, when compared to Aβ42 alone, and is a more easily 
interpretable alternative to the combination of Aβ42, p-tau and t-tau when differentiat-
ing AD from either FTD or non- AD dementia. 
Chapter tWO
41
Introduction
While making an accurate diagnosis is important for management of dementia, differ-
entiating between Alzheimer disease (AD) and other types of dementia using clinical 
criteria is the true clinical challenge: difficult and prone to inaccuracy. The NINCDS-ADRDA 
criteria for AD1 have been validated against neuropathological standards and turned 
out to have a specificity of 23-69% for differentiating AD from other dementias.2,3
 Analysis of cerebrospinal fluid (CSF) has been used increasingly to differentiate the 
various dementia disorders.4 Although CSF analysis of amyloid β42 (Aβ42), phosphorylated 
tau181 (p-tau) and total tau (t-tau) is efficacious in distinguishing between AD dementia 
and non-demented controls, it is inaccurate in separating AD from other types of 
dementia.5-7 CSF biomarker profiles of AD, vascular dementia (VaD), frontotemporal 
dementia (FTD), and dementia with Lewy bodies (DLB) overlap, which makes 
discrimination between these various dementias based on CSF analysis alone difficult.
It has been suggested that relating Aβ42 to the concentration of Aβ40 may improve 
diagnostic accuracy of CSF analysis.8 Aβ40 is the most abundant Aβ peptide in human 
CSF, whereas Aβ42 accounts for only 10% of the total Aβ population.6,9-11 As such, CSF 
Aβ40 concentrations could be considered as the closest possible reflection of the total 
Aβ load in the brain. This total CSF Aβ load shows a large inter-individual variability.12 
Patients with a low total Aβ load and therefore a low CSF Aβ42 concentration11, might 
receive an inappropriate diagnosis of AD if only CSF Aβ42 is considered and an absolute 
cut-off value is used. Similarly, in patients with AD but with a high total Aβ load, CSF 
Aβ42 concentrations may not decrease below the cut-off value and in those cases 
rejection of the diagnosis AD might be incorrect. Since the total Aβ concentration was 
found not to change in various dementia disorders,8,10,13 and Aβ40 concentrations were 
shown to be similar in groups of AD patients, controls and non-AD dementia patients,13-17 
hypothetically the ratio of Aβ42 to Aβ40 reflects the Aβ changes in the brain more 
accurately than Aβ42 alone. 
 It was found in several studies that differentiation between AD and healthy controls, 
subjects with non-AD dementia, or subjects with other neurological disorders, improved 
when using the CSF Aβ42/Aβ40 ratio compared to Aβ42 alone,15,17,18 although these 
results were not confirmed in other studies.19,20 The Aβ42/Aβ40 ratio has previously been 
studied in patients with FTD and AD, and a significantly decreased Aβ40 was found in 
FTD patients, resulting in an increased Aβ42/Aβ40 ratio compared to AD patients.21 In a 
recent review it was concluded that levels of CSF Aβ40 or Aβ42 cannot usefully 
discriminate between AD and DLB,22 although one study found that the Aβ42/Aβ40 ratio 
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improved diagnostic accuracy of AD versus DLB relative to Aβ42 alone.23 To our 
knowledge, the Aβ42/Aβ40 ratio has not been investigated in relation to VaD. 
 We hypothesized that differentiation between dementia syndromes would improve 
by using the CSF Aβ42/Aβ40 ratio since it may eliminate inter-individual differences in 
total Aβ load. Therefore, we explored the CSF Aβ40 concentration and Aβ42/Aβ40 ratio 
in patients with AD, VaD, DLB, FTD and in controls, and we investigated the diagnostic 
value of the Aβ42/Aβ40 ratio in differentiating AD from each of these groups individually 
as well as from the total group of non-AD dementia patients. 
Materials and methods
Patients
Sixty-nine AD, 26 VaD, 27 FTD, and 16 DLB patients were included in this study that was 
based on the CSF database of the Alzheimer Centre of the Radboud University Nijmegen 
Medical Centre. This database contains clinical data as well as biobanked CSF and serum 
of consecutive patients. All patients or their legal representative had given informed 
consent for lumbar puncture. We included all patients with a clinically clear-cut 
dementia diagnosis, whose CSF was available for Aβ40 and Aβ42 analysis. Data on t-tau 
and p-tau were also obtained. A diagnosis was made by a multidisciplinary team, which 
consisted of a geriatrician, neurologist, neuropsychologist, and – if needed – an old-age 
psychiatrist. The panel used the accepted clinical diagnostic criteria, i.e. the NINCDS- 
ADRDA criteria for probable AD, the NINDS-AIREN criteria for probable VaD,  the 1998 
consensus on clinical diagnostic criteria for FTD and the 1996 consensus guidelines for 
the clinical and pathologic diagnosis of DLB.1,24-26 In less than 10% of the cases, the 
clinicians were aware of the CSF results for Aβ42, p-tau and t-tau when establishing the 
clinical diagnosis, but they were never aware of Aβ40 levels.
 The control group consisted of 47 non-demented patients who underwent lumbar 
puncture for various complaints. Most frequently diagnosed were headache (n=10), 
polyneuropathy (n=5),  radiculopathy (n=4), vertigo (n=3), and delirium (n=2). The 
remaining controls had a variety of complaints but turned out not to have central 
neurological problems. CSF cell count, glucose, lactate, haemoglobin, bilirubin, total 
protein and oligoclonal IgG bands were normal in all controls. Patient characteristics are 
listed in Table 1. 
 
Chapter tWO
43
CSF
CSF was collected by lumbar puncture in polypropylene tubes, transported within 30 
minutes to the adjacent laboratory at room temperature, centrifuged after routine 
investigations, and immediately aliquoted and stored at -80 °C until analysis. Levels of 
Aβ42, t-tau, and p-tau in CSF were measured using enzyme linked immunosorbent 
assays (Innogenetics NV, Ghent, Belgium). Inter-assay coefficients of variation for these 
assays were 3.8 – 8.4%.27 CSF Aβ40 was analysed by using a commercial assay based on 
the Luminex technology (BioSource, Invitrogen Ltd, Paisley, UK). Inter-assay coefficient 
of variation for Aβ40 was 5.4% (at 2875 pg/ml; n=32). The lower limit of detection was for 
Aβ42 50 pg/ml and for Aβ40 22 pg/ml.
Statistical analysis
Since p-tau, t-tau, Aβ42, Aβ40, and the Aβ42/Aβ40 ratio were not all normally distributed, 
they were log transformed. Differences in p-tau, t-tau, Aβ42, Aβ40 and the Aβ42/Aβ40 
ratio were analysed using 2-way ANCOVA. Since sex and age did not contribute to the 
differences in Aβ42, Aβ40 and the Aβ42/Aβ40 ratio between dementia groups and 
controls, both (sex and age) were removed from the model and the ANCOVA was 
thereafter rerun. Differences between AD and the other groups were further explored 
using Dunnett’s post-hoc test. 
 We used logistic regression analysis to assess the value of the Aβ42/Aβ40 ratio 
compared to other combinations of CSF biomarkers in differentiating AD from controls, 
from VaD, FTD, DLB, respectively, and from these three groups combined (‘non-AD 
dementia’). Sex and age contributed significantly to the logistic regression models and 
therefore the models were corrected for these factors. Receiver operating characteristic 
(ROC) curves were calculated and the areas under the ROC curves were compared using 
MedCalc (Mariakerke, Belgium). Sensitivity and specificity were determined based on the 
highest Youden index, i.e. the point on the ROC curve at which sensitivity + specificity-1 is 
maximized. All other statistical analyses were carried out using SPSS, version 16.0. 
Results
The mean level of CSF Aβ40 was significantly lower in VaD patients than in AD patients 
(p<0.001), as well as in DLB patients compared to AD patients (p=0.008) (see Table 1 and 
Figure 1. There was no significant difference in Aβ40 levels between AD patients and 
FTD patients (p=0.981) or controls (p=0.384). In AD patients, the concentration of CSF 
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Aβ42 was significantly lower than in VaD and FTD patients and controls (p<0.001), 
whereas the concentration of p-tau and t-tau was significantly higher than in all other 
groups (p<0.001). The Aβ42/Aβ40 ratio was significantly lower in AD patients than in all 
other groups (p<0.001) (see Table 1 and Figure 1). 
 We investigated the diagnostic value of the Aβ42/Aβ40 ratio in several comparisons. 
First, we investigated if the use of the Aβ42/Aβ40 ratio would be superior to the use of 
Aβ42 alone. Differentiation of AD from either VaD, DLB or non-AD dementia significantly 
improved when using the Aβ42/Aβ40 ratio (p<0.01). In contrast, differentiation of AD 
from either FTD or controls did not improve (p>0.05). Second, we analysed the 
diagnostic value of the Aβ42/Aβ40 ratio compared to the combination of Aβ42, p-tau 
and t-tau, which is a frequently used combination of CSF biomarkers in AD research. 
Differentiation of AD from either FTD or non-AD dementia was equally good for the 
Aβ42/Aβ40 ratio or the combination of Aβ42, p-tau and t-tau (p>0.05). Differentiation of 
AD from either controls, VaD or DLB was better using the combination of Aβ42, p-tau 
and t-tau than using the Aβ42/Aβ40 ratio (p<0.05). Third, we analysed if replacement of 
Aβ42 by the Aβ42/Aβ40 ratio in the combination with p-tau and t-tau would improve 
results. Differentiation of AD from both controls and from all dementia groups was 
equally good for both combinations (p>0.05). ROC curves are shown in Figure 2 and 
Figure 3. Sensitivity and specificity, AUC and likelihood ratios of each parameter are 
shown in Table 2.
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Table 1    Clinical characteristics and results of CSF analysis 
controls AD VaD FTD DLB
males/females (n) 23/24 34/35 17/9 19/8 12/4
age (y) 61 ± 8 69 ± 8 72 ± 9 65 ± 7 76 ± 8
disease duration (mo) n.a. 29 ± 23
n=60
35 ± 29
n=20
34 ± 21
n=26
34 ± 27
n=8
t-tau (pg/ml)* 221 ± 80 710 ± 390 391 ± 526 448 ± 315 257 ± 98
p-tau (pg/ml)* 49 ± 16 111 ± 52 46 ± 16 70 ± 36 53 ± 17
Aβ42 (pg/ml)* 840 ± 260 428 ± 127 631 ± 270 786 ± 229 499 ± 179
Aβ40 (pg/ml)* 4035 ± 1177 3698 ± 1096 2850 ± 1031 3590 ± 1038 2830 ± 697
Aβ42/Aβ40 ratio* 0.21 ± 0.04 0.12 ± 0.04 0.23 ± 0.08 0.23 ± 0.06 0.18 ± 0.06
Values are expressed as means ± SD. 
*, p-value <0.001 by ANOVA.
AD, Alzheimer disease; VaD, vascular dementia; FTD, frontotemporal dementia; DLB, dementia with Lewy 
bodies;  t-tau, total tau; p-tau, phosphorylated tau181; n.a., not applicable
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Figure 1    Cerebrospinal fluid Aβ42 and Aβ40 concentrations and Aβ42/Aβ40 ratio 
in controls and patients with various types of dementia 
See text for statistical analyses.
Bold horizontal bar represents the median. Central box: 25th  to 75th  percentile (interquartile range). Vertical 
bar bordered by highest and lowest value within 1.5 * interquartile range.
AD, Alzheimer disease; VaD, vascular dementia; FTD, frontotemporal dementia; DLB, dementia with Lewy 
bodies
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Figure 2    Receiver Operating Characteristic curves comparing Aβ42, and the 
Aβ42/Aβ40 ratio in AD versus controls and versus various types of 
dementia 
AD, Alzheimer disease; VaD, vascular dementia; FTD, frontotemporal dementia; DLB, dementia with Lewy 
bodies.
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Figure 3    Receiver Operating Characteristic curves comparing the Aβ42/Aβ40 
ratio,  the Aβ42/Aβ40 ratio combined with p-tau and t-tau, and the 
combination of Aβ42, p-tau and t-tau in AD versus controls and versus 
various types of dementia 
AD, Alzheimer disease; VaD, vascular dementia; FTD, frontotemporal dementia; DLB, dementia with Lewy 
bodies.
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Discussion
We explored the CSF Aβ40 concentrations in patients with different types of dementia 
and in controls, and examined the value the Aβ42/Aβ40 ratio in differentiating AD from 
controls, from FTD, DLB, VaD, and from these latter three groups combined. The 
observed patterns of Aβ40 and Aβ42 in the various dementia groups are remarkable. As 
expected, the AD group was characterized by normal Aβ40 and low Aβ42 levels, but 
contrary to our expectations, the VaD group had low Aβ40 and intermediate Aβ42 levels, 
whereas the DLB group was characterized by low concentrations of both Aβ40 and Aβ42 
levels. The FTD group had normal Aβ40 and Aβ42 levels.
 Only one study has reported the CSF Aβ40 concentration in patients with VaD. In 
accordance with our results, a lower Aβ40 concentration in VaD patients compared to 
AD patients was found.28 Multiple explanations for this low Aβ40 concentration are 
possible. For example, it may be caused by the ischemic damage that has occurred in 
VaD patients, since cerebral ischemia has been shown to result in plaque formation and 
accumulation of Aβ40 and Aβ4229-31 and, consequently, leads to a reduced CSF 
concentration. In addition, atherosclerosis, one of the risk factors for VaD, may inhibit the 
clearance of Aβ40 across the blood-brain barrier, leading to vascular deposits of Aβ40.32
Our finding of a lower Aβ40 concentration in DLB patients compared to AD is in 
accordance with the literature.12 Possibly, the intraneuronal α-synuclein aggregates that 
are found in DLB affect Aβ metabolism, leading to an overall decrease in Aβ synthesis. 
Results from in vitro research indicate an interaction between α-synuclein and Aβ.33,34 
Neuropathological studies found a positive correlation between Aβ plaque burden and 
α-synuclein load.35,36 Aβ40 plaque level was greater in cases with α-synuclein aggregates 
compared to cases lacking α-synuclein aggregates, while no difference was found in 
Aβ42 plaque burden.35 A greater Aβ40 plaque burden in DLB might explain the decreased 
Aβ40 concentration in CSF that we found.
 The few studies that measured Aβ40 concentration in FTD patients report varying 
results. Our results are supported by previous findings of similar concentrations of Aβ40 
in FTD patients and AD patients.37 In contrast with this, another group reported lower 
Aβ40 concentrations in FTD patients compared to AD patients.21 The varying results 
might be explained by the inclusion of heterogeneous FTD patient groups in research, 
comprising patients with clinically diagnosed FTD, semantic dementia and primary 
progressive aphasia, presumably with different neuropathological substrates. 
 We investigated the Aβ42/Aβ40 ratio under the assumption that Aβ40 closely 
represents the total cerebral Aβ load. Since we found different Aβ40 concentrations in 
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the various dementia groups, it can be debated if the Aβ42/Aβ40 ratio is a good 
representation of the Aβ42 fraction of the total Aβ load and thus eliminates inter- 
individual differences in total Aβ concentrations. Nevertheless, differentiating AD from 
VaD, DLB and non-AD dementia improved when we used this ratio compared to Aβ42 
alone, probably due to the differences in Aβ40 concentrations. Results obtained by 
applying the Aβ42/Aβ40 ratio fulfilled the criteria for biomarkers as established by 
the Working Group on molecular and biochemical markers of Alzheimer’s disease38 in 
differentiating AD from VaD, FTD, DLB, and non-AD, since both sensitivity and specificity 
were >80%.
 The Aβ42/Aβ40 ratio seems to be a good alternative for the combination of Aβ42, 
p-tau and t-tau, to distinguish AD from either FTD or non-AD dementia. The Aβ42/Aβ40 
ratio has the advantage that only two analyses are needed instead of three, and, 
consequently, the results are easier to interpret. The differentiation of AD from non-AD 
dementia is a frequently encountered problem in clinical practice, when dementia can 
be established, but the differential diagnosis encompasses AD and another type of 
dementia. Thus, the use of the CSF Aβ42/Aβ40 ratio may help in this clinical decision 
making. However, the use of four biomarkers, i.e. the Aβ42/Aβ40 ratio combined with 
p-tau and t-tau, did not improve differentiation when compared to the combination of 
the three currently used biomarkers Aβ42, p-tau and t-tau.
 Some bias may have occurred in our analysis since in less than 10% of the patients 
the results of the CSF analysis for Aβ42, t-tau and p-tau were known to the clinicians. 
However, given the small fraction of patients this applies to, we believe that  this did not 
affect our results, also since our sensitivity and specificity results for discriminating AD 
from other dementias using Aβ42 are comparable with the literature.18,39,40 The number 
of patients in our non-AD groups were moderate, yet not very different from the 
numbers mentioned in other studies.12,21,28,37 Besides, the significant results that we 
found had a p-value <0.01, suggesting that these results are not expected to change 
with an increasing number of patients. 
 In summary, the Aβ42/Aβ40 ratio is more accurate for differentiating AD from other 
types of dementia than Aβ42 alone, and can be a good and easier interpretable 
alternative for the combination of the established biomarkers Aβ42, p-tau and t-tau for 
the differentiation of AD from non-AD dementia, which may help to accept or refute the 
clinical diagnosis of AD.
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Abstract
Alpha-synuclein is the major constituent of Lewy bodies found in neurons in dementia 
with Lewy bodies (DLB) and might be of diagnostic value as a biomarker for DLB. We 
hypothesized that, as a consequence of increased accumulation of α-synuclein intra-
neuronally in DLB, the levels of α-synuclein in cerebrospinal fluid (CSF) of DLB patients 
would be lower than in other dementias. Our objective was to investigate the CSF levels 
of α-synuclein in several dementia disorders compared to control levels and to 
investigate the diagnostic value of CSF α-synuclein as a marker to discriminate between 
DLB and other types of dementia. We analysed the levels of α-synuclein in CSF of 
40 DLB patients, 131 patients with Alzheimer disease (AD), 28 patients with vascular 
dementia (VaD), and 39 patients with frontotemporal dementia (FTD). We did not find 
any significant differences in CSF α-synuclein levels between DLB patients and patients 
with AD, VaD or FTD. We conclude that in clinically diagnosed patients, α-synuclein 
does not appear to be a useful biomarker for the differentiation between DLB and other 
types of dementia. 
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Introduction
Dementia with Lewy bodies (DLB) is the second most common type of dementia,1-3 
accounting for 15-20% of cases at autopsy.4 It is difficult to differentiate between DLB and 
other dementias such as Alzheimer disease (AD) using clinical examination.5 Although 
specificity has improved with the introduction of the consensus guidelines for DLB in 
1996,1,6,7 sensitivity  is low,1,3 resulting in many misclassified cases. Differentiation from 
other dementia syndromes is difficult since DLB patients can present with symptoms that 
resemble those of other dementias. Extrapyramidal signs and hallucinations, which are 
characteristic for DLB patients, may also occur in advanced AD. On neuropsychological 
assessment, most DLB patients present with language and memory deficits similar to 
those with AD.8 In one study, most patients misdiagnosed with DLB had AD pathology at 
autopsy.5 Accurately diagnosing DLB is important for its pharmacological management. 
Patient with DLB respond well to cholinesterase inhibitors, but are extremely sensitive to 
the side effects of neuroleptic drugs.3,4 Furthermore, prognosis of patients with DLB may 
be different, with faster deterioration and shorter time between onset of cognitive 
symptoms and death compared to patients with AD.1,5,9
 Analysis of the cerebrospinal fluid (CSF) has been increasingly applied to differentiate 
the various dementia disorders. Especially in AD, a typical CSF pattern is often observed, 
with increased concentrations of total tau protein (t-tau) and phosphorylated tau 
protein (p-tau) and decreased concentrations of the amyloid β42 (Aβ42) protein.10,11 In 
contrast, there are no generally accepted biomarkers to distinguish DLB from other 
types of dementia. Some studies found equally high CSF t-tau concentrations in AD and 
DLB.12,13 In most studies, however, CSF t-tau concentrations were normal to moderately 
elevated in DLB,2,8,12,14-17 with normal concentrations of p-tau.18,19 In contrast, Aβ42 
concentrations were decreased to a similar degree as in AD,2,8,14,16 resulting in a low 
discriminative value of Aβ42 / t-tau analysis to differentiate AD from DLB. 
 Little research has been done with respect to CSF α-synuclein as a diagnostic 
marker. α-Synuclein is the major constituent of Lewy bodies, which are characteristic 
cytoplasmic inclusions in cortical neurons of DLB patients. Initially α-synuclein was 
thought to be an intracellular protein, but recently it was found in CSF and plasma.20 
Tokuda et al found that patients with Parkinson disease (PD) had significantly lower 
α-synuclein levels in their CSF compared to controls.21 This might be explained by 
accumulation of α-synuclein within affected neurons.21 We hypothesized that levels of 
α-synuclein in synucleinopathies such as DLB would be decreased in comparison with 
dementias not characterized by α-synuclein inclusions, such as AD vascular dementia 
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(VaD) and frontotemporal dementia (FTD) and with control levels. Therefore, we 
investigated the CSF levels of α-synuclein in these dementia disorders compared to control 
levels, and studied if CSF α-synuclein may serve as a biomarker for the  differentiation of 
DLB from other dementias.
Materials and Methods
Patients
We screened 526 patients of the CSF database of the Alzheimer Centre of the Radboud 
University Nijmegen Medical Centre for inclusion in this study (Figure 1). This database 
consists of clinical data and biobank materials of consecutive patients, in whom informed 
consent for lumbar puncture was obtained. We excluded 69 patients because CSF was 
not available for α-synuclein analysis. Patients whose diagnosis was uncertain or with a 
diagnosis other than DLB, AD, VaD or FTD (e.g. mild cognitive impairment) (n=98) were not 
included either, as were patients with mixed dementia (n=9). In total, we included 40 DLB, 
131 AD, 39 FTD and 28 VaD patients whose diagnosis was established by a multi disciplinary 
panel, which consisted of a geriatrician, neurologist, neuropsychologist, and –  if needed 
– an old-age psychiatrist. The panel used the accepted clinical diagnostic criteria, i.e. the 
1996 consensus guidelines for the clinical and pathologic diagnosis of dementia with 
Lewy bodies, the NINCDS-ADRDA criteria for AD, the 1998 consensus on clinical diagnostic 
criteria for frontotemporal lobar degeneration, and the NINDS-AIREN criteria for VaD.6,22-24 
If possible, information on MMSE was obtained and Aβ42, p-tau and t-tau were analysed. 
The panel was aware of the CSF results for Aβ42, p-tau and t-tau, but not for α-synuclein, 
when establishing the clinical diagnosis. 
 We compared CSF α-synuclein levels of the dementia patients with those of 57 
control persons aged  >50 years (control group A). Data on Aβ42, p-tau and t-tau was not 
available for this group. In order to have reference levels of Aβ42, p-tau and t-tau levels 
to allow comparison of these variables, we included another 55 control persons (control 
group B). Both control groups underwent lumbar puncture for various reasons. However, 
for inclusion, intensive diagnostic investigations was not allowed to reveal any 
neurological disorder. Moreover, the CSF findings of both control groups for cell count, 
glucose, lactate, haemoglobin, bilirubin, total protein and oligoclonal IgG bands had to 
be normal.
 A total of 238 patients with dementia and 112 controls were included (Figure 1). 
Patient characteristics are listed in Table 1. Characteristics of controls are listed in Table 2. 
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Mean age (± SD) of patients and controls together was 68 (± 10) years and 51% was 
male. AD patients were more often female. FTD patients were significantly younger 
than patients in the other three dementia groups. 
CSF
CSF samples were collected in polypropylene tubes by lumbar puncture and transported 
to the laboratory within 30 minutes after withdrawal. The CSF was centrifuged and 
aliquots of each sample were immediately frozen at -80 °C until analysis. α-Synuclein  in 
CSF was measured using a sandwich Elisa system based on a previously described 
procedure.25 A disposable flat-bottom microtiterplate (Nunc Maxisorp F96, Roskilde, 
Denmark) was coated with 100 µl antibody 211 (0.2 µg/ml in 0.20 M carbonate buffer, pH 
9.6) overnight at 4°C. A plate washer (BioTek, Beun de Ronde, Abcoude, The Netherlands) 
was used to wash the plate five times with 250 µl phosphate buffered saline containing 
0.05% Tween-20 (PBS washing buffer). All further incubations were performed at 37°C, 
unless stated otherwise, and all measurements were performed in duplicate. 250 µl of 
blocking buffer (2.5% gelatin in PBS washing buffer) was added and incubated for 2 
hours. The plate was subsequently washed five times with PBS washing buffer. Next, 100 
µl α-synuclein solution (from 0 to 500 ng/ml diluted in PBS) or CSF was added to each 
CSF α-SynuClein
Figure 1    Overview of the patients included in this study 
AD, Alzheimer disease; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; VaD, 
vascular dementia.
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Excluded patients:
-  69 CSF not available for 
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-  98 insecure/other diagnosis
-  9 mixed dementia
 
Controls
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Table 1    Clinical characteristics and results of CSF analysis of dementia patients 
DLB
n=40
AD 
n=131
FTD
n=39
VaD
n=28
p-value*
No. of males/females 27/13 54/77 24/15 18/10 0.005‡
Age (years) 74.0 ± 8.3 71.7 ± 8.8 66.4 ± 8.6 75.4 ± 8.4 <0.0001
MMSE score 18.9 ± 8.2
n=7
19.6 ± 3.9
n=71
20.3 ± 6.1
n=16
18.5 ± 2.9
n=6
0.843
Amyloid β42 (pg/ml) 533.0 ± 231.0
n=33
451.3 ± 147.2
n=110
702.1 ± 257.8
n=33
650.1 ± 244.6
n=24
<0.0001
T-tau (pg/ml) 318.7 ± 161.6
n=33
716.4 ± 408.9
n=109
407.3 ± 285.9
n=33
400.1 ± 543.1
n=23
<0.0001
P-tau (pg/ml) 56.9 ± 22.2
n=31
108.7 ± 47.0
n=109
68.5 ± 34.6
n=33
52.9 ± 18.6
n=23
<0.0001
α-synuclein (ng/ml) 38.0 ± 29.0 37.0 ± 36.1 49.1 ± 41.5 44.3 ± 40.3 0.187
Values are expressed as means ± SD. *, p-value by ANOVA; ‡, p-value by chi square test.
DLB, dementia with Lewy bodies; AD, Alzheimer disease; FTD, frontotemporal dementia; VaD, vascular 
dementia; MMSE, mini mental state examination (0-30, with higher scores indicating better cognition); 
t-tau, total tau; p-tau, phosphorylated tau.
Table 2    Clinical characteristics and results of CSF analysis of controls 
Control group A
n=57
Control group B
n=55
No. of males/females 30/27 26/29
Age (years) 61.3 ± 8.8 61.1 ± 8.9
Amyloid β42 (pg/ml) n.a. 822.9 ± 256.3 
T-tau (pgm/l) n.a. 212.4 ± 81.6 
P-tau (pg/ml) n.a. 47.5 ± 15.1 
α-synuclein (ng/ml) 30.4 ± 19.1 n.a.
Values are expressed as means ± SD.
T-tau, total tau; p-tau, phosphorylated tau; n.a., not available.
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well and incubated for 2.5 hours. After washing the plate five times with PBS washing 
buffer, 100 µl of antibody FL-140, diluted 1:1,000 in blocking buffer, was added for 1.5 
hours. The plate was washed five times and 100 µl of the peroxidase labeled goat- 
anti-rabbit antibody (dilution 1:5,000 in blocking buffer) was added and incubated for 
1 hour. After a final washing step 100 µl of a freshly prepared solution of tetramethyl 
benzidine (TMB) was applied and incubated for 15 minutes in the dark at room 
temperature. The reaction was stopped with 50 µl 2N H2SO4 and the absorbance was 
measured at 450 nm in an ELISA plate reader (Tecan Sunrise, Salzburg, Austria). The 
technicians performing the analyses did not have access to the clinical data. 
Statistical  analysis
Differences in α-synuclein, age, MMSE score, Aβ42, p-tau, and t-tau between dementia 
groups were analysed by ANOVA. Levels of α-synuclein, Aβ42, p-tau, and t-tau did not 
follow a normal distribution. We used log transformation to analyse these variables. 
Differences in gender distribution among the dementia groups were determined by the 
chi square test. The associations between α-synuclein and age, MMSE score, Aβ42, p-tau 
and t-tau were examined by linear regression. Statistical analyses were carried out using 
SAS, version 8.2.
Results
The mean CSF level of α-synuclein was not significantly different in the four dementia 
groups; nor did we find a significant difference between the dementia groups and the 
control group A. We found no association of CSF α-synuclein with MMSE score, sex, 
Aβ42 or p-tau among the dementia patients. The level of α-synuclein decreased with 
increasing t-tau (B -0.17, p 0.030) and age (B -0.02, p 0.001) among the dementia cases 
(Figure 2). Taking these variables into account did not change our initial findings about 
the absence of an association between dementia type and α-synuclein.
 In comparison with the univariable associations with α-synuclein, the association 
with age remained stable and significant (B -0.02,  p 0.002), while the association with 
t-tau diminished and lost significance (B -0.14, p 0.113) in a linear regression model that 
included both variables as well as dementia type.
 In DLB patients, the concentration of Aβ42 was significantly lower than in the control 
group B, although still above the cut-off value of 500 pg/ml for normal values. P-tau and 
t-tau concentrations were in the range of normal although significantly increased 
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compared to these controls. For AD patients, Aβ42 concentration was significantly 
decreased, while p-tau and t-tau concentrations were significantly higher than in the 
control group B.
Discussion
We investigated CSF α-synuclein in patients with different types of dementia. To our 
knowledge, this is one of the first studies comparing α-synuclein levels in DLB to other 
dementias. Since we did not observe differences in the CSF levels of α-synuclein 
between the various clinically diagnosed dementia disorders, α-synuclein is not a useful 
biomarker for the differentiation between DLB, AD, FTD or VaD. 
 What may have accounted for the lack of difference in α-synuclein levels that we 
observed between the different types of dementia, is that α-synucleinopathies, such as 
DLB, and tauopathies, such as AD and part of the FTD cases, may be disorders with 
considerable overlap, instead of distinct entities.26,27 Neuropathological findings of the 
various disorders have been reported to be overlapping. The presence of Lewy bodies 
in brains of AD patients was higher than expected.26 More than 60% of cases harboured 
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Figure 2    Scatter plot of CSF α-synuclein versus age in the dementia groups 
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α-synuclein positive Lewy bodies,28 whereas 87% of brains with a neuropathological 
diagnosis of DLB also met CERAD criteria for definite or probable AD.26 When Iqbal et al 
divided AD patients into subgroups based on their CSF biomarker profile, a subgroup 
with low Aβ42 and only a slight increase in t-tau levels consisted mainly of cases with 
AD of Lewy body type, their CSF biomarker profile comparable to our DLB group.29 
This supports the hypothesis of overlapping etiology of α-synucleinopathies and 
tauopathies. Interestingly, Lewy body pathology has also been found in brain tissue of 
elderly individuals without cognitive impairment.26,27 
 Another explanation for the lack of difference in α-synuclein levels might be 
heterogeneity within the DLB group. Possibly, there are subgroups within the DLB 
group. For example, patients who display parkinsonism early in the disease could have 
lower levels of α-synuclein than patients whose parkinsonism develops later in the 
course of the disease. We are uncertain about such differences within our DLB group. 
Studies addressing the association of α-synuclein in CSF with PD report contradictory 
findings. Tokuda et al found lower CSF α-synuclein in PD patients compared to controls,21 
which led to the assumption that α-synuclein could be used as a marker for 
α-synucleinopathies. However, others did not find significant differences between PD 
patients and controls.20,30 In Lewy bodies, α-synuclein is aggregated and insoluble.3 
However, under normal conditions α-synuclein is a soluble synaptic protein, that can 
also be found in human CSF and blood plasma of healthy humans,3,16,20 and that may 
be secreted into the CSF by neurons.20,21,31 Possibly, the CSF α-synuclein levels that we 
and others measured reflect a physiological level of soluble α-synuclein, independent 
of α-synuclein accumulation. The levels of α-synuclein that we measured were in 
the same order of magnitude as found in controls by Tokuda et al, using the same 
antibodies.21 
 We found that age had a weak influence on the levels of α-synuclein, with 
α-synuclein decreasing with age. This is consistent with the study by Tokuda et al.21 With 
aging, axonal transport of α-synuclein slows down and the amount of soluble 
α-synuclein decreases.27 This may account for the decreasing levels of α-synuclein found 
in CSF. Our initial finding that the concentration of t-tau increased with decreasing 
α-synuclein lost significance after correcting for age and dementia type.  
 Our study population is representative for the population seen at a memory clinic 
and the CSF data indicate that our study group was very well comparable to the study 
groups used by other research centres. We observed the typical pattern  of decreased 
Aβ42 and increased t-tau /p-tau levels in AD patients.8,10 In DLB we observed comparable 
decreased Aβ42  concentrations, although not as low as in AD, and normal to slightly 
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increased t-tau and p-tau concentrations, as has been reported before.2,12,14-19 Also, our 
observations in the VaD and FTD groups are in accord with previous studies.8,17,32-36
 Although the clinical diagnoses in our study populations were made according to 
accepted clinical criteria, some misclassification of DLB patients as AD patients probably 
has occurred. The presence of AD pathology in DLB modifies its clinical presentation 
with a lower rate of visual hallucinations and parkinsonism.3 This contributes to the 
complicated clinical differentiation between these two types of dementia and once 
more illustrates the urgent need for a discriminative biomarker. Our findings suggest 
that α-synuclein cannot be used as such a diagnostic marker. Future studies, e.g. with 
post-mortem verification of the clinical diagnosis, are warranted to confirm our findings, 
but based on the findings of our study, α-synuclein cannot be advocated as a biomarker 
for DLB. 
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The correlation between 
CSF α-synuclein and CSF Aβ 
This chapter has been published as: CSF α-synuclein concentrations do not fluctuate over hours and are  
not correlated to amyloid β in humans. Petra E. Spies, Diane Slats, Marcel G.M. Olde Rikkert, Jack Tseng,  
Jurgen A.H.R. Claassen, Marcel M. Verbeek, Neurosci Lett 2011;504:336-8
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Abstract
Reports on the value of cerebrospinal fluid (CSF) α-synuclein as a biomarker for dementia 
with Lewy bodies and Parkinson disease are contradicting. This may be explained by 
fluctuating CSF α-synuclein concentrations over time. Such fluctuations have been 
suggested for CSF amyloid β concentrations. Furthermore, a physiological relationship 
between α-synuclein and amyloid β has been suggested based on in vitro research. We 
performed repeated CSF sampling in healthy elderly and Alzheimer disease (AD) 
patients and showed that sinusoidal fluctuations in CSF α-synuclein concentrations 
were not present. Furthermore, we did not find evidence for an interaction between 
amyloid β and α-synuclein concentrations in CSF.
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Alpha-synuclein is an important component of the intraneuronal Lewy bodies that 
accumulate in Parkinson disease (PD) and dementia with Lewy bodies (DLB). 
Cerebrospinal fluid (CSF) concentrations of α-synuclein have been advocated as a 
biomarker for PD and DLB, although this suggestion may be challenged.1-4 In vitro 
research has shown that α-synuclein increases cellular amyloid β (Aβ) secretion and that 
Aβ may stimulate the aggregation of α-synuclein, suggesting a physiological relationship 
between these proteins.5,6 It is therefore conceivable that the CSF concentrations of 
these proteins correlate. Furthermore, recent data demonstrated sinusoidal fluctuations 
in CSF Aβ42 and Aβ40 concentrations that may result from a circadian rhythm,7,8 which 
implies that CSF α-synuclein concentrations may follow a circadian or sinusoidal rhythm 
as well. Such fluctuations in CSF α-synuclein concentrations could explain the 
contradicting results regarding the value of CSF α-synuclein as a biomarker for PD and 
DLB. We aimed to investigate 1) the correlation between CSF α-synuclein and Aβ 
concentrations in healthy elderly, Alzheimer disease (AD) patients and DLB patients; 2) 
the occurrence of sinusoidal fluctuations in CSF α-synuclein concentrations.
 To test for a correlation between CSF α-synuclein and Aβ42 or Aβ40, we performed 
a cross-sectional analysis in 164 persons (n=17 neurological controls, n=113 AD patients 
and n=34 DLB patients) diagnosed in our memory clinic. CSF was obtained by lumbar 
puncture. In this part of the study, CSF α-synuclein was measured using a sandwich 
ELISA based on a previously described procedure.9 Aβ42 was measured using ELISA 
(Innogenetics NV, Ghent, Belgium) and Aβ40 was analyzed using xMAP technology 
(BioSource, Invitrogen Ltd, Paisley, UK). The biomarkers were not normally distributed 
and were log transformed. Pearson’s correlation coefficient was calculated. We did not 
observe a correlation between α-synuclein and Aβ42 in the entire group (r=-0.089, 
p=0.256) or in any of the subgroups (controls: r=0.070, p=0.789; AD: r=-0.069, p=0.468; 
DLB: r=-0.195, p=0.268). Aβ40 concentrations were known of 65 persons (n=6 controls, 
n=45 AD patients, n=14 DLB patients). Again, we did not observe a correlation between 
α-synuclein and Aβ40 in the entire group (r=0.082, p=0.515) or in the AD and DLB 
subgroups (AD: r=0.206, p=0.174; DLB: r=-0.225, p=0.439). The control group was 
considered too small to reliably perform a subgroup analysis.
 To investigate fluctuations in CSF α-synuclein concentrations, we analysed CSF 
samples of 6 healthy controls (59-85 years old) and 6 AD patients (64-77 years old) who 
underwent repeated CSF sampling from an indwelling intrathecal catheter with 1 hour 
intervals.8 The study was approved by the institutional review board and informed 
consent was obtained from all participants. 26-33 samples were available per participant. 
In this study, CSF α-synuclein concentrations were measured by aforementioned ELISA.9 
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CSF Aβ40 was analyzed by ELISA (the Genetics Company, Schlieren, Switzerland) and 
CSF Aβ42 was measured using xMAP-based technology (Innogenetics NV, Ghent, 
Belgium). As previously reported,8 the mean coefficients of variation for Aβ42 and Aβ40 
were 11.1% and 10.9% for AD patients and 14.4% and 11.2% for healthy controls. 
Sinusoidal fluctuations in Aβ42 and Aβ40 concentrations were observed, although much 
less pronounced compared to observations in younger subjects.7 The continuous rise in 
Aβ levels that has been reported in some studies10 was not identified in this study.8 In 
the present study, the mean coefficient of variation for α-synuclein was 21.5% for AD 
patients and 23.6% for healthy controls, while the intra-assay coefficient of variation was 
3.5-14.9%, depending on the α-synuclein concentration.9 Time trends in α-synuclein 
concentrations were analysed with linear mixed model analysis with subject as random 
factor. To account for the longitudinal relationship of samples a first-order autoregressive 
covariance structure was used. No linear trend in α-synuclein concentrations over 33 
hours was observed. To investigate the presence of a sinusoidal pattern we included a 
cosinar analysis in the model. This analysis did not identify sinusoidal variation in CSF 
α-synuclein concentrations (Figure 1). These results did not change when AD patients 
and healthy controls were analysed separately.
 To detect a potential temporal delay in the interaction between CSF α-synuclein 
and Aβ, which cannot be assessed by cross-sectional measurements, we also 
investigated the correlation between α-synuclein and Aβ in the repeated CSF samples 
of these persons (Figure 2). We examined Pearson’s correlation coefficients per individual 
between α-synuclein and Aβ42 at different time lags, by correlating the α-synuclein 
concentration of each time point to the Aβ42 concentration 0 to 6 hours from that time 
point. This time period was arbitrarily chosen as a period in which an effect should be 
detectable.
 We also performed these analyses for α-synuclein and Aβ40, for Aβ42 and α-synuclein 
and for Aβ40 and α-synuclein. A significance level of 0.01 was used in order to maintain 
sensitivity despite multiple comparisons. Twenty-five out of 336 tested correlations 
were significant at this level, 23 in four AD patients and 2 in one healthy control. 
Coefficients ranged between -0.66 and -0.46 except for 3 in one AD patient that ranged 
between 0.54 and 0.66. These correlations were found between all combinations of 
proteins and at all time lags and no consistent pattern in any combination of two 
proteins or at any time lag could be identified. Therefore, these findings were interpreted 
to result from chance.
 In summary, this study demonstrated that CSF α-synuclein concentrations do not 
show sinusoidal fluctuations over a 33-hours period. Therefore, sinusoidal fluctuations 
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Figure 1    Mean concentrations of CSF α-synuclein over 33 hours in AD patients 
(n=6) and healthy elderly controls (n=6) 
Closed circles: AD patients; open squares: healthy controls; bars represent 95% confidence interval.
Closed triangles: Aβ40; open triangles: Aβ42; closed squares: α-synuclein; bars represent 95% confidence 
interval.
Figure 2    Mean concentrations of CSF α-synuclein, Aβ42 and Aβ40 over 33 hours 
in 12 persons (n=6 AD patients and n=6 healthy elderly controls) 
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in the CSF α-synuclein concentrations are unlikely to be the explanation for the 
conflicting reports regarding the value of CSF α-synuclein as biomarker for PD or DLB.1-4 
Other causes that may explain the discrepancies between these reports may comprise 
differences in assays and patient characteristics. Furthermore, this study revealed that 
the interaction between Aβ and α-synuclein as observed in vitro is not reflected in a 
correlation in their CSF concentrations. However, our observations are limited to soluble 
α-synuclein and Aβ42 and Aβ40 as measured in CSF and leave open the possibility that 
intraneuronal or aggregated forms of these proteins interact.
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A. CSF biomarker utilisation in Europe
Cerebrospinal fluid (CSF) biomarker analysis for dementia diagnostics (i.e., the analysis of 
amyloid β42, total tau and phosphorylated tau) is increasingly used in clinical practice.1 
However, there is still debate among researchers and clinicians about the sensitivity and 
specificity of various biomarker analyses, especially when comparing dementia 
subtypes.2 The lack of consensus and heterogeneity for evidence on CSF biomarker use 
and validity is likely to have resulted in variable practices: belief in the utility of biomarker 
measurement has likely stimulated the use of CSF analysis in clinical practice in some 
places whereas elsewhere this practice probably has not been adopted at all. The extent 
of this variability in clinical practice is currently unknown but hypothesised to be 
considerable.3 
Aim 
To investigate the extent to which CSF biomarkers are collected for clinical practice and 
for research purposes in state of the art memory clinics across Europe, with assessment 
of related consenting approaches. 
Methods
We asked all 54 memory research centres from the European Alzheimer’s Disease 
Consortium (EADC) (http://eadc.alzheimer-europe.org/introduction.html) about practical 
and ethical aspects of CSF biomarker collection in dementia diagnostics as part of an 
online survey on medical and research practice in these centres. The EADC includes 
centres from 18 countries. Centres have been selected as EADC members because of 
their expertise in clinical and basic research on Alzheimer disease and related disorders. 
Most centres are leading centres on dementia care and research in their countries.
Results
The survey had a 63% response rate. CSF was collected for routine clinical use in 56% 
and for scientific use in 87% of responding centres but while 56% of the centres took 
CSF routinely, only 44% of all centres used the measurement of CSF biomarkers as part 
of the diagnostic process. Although all centres reported that they obtained informed 
consent before collecting CSF biomarkers, the scope of consent taking was variable: 
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44% of the centres obtained separate consent for each biomarker to be collected 
whereas 85% obtained informed consent for all possible future research use. 
Furthermore, in the case of biomarker research, 65% of the centres retained the ability 
to relate biomarkers to patients. More than half of the centres (59%) reported sending 
materials abroad for diagnostic and/or scientific reasons, but no centres commercially 
sold their biomaterials.
Conclusion
From the centres surveyed here it seems that there is wide acceptance and practice of 
obtaining informed consent for collecting CSF biomarkers across Europe. However, 
there seem to be variable practices with regard to the acquisition of these biomarkers 
for research and clinical use. Also, ethical procedures with respect to handling of these 
materials, such as asking consent for future use, shipment of materials and anonymisation 
of samples, varied between centres. Despite the growing application of biomarkers in 
diagnostic criteria,3,4 we are only at the beginning of a potentially biomarker dominated 
era in dementia research and memory clinics. The successful maturation of this era in 
Europe would be facilitated by the development of practical and ethical guidelines for 
application of CSF biomarkers in dementia care practice as well as in research.5
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B. CSF analysis in the Netherlands
Abstract
Background: Evidence on cerebrospinal fluid (CSF) analysis to demonstrate Alzheimer 
disease has not yet been implemented in diagnostic guidelines. 
Methods: We investigated the use of CSF analysis in a survey among all known memory 
clinics in the Netherlands, of which 85 of 113 (75.2%) responded. 
Results: Sixty percent of respondents used CSF analysis, in 5% (median) of patients. The 
analysis almost always confirmed the working diagnosis in 68.4% and sometimes 
changed it in 28.2%. Complications occurred very infrequently (0%, median) and were 
mild. Reasons not to perform CSF analysis included the lack of clear recommendations 
in diagnostic guidelines. 
Conclusions: These results ask for a guideline update to clarify the use of CSF analysis 
as an add-on diagnostic method.
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Introduction
Recent hypothetical models on Alzheimer disease (AD) biomarker dynamics regard 
cerebrospinal fluid (CSF) biomarker analysis of amyloid β42 (Aβ42), phosphorylated tau 
(p-tau) and total tau (t-tau) to demonstrate AD as evidence based.1 Most diagnostic 
guidelines, however, have not yet implemented this evidence. In contrast to the latest 
AD research criteria,2 the most frequently used AD-criteria, NINCDS-ADRDA and DSM-IV-TR, 
do not include CSF biomarkers.
 Triggered by the gap between biomarker evidence and guidelines, we aimed to 
investigate the current use of CSF analysis in the diagnostic work up of Memory Clinic 
(MC) patients and the clinician’s opinion on reasons to use CSF analysis.
Methods
A questionnaire was sent to all known MCs in the Netherlands, i.e. all centres known to 
perform early dementia diagnostics in a multidisciplinary context. MCs that were 
approached were requested to check our list of MCs to see if any centres were missing. 
The questionnaire was distributed by e-mail and could be returned by e-mail or on 
paper. Participants not responding within two weeks were approached by phone or in 
writing. Approval of this study was not needed in accordance with local regulations.
 With respect to CSF analysis, questions were asked about frequency of use; type of 
patients in whom lumbar puncture was performed; influence of the results on diagnosis; 
reasons to apply or not to apply this method; and frequency and type of complications 
(Appendix).
 One hundred and thirteen MCs were approached, of which 85 responded (75.2%), 
and 84 completed at least part of the questions on CSF analysis. Sixty-two MCs of these 
84 were based in general (54) or academic (8) hospitals.
Results
Fifty MCs (59.5% of respondents, 46 hospital based) used CSF analysis, in 5% (median, 
range 0.01-75%) of patients, most often in patients suspected of mild dementia (Table 1). 
Most of the MCs found that the results almost always confirmed the working diagnosis 
(68.4%) and hardly ever changed it (53.8%), although change was reported to occur 
sometimes by 28.2% of MCs. The results hardly ever contradicted the working diagnosis, 
according to 61.5% of MCs.
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Table 1    Characteristics of the type of patients and results of using CSF 
biomarkers in dementia diagnostics in Dutch memory clinics 
Median (range) No. of MCsa that responded (%b)
Type of patient 
Subjective complaints 0% (0-75%) 26 (52%)
Cognitive disorder, no dementia 5% (0-95%) 32 (64%)
Mild dementia 15% (0-100%) 33 (66%)
Moderate-severe dementia 2% (0-80%) 29 (58%)
Failing procedure 0% (0-10%) 25 (50%)
Refusal patient 5% (0-50%) 30 (60%)
Complications 0% (0-10%) 23 (46%)
CSF confirms diagnosis N (%c) 38 (76%)
Never 1 (2.6%)
Hardly ever 0 (0%)
Sometimes 11 (28.9%)
Almost always 26 (68.4%)
Always 0 (0%)
CSF changes diagnosis N (%c) 39 (78%)
Never 6 (15,4%)
Hardly ever 21 (53,8%)
Sometimes 11 (28,2%)
Almost always 1 (2,6%)
Always 0 (0%)
CSF contradicts diagnosis N (%c) 39 (78%)
Never 5 (12,8%)
Hardly ever 24 (61,5%)
Sometimes 10 (25,6%)
Almost always 0 (0%)
Always 0 (0%)
a MC = memory clinic
b percentage of the MCs responding to the specific question 
c percentage of the 50 MCs using CSF analysis
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Reasons to perform CSF analysis were diagnostic uncertainty; to differentiate between 
dementia types; or to exclude certain diseases such as Creutzfeldt-Jakob disease or 
neurolues; young age of onset; positive family history; the desire for more diagnostic 
certainty, e.g. in case of implications of the diagnosis for the patient’s employment. 
Research on new biomarkers was not mentioned in this sample of memory clinics. 
Reasons not to perform CSF analysis included the lack of clear recommendations in 
guidelines; not being convinced of the diagnostic advantage; other diagnostic methods 
being more accessible; the procedure being too invasive; the presence of contra-indica-
tions for lumbar puncture such as an intracerebral tumor or use of anticoagulants. 
 Lumbar puncture failed in 0% (median, range 0-10%). Five percent (median, range 
0-50%) of patients refused to undergo lumbar puncture. Complications occurred in 0% 
(median, range 0-10%). Post-puncture headache was the only complication reported. 
Discussion
This survey shows that CSF analysis to diagnose dementia has found its way into clinical 
practice, although there is a wide range in the frequency of use. The proportion of 
centres using CSF analysis in the Netherlands is largely the same as the proportion of 
expert centres across Europe using CSF analysis routinely.3 The analysis was most often 
found to confirm the diagnosis, and not to contradict it, although it sometimes led to a 
change in diagnosis. We may conclude that in clinical practice, CSF analysis is perceived 
as sufficiently valid to change the pre-test probability of AD and of inflammatory 
diseases, and thus to change the diagnostic hypothesis. The biomarkers Aβ42, p-tau and 
t-tau are analysed in two core laboratories in the Netherlands (located in Nijmegen and 
Amsterdam), of which the Nijmegen laboratory is certified as the national reference 
laboratory for CSF analyses for AD, which diminishes the analytical variance that is still 
seen in AD biomarker analyses among various laboratories. Newsletters with reference 
standards are regularly sent out from the reference centre to reduce heterogeneity in 
interpretation of the biomarker values. However, the interpretation of the data itself 
could not be controlled for in this study. 
 We did not ask MCs to specify the exact analyses that were performed. In an 
unknown proportion of MCs the standard AD biomarkers Aβ42, p-tau and t-tau may 
have been used, but in some MCs other unspecified CSF analyses may have been 
applied. Chosen analyses depend on the clinical context. As shown by the stated 
reasons to perform CSF analysis, this is both used to exclude diseases and to gain more 
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certainty about the presence of AD pathology. The percentages of confirmation and 
change may therefore reflect test characteristics of the analysis, but also the selection of 
patients in whom lumbar puncture is performed. Complications occurred infrequently 
and were mild, which confirms previous reports suggesting high safety of lumbar 
puncture.4 
 The lack of clear recommendations in dementia guidelines, the uncertainty perceived 
in clinical practice and the heterogeneity of the application of CSF diagnostics found in 
this survey all ask for a dementia guideline update, in which the use of CSF analysis as an 
add-on diagnostic method should be clarified. Although relatively high inter-assay 
variability of CSF biomarker analyses will make it impossible to provide a single reference 
value in a guideline, a high diagnostic performance of CSF biomarkers in diagnosing the 
neurodegenerative diseases causing dementia can be reached when laboratories 
establish their own reference values.5,6 Studies on cost-effectiveness of CSF analysis and 
other AD biomarkers are urgently needed to elucidate the most efficient diagnostic 
pathway, considering all currently available diagnostic biomarkers.
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Appendix
If CSF analysis is not applied for dementia diagnostics within your memory clinic, please 
continue to question 42.
34.  If CSF analysis is applied for dementia diagnostics within your memory 
clinic, what are your reasons to do so?
 1.........................................................................................................................
 2.........................................................................................................................
 3.........................................................................................................................
 ...........................................................................................................................
 ...........................................................................................................................
35. How often does the result of CSF analysis confirm your working diagnosis?
	  Never (0-20%)
	  Hardly ever (20-40%)
	  Sometimes (40-60%)
	  Almost always (60-80%)
  Always (80-100%)
36. How often does the result of CSF analysis change your working diagnosis?
	  Never (0-20%)
	  Hardly ever (20-40%)
	  Sometimes (40-60%)
	  Almost always (60-80%)
  Always (80-100%)
37. How often does the result of CSF analysis contradict your working diagnosis?
	  Never (0-20%)
	  Hardly ever (20-40%)
	  Sometimes (40-60%)
	  Almost always (60-80%)
  Always (80-100%)
38.  In what percentage of patients in the categories below did you perform 
lumbar puncture in 2008?
	  Persons with subjective complaints   ...........%
	  Persons with cognitive complaints, no dementia ...........% 
	  Persons with mild dementia    ...........%
	  Persons with moderate to severe dementia  ...........%
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39. In what percentage of these patients did lumbar puncture fail?
 ...........
40.  a)  In how many patients did complications occur as a result of lumbar puncture?
 ...........
 b) Which were these complications?
  .................................................................................................................
 .................................................................................................................
41.  What percentage of patients refuses lumbar puncture for diagnostic purposes 
when proposed to them?
 ...........%
42.  What are your reasons to decide NOT to use lumbar puncture? (please mark 
your answer, more than one answer possible)
  The procedure is too invasive
  The risk of complications is too large
  Other additional examinations are more accessible 
  Time to results is too long
	  The patient does not fulfill the criteria as formulated in the CBO guidelines*
	  I am not convinced of the diagnostic advantage
	  The guideline dementia does not give clear advice on CSF analysis
  Other: 
 ...........................................................................................................................
 ...........................................................................................................................
 ...........................................................................................................................
 
* Dutch guidelines: http://www.cbo.nl/thema/Richtlijnen/Overzicht-richtlijnen/Geriatrie/
43.  Do you feel you are sufficiently informed about the application of CSF 
analysis in clinical practice?
  Yes  
  No 
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Abstract
Background: We aimed to develop a prediction model based on CSF biomarkers, that 
would yield a single estimate representing the probability that dementia in a memory 
clinic patient is due to Alzheimer disease (AD). 
Methods: All patients suspected of dementia in whom the CSF biomarkers had been 
analysed were selected from our memory clinic database. Clinical diagnosis was AD 
(n=272) or non-AD (n=289). The prediction model was developed with logistic regression 
analysis and included CSF amyloid β42, phosphorylated tau181 and sex. Validation was 
performed on an independent dataset, containing 334 AD and 157 non-AD patients.
Results: The prediction model estimates the probability that AD is present as follows: 
p(AD) = 1/(1+e-(-0.3315 + score)), where score is calculated from -1.9486*ln(amyloid β42) + 
2.7915*ln(phosphorylated tau181) + 0.9178*sex (male = 0, female = 1). When applied to 
the validation dataset, the discriminative ability of the model was very good, area under 
the receiver operating characteristic curve 0.85. The agreement between the probability 
of AD predicted by the model and the observed frequency of AD diagnoses was very 
good after taking into account the difference in AD prevalence between the two 
centres. 
Conclusions: We developed a prediction model that can accurately predict the 
probability of AD in a memory clinic population suspected of dementia based on CSF 
amyloid β42, phosphorylated tau181 and sex. 
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Background
Cerebrospinal fluid (CSF) biomarkers amyloid β42 (Aβ42), phosphorylated tau181 (p-tau) 
and total tau (t-tau) are increasingly used in the clinical diagnosis of Alzheimer disease 
(AD). A guideline for their interpretation is, however, still lacking. The NINCDS-ADRDA 
clinical criteria for dementia due to AD were developed before the biomarker era,1 and 
while the newly proposed research criteria for AD are more recent, they do not provide 
a ready-made guideline for implementation.2,3 A combination of decreased Aβ42 and 
increased t-tau and p-tau concentrations is considered a supportive feature of AD. 
However, minimal deviations from the reference ranges are intuitively less supportive 
than concentrations that deviate strongly from these reference ranges. Clinicians who 
frequently use CSF biomarkers may have developed such an intuitive interpretation of 
the results, but for clinicians with less experience with CSF biomarkers, it can be more 
difficult to draw equivocal conclusions from the results provided by the lab. 
 CSF biomarkers provide excellent differentiation between healthy controls and AD 
patients,4,5 but this is not a real challenge in clinical practice. The question that the 
clinician is mostly faced with, is how to differentiate AD from other dementia disorders 
or from a psychiatric disorder that mimics dementia. Although the reported specificities 
of CSF biomarkers for other dementias are lower than the specificity for healthy 
controls,6-9 they are often used for differential diagnostic purposes in memory clinics.10 
Previously reported models based on CSF biomarkers do however not provide a 
formula that can be applied in clinical practice for the differentiation of AD from non- 
AD dementia.11,12 
 We aimed to facilitate the use of CSF biomarkers in clinical practice by developing 
a prediction model for AD that yields a single estimate that would represent the 
probability that AD is the cause of the dementia in a memory clinic patient. The prediction 
model was validated on an independent database. 
Methods
Development of the prediction model 
All patients with a presumptive diagnosis of dementia who had visited the Radboud 
University Nijmegen Medical Centre (RUNMC) memory clinic between 1993 and 2008 
and of whom CSF was available were selected. The clinical diagnosis was made by a 
multidisciplinary panel that used all available clinical data including neuropsychological 
A prediction model to cAlculAte the probAbility of Ad
94
assessment and MRI, but not the CSF results. Diagnosis was AD (n=272) or non-AD 
(n=289). AD patients fulfilled the NINCDS-ADRDA criteria and DSM-IV-TR criteria for 
dementia. Non-AD patients were defined as patients in whom AD was part of the 
differential diagnosis, but who were eventually diagnosed with another diagnosis, such 
as another type of dementia or a psychiatric disorder causing the cognitive disorder. We 
did not include patients diagnosed with subjective cognitive complaints or mild 
cognitive impairment (MCI), since only part of these patients will progress to develop 
dementia due to AD, and hence they cannot be classified as AD or non-AD. Levels of 
Aβ42, t-tau, and p-tau were measured at the RUNMC laboratory using ELISA (Innogenetics, 
Ghent, Belgium). Patient characteristics are shown in Table 1.
Statistical analysis
The CSF biomarkers were log transformed to reduce strong influence of outliers. The 
prediction model was developed with logistic regression analysis, using group 
membership (AD or non-AD) as dependent variable. Sex and age were included in the 
analysis as readily available patient characteristics. The three log transformed CSF 
biomarkers, sex and age were entered with backward stepwise selection. Significant 
predictors were retained in the model. A significance level of 0.10 was used. The ability 
of the model to discriminate between AD and non-AD was quantified by the area under 
the receiver operating characteristic curve (AUC). Calibration of the model, i.e. the 
agreement between the probability of AD predicted by the model and the observed 
frequency of AD diagnoses, was assessed by plotting the mean predicted probability 
against the observed frequency of AD for each probability class (0-0.1, 0.1-0.2, …, 0.9-1.0). 
Validation of the prediction model
The dataset used for validation of the prediction model consisted of all patients with 
a presumptive diagnosis of dementia who had visited the VUmc Alzheimer Centre 
between 2005 and 2008. Clinical diagnosis was made by a multidisciplinary panel 
and was AD (n=334) or non-AD (n=157). CSF results had not been used for diagnosis; 
all other available data including neuropsychological assessment and MRI had been. 
Levels of Aβ42, t-tau, and p-tau of these patients were measured at the VUmc laboratory 
using ELISA (Innogenetics, Ghent, Belgium) (Table 1).
 Before applying the prediction model on this validation dataset, a shrinkage factor 
was applied, which is a methodological procedure in model validation that accounts for 
the expected overfitting of the developed model.13 The amount of shrinkage was based 
on the p-value of the model and the number of variables analysed. Another adjustment 
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of the prediction model was based on the need to correct for the difference in AD 
prevalence between the centres. Prevalence was defined as the number of AD patients 
among the total number of patients in the dataset. If the prevalence in a new population 
is higher than the prevalence in the population that was used to develop the model, the 
predicted probabilities will underestimate the actual probabilities. A lower prevalence 
in the new population will lead to overestimation of the actual probabilities. Ideally, the 
mean probability predicted by the model should be equal to the observed prevalence. 
The model is adjusted accordingly by correcting the intercept of the logistic regression 
formula.14 We examined two types of adjustment. One is a straightforward adjustment 
based on the discrepancy between the prevalence of AD in the validation and in the 
development datasets: correction factor = ln((prevalence in validation dataset/(1 - 
prevalence in validation dataset))/(prevalence in development dataset/(1 - prevalence 
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Table 1    Characteristics of patients in the development and validation datasets 
Development dataset Validation dataset
AD 
(n=272)
Non-AD
 (n=289)
AD
(n=334)
Non-AD
(n=157)
M/F (n) 111/161 180/109 162/172 97/60
Age (y) 69.4 ± 9.2 68.9 ± 11.1 67.3 ± 9.2 66.1 ± 9.4
MMSE 19 ± 5 20 ± 7 21 ± 5 23 ± 5
CSF Aβ42 (pg/ml) 410 [128-1162] 553 [118-1362] 455 [213-1335] 739 [201-1419]
CSF p-tau (pg/ml) 95 [23-370] 53 [15-378] 82 [16-224] 46 [17-133]
CSF t-tau (pg/ml) 558 [75-2497] 264 [74-13440] 619 [91-3150] 347 [83-1285]
Diagnosis (n)  
VaD
FTLD
DLB
Other dementia †
Psychiatric 
Other ‡
69 (24%)
76 (26%)
50 (17%)
42 (15%)
12 (4%)
40 (14%)
20 (13%)
79 (50%)
32 (20%)
26 (17%)
0
0
Age and MMSE are expressed as mean ± SD, CSF biomarkers are expressed as median [range].
†   Other dementia comprised progressive supranuclear palsy, corticobasal degeneration, Parkinson dementia, 
dementia due to alcohol abuse 
‡  Other diagnoses comprised, amongst others, delirium, normal pressure hydrocephalus, vitamin B12 
deficiency
AD, dementia due to Alzheimer disease; non-AD, non-Alzheimer disease; Aβ42, amyloid β42; t-tau, total tau; 
p-tau, phosphorylated tau181; VaD, vascular dementia; FTLD, frontotemporal lobe degeneration; DLB, 
dementia with Lewy bodies
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in development dataset))). This correction factor can be used under the condition that 
the difference in prevalence between the datasets is not caused by any of the variables 
included in the model. It is added to the intercept of the original model.15,16 This resulted 
in adjusted model A. The other type of adjustment requires information of individual 
cases in the new population on CSF Aβ42, p-tau and sex. The original prediction model 
without the intercept is used to calculate a score per individual, by multiplying the 
coefficients of the model by the individual’s values of CSF Aβ42, p-tau and sex. A logistic 
regression model is then fitted with these individual scores as linear predictor and their 
diagnosis (AD or non-AD) as dependent variable. The slope of this model is fixed at 1. 
The intercept that is obtained is the correction factor, which is added to the intercept of 
the original model.17,18 This resulted in adjusted model B.
 To be able to take into account inter-laboratory variation, both laboratories (that 
participate actively in the Alzheimer’s Association CSF Quality Control program19,20) 
analysed Aβ42, t-tau, and p-tau in 32 randomly chosen CSF samples from the RUNMC 
biobank. For this purpose, the CSF biomarkers were measured in two aliquots of the 
same CSF sample, that were both kept frozen at -80 °C and were thawed only once 
for analysis in either centre. With linear regression a correction factor was calculated 
(Supplementary Figure 1) that could be applied to the CSF values in the validation 
dataset.
 Discrimination of adjusted model A and B was quantified by the AUC. The AUC is 
based on the ranking of the predicted probabilities of the subjects, and is not influenced 
by correction factors. Therefore it is the same for both adjusted models. Calibration was 
assessed by plotting the predicted probabilities against the observed frequency of AD 
in the validation dataset. Statistical analyses were carried out using SAS version 9.2. 
Results
Development of the prediction model
The prevalence of AD in the development dataset was 48%. Ln(Aβ42), ln(p-tau) and 
female sex were significant predictors of a diagnosis of AD (Table 2). Age had no influence. 
Due to a strong correlation with p-tau, the addition of t-tau was not significant. The 
prediction model estimates the probability that AD is present as follows: p(AD) = 1/(1+ 
e-(intercept + score)), where the intercept is -0.3315 and score is calculated from -1.9486*ln(Aβ42) + 
2.7915*ln(p-tau) + 0.9178*sex (Table 2). The AUC of this model was 0.87, indicating very 
good discrimination between AD and non-AD. The agreement between the probability 
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Aβ42 RUNMC = 6.6 + 1.4*Aβ42 VUmc
p-tau RUNMC = 7.7 + 1.1*p-tau VUmc
t-tau RUNMC = 39.6 + 0.80*t-tau VUmc
Diagonal line represents line of perfect agreement between analysis of RUNMC and VUmc.
Aβ42, CSF amyloid β42; p-tau, CSF phosphorylated tau181; t-tau, CSF total tau; RUNMC, Radboud University 
Nijmegen Medical Centre; VUmc, VU University Medical Center
Supplementary Figure 1 
Scatterplots of inter-laboratory variation
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of AD predicted by the model and the observed frequency of AD diagnoses was also 
good (Figure 1): for example of the cases for whom the predicted probability of AD was 
0.1 or less (n=86, mean predicted probability 0.056, i.e. AD expected in 5.6%), 3.5% 
actually had a diagnosis of AD. Likewise, of the cases for whom the predicted probability 
of AD was over 0.9 (n=67, mean predicted probability 0.943, i.e. AD expected in 94.3%), 
91.0% actually had a diagnosis of AD. 
Validation of the prediction model
A shrinkage factor of 0.9813 was applied by multiplying the coefficients in the prediction 
model by this factor (Table 3). The prevalence of AD in the validation dataset was 68%, 
whereas it was 48% in the development dataset. Two types of correction for this difference 
in prevalence were examined, resulting in two adjusted models: model A with simple 
prevalence correction and model B with prevalence correction based on individual data.
 When using the simple correction factor based only on the prevalence of AD in the 
validation dataset, the intercept was adjusted according to the formula: corrected 
intercept = -0.3315 + ln((0.68/(1 - 0.68))/(0.48/(1 - 0.48))) (Table 3; please note that the 
prevalences mentioned in the text are rounded and that the aforementioned calculation 
thus results in an intercept that is slightly different from the one mentioned in the Table). 
This resulted in adjusted model A: p(AD) = 1/(1+e-(intercept + score)), where the intercept is 
0.4840 and score is calculated from -1.9122*ln(Aβ42) + 2.7393*ln(p-tau) + 0.9006*sex. The 
agreement between the probabilities predicted by adjusted model A and the observed 
frequency of AD in the validation dataset was very good in the low and high prediction 
classes (Figure 2a and Supplementary Table 1). For example, of the cases for whom the 
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Table 2    Results of logistic regression analysis for development of the prediction 
model  
Coefficient p-value
intercept -0.3315
ln(Aβ42) -1.9486 <.0001
ln(p-tau) 2.7915 <.0001
sex † 0.9178 <.0001
† male=0, female=1
p(AD) = 1 / (1+e-(-0.3315 + score))
Score = -1.9486 * ln(Aβ42) + 2.7915 * ln(p-tau) + 0.9178 * sex
Aβ42, amyloid β42; p-tau, phosphorylated tau181
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Horizontal axis: probability of AD as estimated by the prediction model (range 0-1). Patients are divided 
into classes of probabilities (0.0-0.1, 0.1-0.2 etc.). Each dot represents the mean probability of patients 
within one class. Vertical axis: actual percentage of AD patients. Each dot represents the percentage of AD 
patients within one probability class. Dotted line represents line of perfect agreement between predicted 
probability and observed percentage of diagnoses.
Figure 1    Calibration plot of predicted probability against observed frequency of 
AD in the development dataset using the original prediction model 
Table 3    Intercept and coefficients of the original prediction model and of the 
adjusted models A and B  
Original model A: Shrinkage + simple 
prevalence correction
B: Shrinkage + prevalence  
correction based on individual data
intercept -0.3315 0.4840 1.1528
ln(Aβ42) -1.9486 -1.9122 -1.9122
ln(p-tau) 2.7915 2.7393 2.7393
sex † 0.9178 0.9006 0.9006
† male=0, female=1
p(AD) = 1 / (1+e-(intercept + score))
Score = coefficient * ln(Aβ42) + coefficient * ln(p-tau) + coefficient * sex 
Aβ42, amyloid β42; p-tau, phosphorylated tau181
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A: adjusted model A with simple correction for difference in prevalence 
B: adjusted model B with extensive correction for difference in prevalence
Horizontal axis: probability of AD as estimated by the prediction model (range 0-1). Patients are divided 
into classes of probabilities (0.0-0.1, 0.1-0.2 etc.). Each dot represents the mean probability of patients 
within one class. Vertical axis: actual percentage of AD patients. Each dot represents the percentage of AD 
patients within one probability class. Dotted line represents line of perfect agreement between predicted 
probability and observed percentage of diagnoses.
Figure 2    Calibration plot of predicted probability against observed frequency of 
AD in the validation dataset 
101
predicted probability of AD was 0.1 or less (n=52, mean predicted probability 0.060, i.e. 
AD expected in 6.0%), 9.6% actually had a diagnosis of AD; of the cases for whom the 
predicted probability of AD was over 0.9 (n=99, mean predicted probability 0.940, i.e. 
AD expected in 94.0%), 91.9% had a diagnosis of AD.  In the middle classes the observed 
frequency of AD was higher than predicted, for example, of the cases for whom the 
predicted probability of AD was 0.4-0.5 (n=22, mean predicted probability 0.440, i.e. AD 
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Supplementary Table  1
Observed number of cases per class of predicted probability in the validation 
dataset
a: adjusted model A with simple correction for difference in prevalence
Class Mean predicted 
probability of AD
n per class AD, n (%) Non-AD, n (%)
0-0.1 5.96% 52 5 (9.62%) 47 (90.38%)
0.1-0.2 14.22% 44 9 (20.45%) 35 (79.55%)
0.2-0.3 25.08% 26 14 (53.85%) 12 (46.15%)
0.3-0.4 34.25% 29 11 (37.93%) 18 (62.07%)
0.4-0.5 43.98% 22 15 (68.18%) 7 (31.82%)
0.5-0.6 55.92% 45 35 (77.78%) 10 (22.22%)
0.6-0.7 64.77% 36 30 (83.33%) 6 (16.67%)
0.7-0.8 75.33% 57 50 (87.72%) 7 (12.28%)
0.8-0.9 85.82% 81 74 (91.36%) 7 (8.64%)
0.9-1.0 93.97% 99 91 (91.92%) 8 (8.08%)
b: adjusted model B with extensive correction for difference in prevalence
Class Mean predicted 
probability of AD
n per class AD, n (%) Non-AD, n (%)
0-0.1 6.72% 21 3 (14.29%) 18 (85.71%)
0.1-0.2 14.92% 39 3 (7.69%) 36 (92.31%)
0.2-0.3 24.06% 29 7 (24.14%) 22 (75.86%)
0.3-0.4 34.84% 21 7 (33.33%) 14 (66.67%)
0.4-0.5 45.26% 27 14 (51.85%) 13 (48.15%)
0.5-0.6 56.24% 28 14 (50.00%) 14 (50.00%)
0.6-0.7 66.74% 25 17 (68.00%) 8 (32.00%)
0.7-0.8 74.92% 54 46 (85.19%) 8 (14.81%)
0.8-0.9 85.48% 77 66 (85.71) 11 (4.29)
0.9-1.0 95.02% 170 157 (92.35) 13 (7.65)
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expected in 44.0%), 68.1% actually had a diagnosis of AD. Mean predicted probability, 
which translates to the predicted prevalence, was 0.58. 
 For the second, more extensive correction resulting in adjusted model B, the scores 
of the individual cases in the validation dataset, as obtained with the original prediction 
model, were fitted in a logistic regression model with a slope fixed at 1. The intercept of 
this logistic regression model was 1.4843 and this was added to the intercept of our 
original prediction model, resulting in an adjusted intercept of 1.1528 (Table 3). Adjusted 
model B was: p(AD) = 1/(1+e-(1.1528 + score)), score = -1.9122*ln(Aβ42) + 2.7393*ln(p-tau) + 
0.9006*sex (Table 3). 
 The agreement between the probabilities of AD predicted by adjusted model B and 
the observed frequency of AD was very good in all classes (Figure 2b and Supplementary 
Table 1). For example, of the cases for whom the predicted probability of AD was 0.1 or 
less (n=21, mean predicted probability 0.067, i.e. AD expected in 6.7%), 14.3% actually 
had a diagnosis of AD; of the cases for whom the predicted probability of AD was 
0.4-0.5 (n=27, mean predicted probability 0.453, i.e. AD expected in 45.3%), 51.9% had a 
diagnosis of AD; and of the cases for whom the predicted probability of AD was over 0.9 
(n=170, mean predicted probability 0.950, i.e. AD expected in 95%), 92.4% had a diagnosis 
of AD. Mean predicted probability was 0.68, equal to the prevalence of AD in this 
dataset.
 When correction for inter-laboratory variation was applied to the CSF biomarker 
values in the validation dataset, the performances of both adjusted models (A and B) 
remained largely the same; mean predicted probability was 0.57 and 0.68, respectively 
(Supplementary Figure 2). 
 The AUC of adjusted model A and B was 0.85, indicating that the ability of the 
model to discriminate between AD and non-AD was very good. 
Discussion
We developed a prediction model that yields the probability that a patient from the 
memory clinic population suspected of dementia has AD. The probability is calculated 
from the patient’s sex combined with the levels of CSF Aβ42 and CSF p-tau. The model 
was built using a dataset containing over 500 patients and was validated on an 
independent and comparably large dataset. An important feature of this model is that 
it takes into account the differential diagnostic dilemma that is often the reality of 
clinical practice. When a previously described model based on CSF Aβ42 and tau aimed 
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A prediction model to cAlculAte the probAbility of Ad
A: adjusted model A with simple correction for difference in prevalence
B: adjusted model B with extensive correction for difference in prevalence
Horizontal axis: probability of AD as estimated by the prediction model (range 0-1). Patients are divided 
into classes of probabilities (0.0-0.1, 0.1-0.2 etc.). Each dot represents the mean probability of patients 
within one class. Vertical axis: actual percentage of AD patients. Each dot represents the percentage of AD 
patients within one probability class. Dotted line represents line of perfect agreement between predicted 
probability and observed percentage of diagnoses.
Supplementary Figure 2 
Calibration plot of predicted probability against observed frequency of AD in the 
validation dataset, corrected for inter-laboratory differences 
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to discriminate AD from non-AD dementia, almost half of the non-AD patients were 
incorrectly classified as AD.12 Another model based on Aβ42 and p-tau could very well 
discriminate between AD and controls and correctly identified MCI patients that would 
progress to AD, but did not offer a formula that can be used by others.11 We have 
provided the details of our model to allow others to use it and adjust it, and in doing so 
retain the information of over 1,000 patients. The complex formula of the prediction 
model can be programmed in an application that will only require the clinician to enter 
the three parameters sex, Aβ42 and p-tau.
 The variables that were selected in our model are in line with previous research. 
Epidemiological studies indicate that AD is more frequent in women.21,22 CSF Aβ42 and 
p-tau were found to identify AD in a group of controls and MCI patients.11 In addition, it 
has been shown that this combination of biomarkers may help to differentiate AD from 
VaD23, DLB24 and FTD.25 Total tau on the other hand is considered a general marker of 
neurodegeneration and the least specific of the three CSF biomarkers.7 
 An important step in creating a prediction model is its validation. We validated our 
model using an independent dataset and by examining two different types of 
adjustment for a difference in prevalence. Model A can be calculated and applied by 
other centres to adjust the model to their local situation. The minimum requirement for 
this correction is to know the prevalence of AD in that centre.14 The possibility to adjust 
our model is an important advantage of our approach since existing knowledge can be 
incorporated into the model without loss of information and without the need to 
develop a new model. Calibration can further be fine-tuned with individual data (model 
B), but in that case a complete dataset is required, which might be more difficult to 
acquire. However, the prediction model can be used regardless of which of these two 
adjustments is applied, as with both adjustments the discrimination between AD and 
non-AD was very good (AUC = 0.85) and agreement between predicted probability and 
observed frequency of AD was good to excellent, especially when the predicted 
probabilities for AD were low or high. The low and high probabilities are also clinically 
the most meaningful. For example, even with perfect agreement between predicted 
probability of AD and observed frequency of AD, a calculated probability of AD of 50% 
will be of no aid in the differential diagnosis between AD or non-AD dementia. In 
contrast, calculated probabilities of, for instance, less than 20% or over 80%, will truly 
inform decision making, and in our models provide an accurate prediction of the 
probability of AD. 
 Remarkably, correction for inter-laboratory variation did not influence our results. 
Differences between the laboratories may have been diminished by inclusion of large 
Chapter Six
105
groups of patients and because the laboratories used the same enzyme linked 
immunosorbent assays. Inter-laboratory variation was substantial in a multicentre 
analysis, but decreased with the use of the same assay.26 Apparently, the quality of the 
CSF analyses performed by the two laboratories in this study is comparable. However, 
substantial inter-laboratory variation may still exist when the results of our laboratories 
are compared to other laboratories, especially if different assays are used. To take this 
inter-laboratory variation into account, a correction factor can be calculated and applied 
to the values of CSF Aβ42 and p-tau. Such a correction factor may be derived from the 
ongoing international Quality Control program by the Alzheimer’s Association.19,20
 Our model provides a continuous outcome. We decided not to calculate an optimal 
cut-off point that yields the best ratio between true positives and false negatives. 
Defining the ‘best’ ratio is arbitrary, and although a dichotomous outcome would 
appear to make clinical diagnosing easier, it would be at the cost of loss of information. 
As an example, let us consider a 70% or higher probability of AD as supporting a 
diagnosis of AD and a probability of less than 70% as supportive of a non-AD diagnosis. 
Sensitivity would be 80.5%, specificity 79.6%, positive predictive value 89.4%, negative 
predictive value 65.8%, and 80.2% of cases would be correctly classified (data not 
shown). Although these percentages appear very promising, such a dichotomous 
cut-off value means that when a patient has a 69.9% probability of AD and another has 
a 70.1% probability of AD, the former patient would be classified as non-AD and the 
latter as AD, whereas objectively their chance of having AD would be equal. 
 How should the probability of AD as derived from our model be interpreted and 
implemented? For a clinically meaningful interpretation, this estimate should not be 
interpreted on its own, but should be weighed against the prior probability of AD, 
which the clinician derives from interpretation of a combination of history taking, 
physical examination, neuropsychological evaluation and neuroimaging. Theoretically, all 
these factors could be included in a prediction model. It is, however, difficult to specify 
which items of, for example, history taking or neuropsychological testing should be 
included, especially since neither has reached any form of standardization across 
centres.
 It is important to emphasize that the prediction model is applicable in the memory 
clinic population suspected of dementia. The model is not yet validated for MCI patients 
or patients for whom AD is not part of the differential diagnosis. However, both in 
multicentre studies and in meta-analyses it has repeatedly been shown that 
combinations of CSF biomarkers can identify incipient AD in MCI patients.27-30 We 
therefore have reason to speculate that our prediction model will be of value in MCI 
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patients as well, to discriminate MCI patients with AD pathology from those without AD 
pathology, but to confirm this assumption the prediction model should first be validated 
in a group of MCI patients.
 A limitation of our model is one that is common in dementia research: we used the 
clinical diagnosis as a reference standard, and some misclassifications are bound to have 
occurred. This limitation is not easily overcome. Not only is it difficult to obtain neuro-
pathological information of this many patients, but even a neuropathological diagnosis 
is not as unequivocal as it is sometimes presented, especially when the clinical picture 
is unclear.31 More recent developments such as amyloid imaging by 11C- Pittsburgh 
Compound B cannot serve as a reference standard, since positive scans are found in 
33% of healthy controls32 and it is as yet unknown whether these represent very early AD 
or false-positives. Diagnoses in our datasets were made by multidisciplinary panels 
highly experienced in diagnosing dementia and although some misclassifications are 
not ruled out, our model reflects current clinical practice in the best possible way. 
 To conclude, we developed a prediction model that can serve as a first step in the 
implementation of CSF biomarker analysis in diagnosing dementia due to AD in the 
memory clinic population suspected of dementia. 
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Biomarkers for Alzheimer disease (AD) such as hippocampal atrophy and abnormal 
concentrations of cerebrospinal fluid (CSF) amyloid β42 (Aβ42), phosphorylated tau181 
(p-tau) and total tau (t-tau) have become established tools in the diagnostic work-up of 
patients suspected of dementia. Recently, AD research has seen a shift in focus towards 
the prodromal and preclinical stages of this disease, at the same time creating a shift in 
emphasis from clinical criteria towards biomarkers that represent core features of AD. 
The CSF biomarkers Aβ42, p-tau and t-tau are promising candidates, as they reflect the 
neuropathologic features of AD and research indicates they become abnormal early in 
the disease process. However, data are currently lacking regarding the exact timing of 
these biomarkers becoming abnormal, and the order in which these events happen. 
Longitudinal studies to elucidate the dynamics of this process are still ongoing, but 
several hypothetical models have been proposed. These models are relevant in 
providing a framework for further research, for example to establish a paradigm in 
which biomarker changes over time could become surrogate end-points in disease 
modification trials. In addition, biomarker dynamics might provide information on 
disease stage and progression once these models have been confirmed.
 An interesting feature that these models have in common is that they make a clear 
distinction between the moment that CSF Aβ42 becomes abnormal and the moment 
that CSF tau becomes abnormal. Amyloid deposition (resulting in reduced levels of CSF 
Aβ42) is suggested to be the earliest event, occurring long before cognitive symptoms 
are apparent, and plateauing early in the disease. Tau on the other hand is suggested to 
become abnormal much later, when clinical symptoms are already present, and to 
continue to increase in patients who progress from mild cognitive impairment (MCI) to 
moderate and severe dementia.1,2
 We question this distinction in timing between amyloid and tau. To illustrate that 
these models can be challenged by empirical data, we present a case of early-onset AD 
with the longest follow-up of CSF biomarkers reported in the literature. During the nine 
years between the earliest clinical manifestation and advanced dementia, we noted no 
essential changes in CSF Aβ42, p-tau and t-tau. At age 53, this man presented with a mild 
memory disorder objectified by neuropsychological testing. Neuroimaging (CT 
cerebrum) was normal, but CSF analysis showed abnormal results: Aβ42 294 pg/ml 
(reference value >500 pg/ml), p-tau 141 pg/ml (<85 pg/ml), and t-tau 660 pg/ml (<350 
pg/ml).3 No interference with activities of daily living was established and MCI was 
diagnosed. Over the next four years he gradually progressed – confirmed by repeated 
neuropsychological evaluation – to a diagnosis of probable AD, Clinical Dementia 
Rating (CDR) 1. Nine years after first contact, we re-evaluated this patient, now 
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progressed to CDR 2, with marked brain atrophy on CT. Lumbar puncture showed Aβ42 
399 pg/ml, p-tau 108 pg/ml, t-tau 655 pg/ml. 
 This case suggests that either there is no delay between changes in CSF Aβ42, p-tau 
and t-tau, or that the change in tau occurs much earlier than suggested, that is, already 
in the preclinical stage. Studies in MCI patients support this by showing that both CSF 
Aβ42 and tau are already abnormal in those patients who progressed to AD at follow 
up.4 We observed no further decrease in Aβ42 or increase in p-tau or t-tau during disease 
progression in this case. This observation is supported by the few longitudinal studies 
performed so far in MCI and AD patients – albeit with a much shorter follow up of 2 
years – that show a remarkable stability of CSF Aβ42 and t-tau concentrations.4,5 This 
argues against the assumption that a change in pathological direction of these 
biomarkers could be of use as surrogate markers to reflect progression of disease.
 This case questions models built largely on cross-sectional data. Inter-individual 
differences in progression rate and disease duration at diagnosis make cross-sectional 
studies unsuitable for inferences about the timing and order of events. Longitudinal 
studies covering the full spectrum of the disease, with measurement of imaging and 
biochemical markers, will be needed before a valid temporal model can be constructed. 
We speculate, however, that such studies will fail to demonstrate a clear distinction 
between the timing of Aβ42 and tau becoming abnormal. Likely, they will demonstrate 
a lack of relevant CSF Aβ42, p-tau and t-tau changes over time in the transition from 
early MCI to AD.
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Abstract
Objective: Aim of the study was to investigate the influence of CSF Aβ42, p-tau and 
t-tau on cognitive functioning. 
Methods: We analyzed the ability of the CSF biomarkers amyloid β42, phosphorylated 
tau181 and total tau to predict the results on a cognitive screening test that assesses 
multiple cognitive domains (CAMCOG-R) in 65 memory clinic patients (73.1 ± 8.2 years) 
(n=30 probable Alzheimer disease (AD), n=7 possible AD, n=12 non-AD dementia, n=16 
mild cognitive impairment). 
Results: We found no correlations between CSF biomarkers and CAMCOG-R performance 
in the whole group, nor in subgroups based on aberrant biomarker concentrations. 
Discussion: Changed concentrations of CSF amyloid β42, p-tau and t-tau cannot be 
directly linked to cognitive function in our sample of patients with cognitive impairment. 
Possibly, compensatory mechanisms such as cognitive reserve determine cognitive 
performance, rather than the absolute amount of damage caused by Aβ deposition and 
tangle formation. In addition, abnormal CSF biomarker concentrations may not be a 
direct reflection of the amount of neuronal damage, but merely serve as an indicator of 
AD pathology.
Conclusion: While CSF biomarkers are valuable in establishing AD pathology, they 
cannot be used to predict severity of cognitive impairment.
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Introduction
Cerebrospinal fluid (CSF) biomarkers amyloid β42 (Aβ42), phosphorylated tau181 (p-tau) 
and total tau (t-tau) concentrations are altered in Alzheimer disease (AD) patients 
compared to controls. In other types of dementia and also in part of the patients with 
mild cognitive impairment (MCI), changes in these biomarker concentrations, although 
less specific, have been reported.1-3 Aβ is said to be neurotoxic,4 while CSF tau and p-tau 
are suggested to reflect neurodegeneration.5 Likely, pathological concentrations of 
these proteins induce or signal neuronal damage, resulting in cognitive impairment. 
 To date, research on the correlation between CSF biomarkers and cognitive 
functions, however, shows contradicting results. In AD patients, inconsistent correlations 
between the Mini Mental State Examination (MMSE) and Aβ42 have been reported.6-9 A 
correlation between the MMSE and tau was often lacking,6,7,9 but sometimes present.9 
The MMSE is a cognitive screening test that is easily applicable in clinical practice, but 
lacks sensitivity and specificity and may be biased by lack of correction for educational 
level.10,11 This possibly explains these inconsistent results. A more extensive assessment 
of cognitive functioning may be a more valid approach to study the relation between 
CSF biomarkers and cognitive functioning. The few studies that have used such an 
extensive assessment again showed inconsistent results. In AD patients, a weak 
correlation between a paired-associate memory test and CSF p-tau and t-tau, but 
not Aβ42, has been reported,12 while others failed to find a correlation between the 
Cambridge Cognitive Examination (CAMCOG), a cognitive measure that covers multiple 
domains, and CSF tau.13 In a heterogeneous group of MCI and dementia patients (both 
AD and non-AD), a correlation was found between false recognition and levels of CSF 
Aβ42, but not t-tau.14
 We aimed to investigate the influence of CSF Aβ42, p-tau and t-tau concentrations 
on cognitive functioning. We hypothesized that changes in these CSF biomarkers 
reflect neuronal damage and directly underlie cognitive impairment. Therefore, we 
expect a correlation between CSF biomarkers and cognitive performance, irrespective 
of the clinical diagnosis. To test this hypothesis, we retrospectively investigated a 
heterogeneous group of memory clinic outpatients, using the CAMCOG-R as a multiple- 
domain cognitive assessment.
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Methods
This retrospective study used the database of the memory clinic of the Radboud University 
Nijmegen Medical Centre/Alzheimer Centre Nijmegen. We included all outpatients who 
visited our memory clinic between 2005 and October 2009 and underwent lumbar 
puncture as part of their diagnostic work up. All patients had a diagnosis of either mild 
cognitive impairment (MCI) or a type of dementia (note that no lumbar punctures have 
been performed in participants without impairment on cognitive screening tests at 
admission to the memory clinic). We used the Revised Cambridge Cognitive Examination 
(CAMCOG-R) as a measure of cognitive functioning.15 Its score ranges from 0-104, with a 
higher score indicating a better performance. Cut-off scores adjusted for age and 
education level have been established. Performance can be divided into a memory and a 
non-memory section (maximum score 37 and 67, respectively). These sections have been 
shown to discriminate between normal aging and early AD.16 Time between lumbar 
puncture and CAMCOG-R had to be less than 3 months. CSF was collected in polypropylene 
tubes, transported at room temperature to the adjacent laboratory within 30 minutes, 
centrifuged after routine investigations, and immediately aliquoted and stored at -80 °C 
until analysis. Levels of Aβ42, t-tau, and p-tau in CSF were measured using enzyme linked 
immunosorbent assays (Innogenetics, Ghent, Belgium).
 Sixty-five patients (32 males) were included. Of these, 30 were eventually diagnosed 
with probable AD and 7 with possible AD according to the NINCDS-ADRDA criteria,17 16 
were diagnosed with MCI according to the criteria of the International Working Group 
on Mild Cognitive Impairment,18 and 12 with another type of dementia (5 vascular 
dementia, 2 frontotemporal dementia, 3 dementia with Lewy bodies, 2 dementia of 
unknown cause) (see Table 1). Mean age (± SD) was 73.1 (± 8.2) years.
 We used linear regression to examine the relation between CSF biomarkers and the 
performance on the CAMCOG-R. As dependent variable we used the CAMCOG-R score, 
related to the cut-off value, since this cut-off is adjusted for age and education. This relative 
score was calculated using the following formula: total score/cut-off * 100, and: (non-)
memory score * (cut-off/maximum score). Aβ42, p-tau181 and t-tau concentrations were 
not normally distributed and were log transformed. Analyses were corrected for sex. 
Primary analyses included the total sample of 65 patients, predicting the CAMCOG-R total 
score and the scores on the memory and non-memory sections using CSF biomarkers. 
For secondary analyses, we divided the sample into subgroups based on their biomarker 
results to increase the likelihood of a neurodegenerative disorder being present. We used 
previously established cut-off values2 (see Table 2) and reran our linear regression models. 
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We did not use the clinical diagnoses for subgroup analyses, since both CAMCOG-R and 
results of CSF analyses may have influenced the diagnostic decision making, whereas CSF 
biomarker concentrations are an objective measure and therefore subgroup analyses 
based on these concentrations are more likely to yield valid results.
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Table 1    Characteristics of total sample and of subgroups based on clinical 
diagnosis 
Total  
sample
Probable  
AD
Possible  
AD
Other types 
of dementia
MCI
M/F 32/33 11/19 4/3 6/6 11/5
Age (y) 73.1 ± 8.2 71.5 ± 8.8 74.3 ± 8.5 76.1 ± 7.5 73.1 ± 7.5
Years of education 10.6 ± 3.8 10.4 ± 3.9 12.0 ± 4.2 11.9 ± 4.3 9.6 ± 2.8
MMSE 21.3 ± 5.2 19.2 ± 3.9 23.6 ± 6.5 19.7 ± 6.2 25.7 ± 2.9
CAMCOG-R total 67.9 ± 15.8 60.5 ± 11.7 73.6 ± 18.4 64.3 ± 18.8 82.0 ± 7.7
CAMCOG-R memory 20.2 ± 6.8 17.0 ± 4.8 22.4 ± 8.4 20.4 ± 7.7 25.2 ± 5.5
CAMCOG-R  
non-memory
47.7 ± 10.7 43.5 ± 8.9 51.1 ± 11.6 43.8 ± 12.4 56.8 ± 5.2
CSF Aβ42 (pg/ml) 571 ± 225 514 ± 210 506 ± 66 636 ± 232 657 ± 264
CSF t-tau (pg/ml) 570 ± 399 706 ± 464 739 ± 340 334 ± 214 416 ± 250
CSF p-tau181 (pg/ml) 91 ± 47 110 ± 52 110 ± 27 55 ± 30 75 ± 33
Values are expressed as means ± SD. 
AD, Alzheimer disease; MCI, mild cognitive impairment; Aβ42, amyloid β42; t-tau, total tau; p-tau181, 
phosphorylated tau181.
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Results
Figure 1 shows the correlation between each of the CSF biomarkers and the total 
CAMCOG-R score. In the total sample including all 65 patients, neither CSF Aβ42, p-tau181, 
t-tau, nor the p-tau/Aβ42 ratio was a significant predictor of the total score on the 
CAMCOG-R. Using the memory score and non-memory score as dependent variables in 
the linear regression model did not change these results.
 With respect to the secondary analyses, only three models of the 36 models tested 
showed a statistically significant outcome. First, in the group with an aberrant Aβ42 
concentration, a higher Aβ42 was related to a higher total CAMCOG-R score (B 34.8, 
p=0.040). Second, in the group with an aberrant p-tau181 concentration, a higher t-tau 
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Table 2    Characteristics of subgroups based on CSF biomarker results
Aberrant Aβ42* Aberrant 
p-tau181*
Aberrant t-tau* All 3  
biomarkers 
aberrant*
Diagnoses
Probable AD
Possible AD
Other dementia
MCI
19
3
4
7
17
6
2
6
23
6
4
8
13
3
1
4
M/F 14/19 16/15 21/20 10/11
Age (y) 71.3 ± 8.0 71.8 ± 8.4 71.7 ± 8.0 70.5 ± 8.8
Years of education 11.3 ± 3.9 10.8 ± 3.9 10.9 ± 3.8 11 ± 3.9
MMSE 20.8 ± 5.5 21.3 ± 6.0 21.2 ± 5.7 20.9 ± 6.1
CAMCOG-R total 65.6 ± 16.4 68.3 ± 17.5 68.2 ± 16.6 67.1 ± 17.6
CAMCOG-R memory 19.5 ± 6.4 20.2 ± 7.0 19.6 ± 7.0 19.7 ± 7.0
CAMCOG-R  
non-memory
46.4 ± 11.5 48.2 ± 11.8 48.6 ± 11.0 47.4 ± 11.9
CSF Aβ42 (pg/ml) 410 ± 73 478 ± 132 515 ± 185 412 ± 70
CSF t-tau (pg/ml) 659 ± 415 881 ± 366 771 ± 374 876 ± 359
CSF p-tau181 (pg/ml) 103 ± 50 131 ± 36 116 ± 42 132 ± 36
Values are expressed as means ± SD. 
AD, Alzheimer disease; MCI, mild cognitive impairment; Aβ42, amyloid β42; t-tau, total tau; p-tau181, 
phosphorylated tau181.
* Aberrant Aβ42: < 500 pg/ml; aberrant p-tau181: >85 pg/ml; aberrant t-tau: >350 pg/ml.2
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was related to a lower total CAMCOG-R score (B -24.9, p=0.015). Last, in the group with 
an aberrant t-tau concentration, a higher t-tau was related to a lower non-memory 
score (B -5.9, p=0.046). All other secondary analyses (k=33) were not significant (data not 
shown).
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Figure 1    Scatter plots of CSF biomarkers vs total CAMCOG-R score (adjusted for 
age and education)  in patients with probable Alzheimer disease (AD), 
possible AD, non-AD dementia and mild cognitive impairment (MCI) 
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Discussion
We investigated the correlation between CSF biomarkers and cognitive functioning as 
measured with an extensive cognitive screening instrument that covers all major 
cognitive domains. We did not find such a correlation in a heterogeneous group of 
patients with cognitive impairment. Secondary analyses in subgroups characterized by 
abnormal biomarker profiles did not convincingly change this finding. 
 Our results are in agreement with previous research that reported no correlation 
between the CAMCOG and CSF tau in AD patients.13 However, we did not replicate 
previously reported findings between CSF biomarkers and memory function.12,12,14 
Memory function is validly assessed by the memory section of the CAMCOG-R,16 
indicating that a correlation, if present, should have been detected in our study. 
Moreover, it is remarkable that previous studies found correlations in the same cognitive 
domain but with different CSF biomarkers. That is, one found a correlation with p-tau 
and t-tau, but not with Aβ42,12 while another found a correlation with Aβ42, but not with 
tau.14 It is difficult to explain this discrepancy; it is unlikely that this discrepancy can be 
attributed to differences in patient samples – only AD patients, versus a heterogeneous 
group of MCI and dementia patients, among which AD patients. Furthermore, this 
cannot explain why we did not find a correlation with Aβ42 in our heterogeneous group. 
In addition, a large number of tests and analyses have been performed in these previous 
studies that had not been corrected for multiple comparisons. The reported correlations 
were weak to moderate at best and in one study possibly driven by a cluster of patients 
with extreme values of p-tau and t-tau.12 Consequently, it is possible that these previous 
findings are the result of a Type I error (i.e. false positive results).
 We hypothesized that changes in Aβ42 and p-tau and t-tau, as measured in CSF, 
would reflect neuronal damage leading to impaired cognitive functioning. The present 
findings indicate that these changed concentrations in CSF cannot be directly linked to 
cognitive functioning. There are several explanations for this. First, it may not only be 
the absolute amount of damage caused by Aβ deposition and tangle formation that 
determines cognitive performance, but also compensatory mechanisms, such as inter-
individual differences in cognitive reserve. Plaques and tangles have indeed been found 
in individuals with no signs of cognitive impairment during life,19 suggesting that these 
individuals could somehow compensate for the neuronal damage induced by the 
plaques and tangles. Moreover, it has been shown that plaque burden is a poor correlate 
of cognitive status at the time of death.20
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 Alternatively, abnormal CSF biomarker concentrations may not be a direct reflection 
of neuronal damage, but merely serve as an indicator of AD pathology. For example, in 
prodromal AD, i.e. patients with MCI who developed AD at follow-up, aberrant 
concentrations of CSF biomarkers have been found.3,21 Furthermore, in patients with 
established dementia, concentrations of CSF biomarkers remained stable during 
follow-up, while cognitive performance deteriorated.22-24 A correlation between CSF 
Aβ42 and post-mortem plaque burden has been reported to be present25 as well as 
absent.26
 In AD, it has been hypothesized that amyloid deposition reaches a plateau before 
clinical symptoms are apparent.5,27 Increased tau is suggested to develop later and to 
continue to increase during disease progression.5 According to this model, one would 
not expect a correlation between Aβ42 and cognitive functioning in AD patients, but 
one would expect a correlation between p-tau and t-tau and cognitive functioning in 
AD patients, regardless of causality. To prevent ourselves from merely finding a 
correlation between two features of one disease, we examined a heterogeneous group 
of patients with cognitive impairment. We did not find a correlation between CSF 
biomarkers and cognitive functioning, showing that CSF biomarkers do not directly 
underlie cognitive impairment in a concentration-dependent way.
Conclusion
Concentrations of CSF amyloid β42, p-tau and t-tau have no clear relationship with 
cognitive functioning once cognitive decline has started. Severe cognitive impairment 
can be present in the absence of biomarker abnormality, and vice versa. Cognitive 
performance may be determined by other factors than the absolute amount of damage 
the brain has suffered, such as cognitive reserve. In addition, abnormal CSF biomarker 
concentrations may not reflect the amount of neuronal damage, but merely serve as an 
indicator of Alzheimer disease. Clinicians should be cautious that CSF biomarkers can be 
valuable in establishing AD pathology, but they cannot be used to predict severity of 
cognitive impairment. Future studies on the relation between cognitive function and 
CSF biomarkers should focus on the rate of cognitive decline over time.
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Abstract 
Objective: Preclinical and post-mortem studies suggest that Alzheimer disease (AD) 
enhances the susceptibility to develop cerebrovascular disease (CVD). The objective of 
this study was to investigate this association in a memory clinic population.
Methods: In 81 memory clinic patients (n=42 with AD) the cross-sectional association 
between AD and the presence and severity of CVD was investigated with logistic and 
linear regression analysis. Additionally, the influence of AD on the relation between 
vascular risk factors and CVD was studied. Analyses were adjusted for age. AD was 
defined as impairment in episodic memory, hippocampal atrophy and an aberrant 
concentration of cerebrospinal fluid (CSF) biomarkers. CVD was assessed on MRI through 
a visual rating scale. CSF amyloid β42, amyloid β40 and APOE-ε4 status are all suggested 
mechanisms for increased CVD risk in AD, and their associations with CVD were analyzed.
Results: AD was neither associated with the presence (p=0.332) nor with severity of 
CVD (p=0.926). Expectedly, patients with more vascular risk factors had more CVD, but 
this relationship was not influenced by presence or absence of AD (p=0.104). An 
association between either CSF amyloid β42, amyloid β40 or APOE-ε4 status and CVD 
was not found, nor did these variables change the relation between vascular risk factors 
and CVD.
Conclusions: In this memory clinic population, CVD in patients with AD was fully 
accounted for by vascular risk factors and age and was comparable to CVD in patients 
without AD. These results do not support the notion that AD pathology leads to CVD. 
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Introduction
A growing body of research suggests that Alzheimer disease (AD) increases the 
susceptibility to develop cerebrovascular disease (CVD), including post-mortem findings 
of more severe CVD in AD patients compared to controls.1-6 However, most studies were 
performed in animals and convincing translational evidence in living humans is scarce. 
Importantly, no research has been performed in a representative clinical setting (e.g. a 
memory clinic population). This study aimed to explore evidence for this increased risk 
for CVD in a clinical sample of patients with AD, by investigating whether these AD 
patients demonstrate more CVD on MRI, compared to patients without AD, and whether 
the relation between risk factors for vascular disease and CVD is influenced by the 
presence of AD. In addition, we investigated candidate mechanisms for this relationship, 
using cerebrospinal fluid (CSF) amyloid β42 (Aβ42), CSF Aβ40 and APOE-ε4 status. 
Observations in families harboring amyloid precursor protein (APP) mutations suggest 
that Aβ deposition, a hallmark of AD, may lead to CVD. Affected family members suffered 
from dementia, cerebral hemorrhage and white matter damage, attributed to the 
deposition of Aβ in cerebral blood vessels known as cerebral amyloid angiopathy 
(CAA).7,8 Furthermore, severe vascular dysfunction and a distorted vascular architecture 
were noted in transgenic mice overexpressing APP and were attributed to Aβ.2,3 Based 
on these findings, CSF Aβ42 and Aβ40, as markers of amyloid pathology,9,10 are expected 
to be related to vascular dysfunction and thus to be related with the extent of CVD: a 
lower CSF Aβ42 or Aβ40 (reflecting more severe Aβ pathology) is associated with more 
severe CVD. Next, APOE-ε4 is reported to be a risk factor both for vascular disease and 
for AD.11,12 Therefore, an association between AD and CVD may be explained by APOE-ε4 
status. 
Material and Methods
Study population
We included consecutive patients who visited our memory clinic and who underwent 
both MRI and a lumbar puncture, n=81. Baseline characteristics are summarized in 
Table 1. History of vascular events (present or absent), diabetes mellitus (present or 
absent), hypertension (present or absent) and smoking status (current or non-smoker) 
were registered from patient records. Vascular events comprised myocardial infarction, 
stroke, TIA, percutaneous transluminal coronary angioplasty or coronary artery bypass 
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grafting. Hypertension was defined as use of any antihypertensive medication or systolic 
blood pressure ≥ 140 mmHg. 
MRI assessment
Two clinical researchers (PS, JC) independently rated severity of CVD on MRI FLAIR 
transverse sections, using the age-related white matter changes (ARWMC) visual rating 
scale.13 This scale assesses 5 brain areas and takes into account lacunar infarcts as well 
as white matter lesions. The scale ranges from 0 to 30, in this study scores ranged from 
0 to 20. Medial temporal lobe atrophy (MTA) was assessed visually on a scale from 
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Table 1    Baseline characteristics of the patients included in this study 
Total group AD Non-AD
M/F, n 48/33 22/20 26/13
Age, mean ± SD (y) 70.9 ± 8.3 73.5  ± 6.3 68.1 ± 9.2
MMSE, mean ± SD 24.0 ± 3.7 22.9 ± 4.0 25.2 ± 3.0
Vascular events present, n 17 (21%) 12 (71%) 5 (13%)
Hypertension, n 68 (84%) 37 (88%) 31 (80%)
Current smoker, n 14 (17%) 8 (22%) 6 (18%)
Diabetes, n 13 (16%) 6 (14%) 7 (18%)
Vascular risk factor score, n 0
1
2
8
56
17
3
27
12
5
29
5
ARWMC, median [range] 1.5 [0-20] 2.5 [0-14] 1.5 [0-20]
MTA, median [range] 2.0 [0.5-4] 2.5 [2.0-4] 1.5 [0.5-4]
CSF Aβ40, median [range] (pg/ml) 2576 [413-6918] 2458 [413-6918] 2985 [647-6042]
CSF Aβ42, median [range] (pg/ml) 496 [248-1474] 469 [248-1166] 583 [329-1474]
CSF p-tau, median [range] (pg/ml) 80 [29-201] 87 [36-201] 70 [29-186]
CSF t-tau, median [range] (pg/ml) 425 [108-1529] 446 [146-1516] 346 [108-1529]
APOE genotype, n APOE-ε4+
APOE-ε4-
38
27
23
12
15
15
Clinical diagnosis, n SCI
MCI
ADem.
Other dem.
10 (12%)
24 (30%)
36 (44%)
11 (14%)
0 
12 (29%)
24 (57%)
6 (14%)
10 (26%)
12 (31%)
12 (31%)
5 (13%)
AD, Alzheimer disease (based on research criteria); non-AD, non-Alzheimer disease; CVD, cerebrovascular 
disease; MTA, medial temporal lobe atrophy; Aβ40, amyloid β40; Aβ42, amyloid β42; p-tau181, phosphorylated 
tau181; t-tau, total tau; SCI, subjective cognitive impairment; MCI, mild cognitive impairment; ADem., 
clinically established dementia due to Alzheimer disease; Other dem., other types of dementia.
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0 to 4, using T1 coronal sections.14 The intraclass correlation coefficient15 (95% CI) was 
0.88 (0.82 to 0.92) for the ARWMC, 0.75 (0.63 to 0.83) for right MTA and 0.67 (0.52 to 0.78) 
for left MTA. If total score differed 2 points or more between the raters on either scale, 
the MRI was reviewed to reach consensus. ARWMC scores and MTA scores of both raters 
were averaged for statistical analysis. When left and right MTA score differed, the highest 
score was used.
CSF analysis
CSF was collected in polypropylene tubes, transported at room temperature to the 
adjacent laboratory within 30 minutes, centrifuged after routine investigations, and 
immediately aliquoted and stored at -80 °C until analysis. Concentrations of Aβ42, 
phosphorylated tau181 (p-tau) and total tau (t-tau) were measured using ELISAs 
(Innogenetics NV, Ghent, Belgium). CSF Aβ40 was analyzed by a commercial assay based 
on the Luminex technology (BioSource, Invitrogen Ltd, Paisley, UK). APOE genotype of 
65 patients was available.
Classification of patients
Patients were classified as ‘AD’ (AD present) or ‘non-AD’ (AD absent) (Table 1), according 
to the new research criteria for Alzheimer disease:16 impairment in episodic memory 
(Rey Auditory Verbal Learning Test), an MTA-score of at least 2, and an aberrant 
concentration of at least one of the three CSF biomarkers (i.e. Aβ42 below, or p-tau or 
t-tau above the reference value established in our own laboratory17). Classification into 
AD or non-AD was based solely on these parameters and did not take into account the 
severity of CVD on MRI. The clinical diagnosis was not used because it could have been 
influenced by CVD on MRI, with the effect that patients with more severe CVD may have 
been less likely to receive a diagnosis of AD, which would lead to an underestimation of 
the association between AD and CVD. An additional benefit of using this definition 
instead of the clinical diagnosis is that it will result in inclusion of all patients with 
Alzheimer disease (including those in mild cognitive impairment stage) and not only of 
patients with a clinically established dementia due to Alzheimer disease. 
Statistical analysis
The association between AD (present vs. absent) and CVD (present vs. absent, with 
present defined as an ARWMC score of at least 1) was investigated with logistic regression 
analysis to allow correction for age. The association between AD (dichotomous) and 
CVD severity (continuous, using ARWMC score) was investigated with linear regression 
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analysis. This analysis, and all further analyses, were also adjusted for age, since age is 
a strong independent predictor for CVD.18
 To study whether AD influenced the association between vascular risk factors and 
CVD, vascular risk factors were summarized into one score as follows: 0, no history of 
vascular events and no other risk factors (diabetes mellitus, hypertension or current 
smoker); 1, no history of vascular events but at least one risk factor present; 2, history of 
vascular events and at least one other risk factor present. An interaction term (AD * 
vascular risk factor score) was then introduced in the linear regression model. 
 To explore the possible factors explaining an association between AD and CVD, we 
investigated the association between, subsequently, CSF Aβ42, CSF Aβ40, and APOE 
status (presence of an APOE-ε4 allele) and CVD. In addition, we studied whether each of 
these variables influenced the association between vascular risk factors and CVD by 
introducing interaction terms. CSF Aβ42 and Aβ40 were log transformed to approach 
normal distribution. All statistical analyses were performed with SPSS 16.0.
Results
To investigate the hypothesized increased susceptibility to develop CVD in AD, first the 
extent of CVD on MRI was compared between memory clinic patients who did and 
those who did not have evidence for AD based on the research criteria for AD. AD was 
neither associated with the presence of CVD (p=0.332) nor with severity of CVD 
(p=0.926). The 1.0 point higher median ARWMC in AD patients was explained by the 
higher mean age in this group (Beta for age 0.18, p=0.001). The association between 
vascular risk factors and ARWMC (Beta=2.23, p=0.004) was not influenced by the 
presence or absence of AD (p=0.104). 
 Next, we investigated whether biomarkers associated with AD (CSF Aβ42, Aβ40, and 
APOE status) were related to CVD, because in animal studies each of these biomarkers 
has been associated with cerebrovascular dysfunction. However, neither CSF Aβ42 nor 
CSF Aβ40 concentrations were associated with the presence (p=0.81 and p=0.87) or 
severity (p=0.11 and p=0.53) of CVD (Figure 1), nor did they change the association 
between vascular risk factors and CVD severity (p=0.36 and p=0.79). Carrying an 
APOE-ε4 allele was not associated with CVD (p=0.42). Unexpectedly even, in contrast 
with the hypothesis that APOE-ε4 carriers are more susceptible to cerebrovascular 
disease,11 the ARWMC score was 1.5 points lower in patients with an APOE-ε4 allele 
(p=0.038). However, when the model was adjusted for vascular risk factors, the 
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association lost significance (p=0.111). The association between vascular risk factors and 
CVD severity was not different between patients with or without an APOE- ε4 allele 
(p=0.424). Thus, APOE-ε4 status was associated with vascular risk factors, but did not 
increase susceptibility to develop CVD. 
Discussion
We have investigated the hypothesis that AD patients are more prone to CVD in 81 
patients who attended our memory clinic, and who had all undergone a routine but 
comprehensive diagnostic workup. Contrary to the hypothesis, the presence and severity 
of CVD were not related to whether or not patients had AD. More precisely, the extent of 
CVD was fully accounted for by classic vascular risk factors and age. These results were not 
attributable to confounding by a clinical diagnosis of AD (that may have been influenced 
by MRI findings of CVD), because presence of AD was defined by AD research criteria, 
using cognitive, neuroimaging and CSF biomarkers, blinded for ARWMC scores.  
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Open circles: patients with Alzheimer disease (based on research criteria, see text for explanation); closed 
squares: non-Alzheimer disease
Figure 1    Scatterplot of log transformed CSF Aβ42 vs ARWMC score 
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 Our results do not support the notion that having AD increases susceptibility to 
develop CVD. Previous studies, however, strongly suggested an etiological relationship 
between AD and CVD. Most of that research was performed in transgenic mice with 
mutated APP genes that abundantly produce Aβ. Vascular function and vascular 
architecture in these mice were severely affected by Aβ,2,3 as was their ability to adapt to 
changes in their systemic blood pressure in order to stabilize cerebral perfusion, which 
led to an increased risk of cerebral ischemia during systemic hypotension.4 Assuming 
that cerebrovascular function is similarly affected in AD patients, it was hypothesized 
that AD patients – compared to non-AD patients – have an increased prevalence and 
severity of CVD. We were unable to confirm this, as presence and severity of CVD were 
comparable between AD and non-AD patients in our population. 
 Since previous studies with transgenic mice attributed vascular effects to Aβ, we 
also investigated the possible association of CSF Aβ42 and Aβ40 with CVD in our clinical 
population. Under the prevailing assumption that low concentrations of Aβ42 and Aβ40 
in CSF reflect increased deposition of these proteins in the brain parenchyma and 
vasculature, respectively, we hypothesized an inverse relation between CSF Aβ 
concentrations and severity of CVD: lower CSF Aβ concentrations reflect more severe 
Aβ pathology and are associated with more severe CVD. However, no such relationship 
between severity of Aβ  pathology and CVD was found. 
 The apparent discrepancy between transgenic mice studies and our results may 
lead to the question whether these animal studies are truly a valid translational model 
for human AD. In general, translational failures are not uncommon, which may partly be 
explained by a lack of external validity of some animal models.19 In the case of AD, there 
are obvious differences between the various APP mice models and sporadic AD. For 
example, the engineered overproduction of Aβ in transgenic APP mice may be 
representative for the rare cases of familial AD, but such overproduction is not evident 
in sporadic AD (although it is not definitely ruled out either20). The properties of Aβ in 
transgenic APP mice are also different: it aggregates in a much shorter time-frame than 
in human AD and, when in plaques, dissolves more easily.21 Likewise, proteins that 
co-deposit with Aβ in human AD brains, are rarely found in plaques in mice.21 In line 
with these differences, it is not surprising that some findings in animals cannot be 
replicated in human AD. The Aβ42 immunization trials, that were very successful in mice 
but failed in human studies, are a well-known example.22 Similarly, preservation of 
cerebral blood flow during systemic blood pressure fluctuations was severely impaired 
in transgenic APP mice, but was intact in AD patients.23 
 Aside from questioning whether mouse models are representative for human 
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disease, it should be stressed that signs of CVD such as infarcts or white matter lesions 
have not been investigated in transgenic APP mice. This leaves open the possibility that 
the Aβ-induced distorted cerebral vasculature and endothelial dysfunction in these 
mice do not lead to infarcts or white matter lesions, and would thus go unnoticed on 
MRI.2,3 It is therefore conceivable that Aβ affects the cerebral vasculature in AD patients 
as it does in transgenic APP mice, but that the resulting vascular dysfunction does not 
lead to lesions that can be detected as CVD on MRI. If this were the case, however, the 
question rises what the clinical relevance of such vascular dysfunction would be.  
 Human data suggesting that AD induces CVD stem mostly from autopsy studies. 
Patients fulfilling the criteria for definite AD at autopsy had more watershed infarcts, 
which led to the suggestion that AD lowers the threshold for development of CVD.1 This 
lowered threshold implies that for the same vascular risk factors, CVD would be more 
severe when AD pathology is present. This was not confirmed in our in vivo study, 
where AD had no influence on the relation between vascular risk factors and CVD. An 
important side note to the autopsy study is that patients with hypertension or lacunar 
infarcts were excluded, resulting in a highly selected population.1 Therefore, the results 
of that study do not apply to a memory clinic population, where a large proportion has 
hypertension.24 In our sample, for example, over 80% of patients had hypertension.
 We repeated our analyses with APOE, since the presence of an APOE-ε4 allele is a 
risk factor for AD but has also been associated with vascular disease.11 The previously 
suggested link between AD and CVD (increased expression of CVD in AD) may thus be 
explained because APOE-ε4 promotes both diseases. Contrary to previous findings, 
however, we found that CVD severity was less in APOE-ε4 carriers compared to 
non-carriers. When adjusted for vascular risk factors, this association lost significance. It 
appears that APOE-ε4 status does not increase susceptibility to CVD and does not 
account for an association between AD and CVD.
 Our results are supported by cohort studies with autopsy data that showed a 
co-occurrence of AD pathology and vascular lesions,25,26 without evidence for a 
synergistic effect between AD pathology and cerebral infarcts.25 Since selection bias is 
inherent to these autopsy studies – these studies are often performed in cohorts of 
religious orders, and subjects who agree to autopsy may be different from those who 
do not agree – the authors concluded that in vivo confirmation of their findings was 
desired.25 A major strength of our study is therefore that we investigated a representative 
sample – a memory clinic population – with data obtained in vivo. Furthermore, we 
used an unbiased definition of AD that was based on positive biomarkers, consistent 
with the latest research criteria for AD.16
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 A limitation of our study is its cross-sectional design, which is not suitable to study 
causality. However, if two factors are causally related – in this study AD and CVD – these 
factors cluster more frequently than is expected by chance, and therefore a cross-sec-
tional design should find an association between these factors. The purpose of this 
study was to investigate the existence of an association between AD and CVD, with the 
premise that causality between these factors had already been inferred from previous 
work. Therefore, the absence of this association in this cross-sectional design advocates 
against the existence of a causal relationship between AD and CVD. 
 Based on the comparable distribution of ARWMC scores in the two groups, it is not 
expected that a larger sample size would have led to different findings. Much larger 
samples may provide sufficient power to detect small (≤1.0) differences in ARWMC 
score, but such a finding would have no clinical significance. 
 Although this study used FLAIR sections to assess white matter lesions, subtle 
vascular damage may have been missed that would have been visible with a more 
sensitive method such as diffusion tensor imaging.27 However, this limitation applies to 
both the AD and the non-AD patients: there is no reason to assume that lesions were 
selectively underestimated in AD. A visual rating scale was used to evaluate white 
matter lesions. More detailed analysis of white matter lesions can be obtained by 
volumetric methods, which express the extent of white matter lesions in ml. However, 
the visual scale is widely used in clinical studies and shows excellent correlation with 
these volumetric measurements.28 
 Finally, both AD and CVD are slowly progressive diseases, with little variation in their 
biomarkers that were studied here. Therefore, even with a cross-sectional design with a 
single time point measurement, it is possible to reliably study associations between 
these two diseases. 
 To conclude, data obtained in vivo from a sample of memory clinic patients showed 
that the severity of CVD on MRI was not influenced by AD, nor by surrogate markers of 
AD pathology, but was fully accounted for by vascular risk factors and age. CVD in 
patients with AD was comparable to CVD in patients without AD. The postulated 
increased susceptibility of AD patients to CVD was not confirmed. 
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Abstract
Cerebrospinal fluid (CSF) amyloid β42 (Aβ42) concentrations are decreased in patients 
with Alzheimer disease (AD). Consequently, low Aβ42 is considered a positive biomarker 
for AD and use of this biomarker is increasingly proposed for early detection of the 
disease. Surprisingly, the mechanisms that underlie the decrease in CSF Aβ42 remain 
speculative. Better understanding of this biomarker is an essential step to unravel AD 
pathophysiology and to develop and evaluate treatment. Therefore, we systematically 
examined the possible reasons for the decreased CSF Aβ42 concentration in AD. Under 
normal conditions, Aβ42, after its production, is secreted into the brain interstitial fluid 
(ISF). It can be degraded by proteases, taken up by microglia, or cleared from the ISF 
across the blood-brain barrier. Alternatively, it can be transported to the CSF and be 
cleared from there. Aggregation of Aβ42 appears the most likely cause for the decreased 
CSF Aβ42 concentration in AD: the aggregated state inhibits Aβ42 from being transported 
from the ISF to the CSF. Evidence for other possibilities such as a decreased production 
of Aβ42, an increased proteolytic breakdown or microglial uptake of Aβ42, or an increased 
clearance of Aβ42 to the blood, is – at best – scarce or even absent. 
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Introduction
The characteristic plaques of Alzheimer disease (AD) were discovered by Aloïs Alzheimer 
in 1906, but it was not until the 1980s that it was demonstrated that these plaques 
consist of the amyloid β protein (Aβ).1-3 The realization that this protein was the same as 
the protein accumulating in brains of patients with Down syndrome led to the discovery 
of the amyloid precursor protein (APP),  located on chromosome 21, as the precursor 
protein of Aβ.4 Subsequently, pathogenic mutations in the APP gene were discovered in 
familial AD.5-8 In the 1990s, Aβ could be measured in cerebrospinal fluid (CSF) for the first 
time.9,10 It was thereafter repeatedly shown that CSF Aβ42 was decreased in AD.11-14 
Nowadays, it is an accepted biomarker for AD15,16 that is frequently used in clinical 
practice.17,18 Surprisingly, the cause of its decrease has not yet been fully elucidated, 
although several explanations have been offered: changes in Aβ generation or 
degradation may affect the CSF concentration, or an alteration in the solubility of Aβ42 
may diminish clearance of Aβ42 from the interstitial fluid (ISF) to CSF.11-14 Determination 
of the CSF Aβ42 concentration in AD may be masked by its interaction with binding 
proteins, such as apolipoprotein J or E, or an increased clearance of Aβ42 from CSF might 
explain the diminished levels of Aβ42 in the CSF of AD patients.14
 In spite of all these suggestions, the actual explanation for the decreased CSF Aβ42 
in AD remains largely unidentified. Here, we will review the evidence for each of the 
proposed explanations to create a better understanding of the underlying mechanisms 
that lead to its recognition as an important AD biomarker. 
Aβ42 metabolism
1. Production of Aβ42
Aβ42 is produced by sequential cleavage of the amyloid precursor protein (APP) 
(Figure 1). APP is a membrane-bound protein whose function remains unclear, although a 
role in cell adhesion, cell growth and synaptogenesis has been suggested.19,20 APP can be 
cleaved by either α- or β-secretase, and subsequently by γ-secretase. Whether Aβ is 
produced from APP depends on which of these enzymes first cleaves APP.
 Cleavage of APP by α-secretase at the plasma membrane or in the trans-Golgi 
network  generates N-terminal fragment soluble APP-α (sAPP-α) and C-terminal 
fragment C83.21 sAPP-α is released into intracellular vesicles or extracellularly. C83 remains 
membrane-bound and is cleaved by γ-secretase to produce p3 (Aβ17-40 and Aβ17-42/43) 
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and APP intracellular domain (AICD) (CT57-59).22-25 The latter is released into the cytoplasm. 
This pathway is called the non-amyloidogenic pathway since no Aβ40 or Aβ42 is produced.
 Cleavage of APP by β-secretase, the amyloidogenic pathway, takes place in the 
trans-Golgi network and in endosomes 20,26 and generates N-terminal fragment soluble 
APP-β and C-terminal fragment C99. sAPP-β – just like sAPP-α – can be released into 
intracellular vesicles or extracellularly. C99 remains membrane-bound and is subsequently 
cleaved by γ-secretase to produce Aβ42 or Aβ40 and AICD.22,23 Cleavage by γ-secretase 
takes place in the endoplasmatic reticulum, trans-Golgi network, endosomes, and for a 
small part at the plasma membrane.26 Other isoforms of Aβ have been identified as well, 
with heterogeneity either at the C- or N-terminus of the peptide, but for clarity this 
review will be limited to Aβ42 and Aβ40.
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Figure 1    The non-amyloidogenic and amyloidogenic pathways of APP 
processing 
APP is cleaved by either α- or β-secretase. Cleavage by α-secretase (the non-amyloidogenic pathway) 
generates sAPP-α and C83 (left). Cleavage by β-secretase (the amyloidogenic pathway) generates sAPP-β 
and C99 (right). C83 is cleaved by γ-secretase, generating AICD and p3 (not shown). C99 is also cleaved by 
γ-secretase, generating AICD and Aβ (right). (See text for abbreviations.)
Republished with permission from the American Society for Clinical Investigation, from The role of cerebral 
amyloid β accumulation in common forms of Alzheimer disease, S. Gandy, J Clin Invest 2005;115:1121-9; 
permission conveyed through Copyright Clearance Center, Inc.
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 The amyloidogenic and non-amyloidogenic pathways are mutually exclusive.22 APP 
molecules that are not cleaved at the cell membrane by α-secretase can be internalized by 
endocytosis and subsequently be cleaved by β-secretase.27 Redistribution of APP 
towards either the cell membrane or the cell interior can therefore influence the 
proteolytic pathway that APP undergoes.22
 Aβ42 and Aβ40 are either retained in cells or secreted into the ISF that surrounds the 
brain cells.23 The equilibrium between intra- and extracellular Aβ42 and Aβ40 is in part 
regulated by active transport via the receptor for advanced glycation end products 
(RAGE),28 a multiligand receptor of the immunoglobulin family.29 
2. Degradation of Aβ42 
2.1. Proteases
Several proteases can break down Aβ (both Aβ42 and Aβ40) in vitro; in vivo evidence 
stems mostly from animal studies. Insulin-degrading enzyme (IDE) and neprilysin have 
received most attention. IDE is a zinc-metalloproteinase present in the cytosol, in 
intracellular membranes and at the cell surface.25,30-32 It is secreted by neurons32 and has 
also been found in CSF.25 It can therefore degrade both intracellular and extracellular Aβ. 
IDE only degrades soluble, monomeric Aβ.25,30,31 The cleavage products are not 
neurotoxic and are not prone to accumulate in plaques.25 Neprilysin is an axonal and 
synaptic membrane-anchored protein with its catalytic site facing the cell exterior31,32 
and is therefore primarily involved in the breakdown of extracellular Aβ42. It can degrade 
monomeric as well as oligomeric Aβ.32
 Other proteases that have been reported to degrade Aβ in vitro include matrix me-
talloproteinase-9, angiotensin converting enzyme, cathepsin D, plasmin and endothelin 
converting enzyme-1.32,33 Aβ aggregates can stimulate tissue-type and urokinase-type 
plasminogen activator to generate plasmin. Plasmin can degrade both monomeric Aβ 
and Aβ fibrils in vitro, although degradation of fibrils is far less efficient. Its role in 
degrading Aβ in vivo is unclear.33  
2.2. Microglia
Microglia are the macrophages of the brain. They take up soluble Aβ by macropinocy-
tosis and possibly by binding of Aβ to the low-density lipoprotein receptor-related 
protein (LRP).34 Fibrillar forms of Aβ interact with the microglia cell surface and bind to 
the CD36 receptor expressed by microglia. CD36, a major pattern recognition receptor, 
mediates the microglial response to Aβ, leading to an intracellular signaling cascade 
that stimulates phagocytosis.35 Ablation of microglia in mice led to an increase in soluble 
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Aβ40 and Aβ42, but had no influence on number and size of Aβ plaques.36 This would 
support the idea that microglia are inefficient in degrading fibrillar Aβ.34 However, others 
have found that upon activation, for example by cerebral ischemia or after vaccination 
with Aβ specific antibodies, microglia can degrade fibrillar Aβ.37-39 
3. Clearance of Aβ42
Aβ42 and Aβ40 can also be cleared from the extracellular compartment. It can be cleared 
from the ISF across the blood-brain barrier towards the circulation, or it can be 
transported from the ISF to the CSF, and be cleared from there. Alternatively, Aβ can be 
transported with the ISF or CSF to the peripheral lymphatic system (Figure 2). 
3.1. Active transport of Aβ from ISF to systemic circulation
Both Aβ42 and Aβ40 can be removed from ISF to the blood by crossing the blood-brain 
barrier. The blood-brain barrier is primarily formed by endothelial cells in brain capillaries 
that are closely connected via tight junctions which exclude the transfer of many 
macromolecules from ISF into blood.40 Astrocytes and pericytes may also play a role in 
the control of transport across the blood-brain barrier. Aβ42 and Aβ40 are primarily 
transported across the blood-brain barrier by LRP.29 LRP is a multiligand lipoprotein 
receptor that mediates endocytosis of secreted proteins. It provides a rapid transport of 
brain-derived Aβ into the blood.41 LRP-mediated transport is more efficient for Aβ40 
when compared to Aβ42,29,31 probably related to Aβ40’s lower propensity to aggregate. 
Aβ42 and Aβ40 that is produced in the periphery can enter the brain ISF from the 
systemic circulation by active transport across the blood-brain barrier via RAGE, which 
is expressed on the luminal surface of brain vessels.29 
3.2. Drainage of Aβ with ISF to lymphatics
One of the routes that ISF can follow is drainage along axonal tracts and through 
perivascular spaces. ISF travels along these perivascular spaces towards the surface of the 
brain and exits at the base of the skull, where it drains to regional lymph nodes in the 
neck.42 The idea that Aβ is transported together with ISF along this pathway is supported 
by the fact that Aβ has been found in the basement membranes of capillary and arterial 
walls, but was not detectable further downstream in the walls of the carotid arteries.43
3.3. Transport of Aβ from ISF to CSF
Another route for ISF is towards the CSF, where it constitutes 10-30% to the total CSF 
production.44 ISF mixes with CSF at the ventricles and presumably also in the sub - 
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arachnoid compartment.40,44 Whether Aβ reaches the CSF via this route is uncertain. The 
glia limitans and the pia mater separate ISF from CSF in the subarachnoid space, 
however, the extent to which these layers block the passage of solutes and ISF into CSF 
is unknown. They may be fully permeable to fluid and small molecules,29 but on the other 
hand, the presence of Aβ deposits in the glia limitans in AD suggests that transport of Aβ 
from ISF to CSF is limited in the subarachnoid compartment.43 
The concentration of Aβ40 in CSF is about 6-fold greater than the concentration of 
Aβ42;45-47 in AD, the decreased concentration of CSF Aβ42 makes the CSF Aβ40 
concentration at least 10-fold that of CSF Aβ42.46-48 
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Figure 2    Schematic view of Abeta42 and Abeta40 clearance
Aβ can be Aβ42 or Aβ40. Solid arrows depict active transport of Aβ; dashed arrows depict passive transport 
of Aβ together with ISF or CSF.
BBB = blood-brain barrier; BCB = blood CSF barrier at choroid plexuses; AV = arachnoid villi
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3.4. Absorption of Aβ from CSF to systemic circulation 
Labeled Aβ injected into CSF of rats was detectable in blood a few minutes after 
injection.49 From cell culture research it was inferred that Aβ can be absorbed from CSF 
at the choroid plexuses.50 The endothelium of the blood vessels within the choroid 
plexus is leaky, but the epithelium between blood vessels and ventricular CSF contains 
tight junctions and forms the blood-CSF barrier (which should not be confused with the 
blood-brain barrier). Small molecules can enter or leave the brain.40 Uptake of Aβ 
peptides at the choroid plexus was rapid and occurred as a non-diffusional, yet unclear 
uptake process. Efflux of Aβ from CSF to blood was favored over influx from blood into 
CSF.50 In addition to the blood-CSF barrier, CSF drains to blood in the subarachnoid 
compartment, where CSF drains into the major venous sinuses via arachnoid 
granulations. Tight junctions in these granulations prevent passage of proteins,51 and it 
is therefore unclear whether Aβ can be cleared from CSF to blood in this way.
3.5. Drainage of Aβ with CSF to lymphatics 
The perineural sheath along the olfactory nerve represents another pathway of CSF 
drainage. The olfactory nerve fibers enter the nasal mucosa in the roof of the nasal 
cavity. At this point CSF drains from the perineural subarachnoid space into the 
extracellular matrix, where it is absorbed by blind-ended lymphatic capillaries, and 
drained to the regional lymph nodes that serve the nasopharynx.44,51 CSF also flows 
along the perineuronal sheaths of the cranial and spinal nerves to regional lymphatics 
40,51,52 It seems plausible that Aβ is cleared together with CSF via this pathway, but studies 
to confirm this are currently lacking. 
Why is CSF Aβ42 decreased in Alzheimer disease?
Several morphological changes that are related to the fate of the Aβ42 peptide have been 
observed in AD. Upon post-mortem examination, Aβ plaques are found: diffuse plaques 
that contain only Aβ42, and classic plaques that consist of both Aβ42 and Aβ40.53,54 In most 
AD cases, at least a mild degree of cerebral amyloid angiopathy is found as well, that 
consists of Aβ deposits in the walls of leptomeningeal and cortical arteries and less 
frequently in capillaries.55 In contrast to the plaques, these vascular deposits contain 
mostly Aβ40.56 The concentration of both Aβ42 and Aβ40 in the AD brain is thus 
increased.57,58 However, the CSF concentration of Aβ42 is decreased in AD patients, while 
the CSF Aβ40 concentration is unaltered.14,48 We will focus on reasons why CSF Aβ42 is 
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decreased, while keeping in mind the other changes that occur in AD. Table 1 provides an 
overview of these reasons and the arguments supporting or contradicting them.   
1. Is Aβ42 production reduced?
Theoretically, a decreased concentration of Aβ42 in CSF could simply be the result of a 
decreased production of Aβ42, for example by a reduction in the number of viable 
neurons that produce Aβ. However, several arguments make this unlikely. First, a 
decreased production does not logically connect to an increased Aβ42 load in the brain. 
Second, if the production of Aβ42 were decreased, the production of Aβ40 would 
probably be decreased as well, since Aβ42 and Aβ40 likely share the same production 
pathway. This should then lead to a decreased CSF Aβ40 concentration, which, however, 
is not observed in AD. Third, a decreased concentration of CSF Aβ42 is also found in 
familial AD and in Down syndrome, disorders in which overproduction of Aβ42 has been 
clearly demonstrated.59-62 Decreased Aβ42 thus exists despite overproduction, which 
implies that factors other than production play a role in causing the decreased CSF 
concentration. 
 An alternative theory is that Aβ42 secretion from the cell is decreased, leaving less 
Aβ42 available in the ISF for transport to the CSF. Although intraneuronal Aβ aggregation 
has been described in triple transgenic mouse models,63 Aβ predominantly accumulates 
extracellularly in human AD. This implies that the secretion of Aβ from the cell to the 
exterior is not diminished and that a decreased secretion of Aβ42 by the cell is unlikely 
to be the cause of the decreased CSF Aβ42 concentration. 
 Supporting these arguments against a decreased production or secretion of Aβ42 
is a study showing that the production rate of Aβ42 and Aβ40, as measured in CSF using 
labeled Aβ42 and Aβ40, did not differ between controls and AD patients.64
2. Is Aβ42 degradation increased?
It can be hypothesized that an increase in proteolytic breakdown of Aβ42 leads to a 
decreased CSF Aβ42 concentration. However, an increase in proteolytic breakdown 
would clear the brain from not only Aβ42, but also from Aβ4065 and would preclude 
formation of plaques. Understandably, research has focused on finding defects in 
proteolytic degradation of Aβ rather than overactivity of these proteases to explain the 
elevated cerebral levels of Aβ.32,33 It appears that levels of neprilysin decrease with 
aging66 and that low levels of neprilysin make certain brain areas more vulnerable to Aβ 
deposition,67,68 suggesting that  proteolytic activity is decreased rather than increased. 
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Table 1    Overview of arguments supporting or contradicting the hypothetical 
mechanisms that could explain the decreased CSF Aβ42 concentration  
in AD 
Hypothetical mechanism Supporting arguments Contradicting arguments
Decreased production of Aβ42 -  Could be the result of a 
reduction in viable neurons 
due to neurodegeneration
-  An increased brain Aβ42 load 
is found post-mortem
-  Aβ40 shares the same 
production pathway as 
Aβ42 but CSF Aβ40 is not 
decreased
-  Disorders with an increased 
production of Abeta have 
decreased concentrations of 
CSF Aβ42 
-  The production of Aβ42 
in AD did not differ from 
controls in a labeling study
Decreased secretion of Aβ42 
from neurons 
-  Intraneuronal Aβ 
aggregation has been 
described in Tg mice
-  The typical Aβ plaques of  
AD are found extracellularly
Increased degradation of 
Aβ42 
-  An increased brain Aβ42  
load is found post-mortem
-  Increased degradation 
would probably affect Aβ40 
as well, yet the CSF Aβ40 
concentration is unchanged
-  Levels of neprilysin (one of 
the proteases involved in Aβ 
degradation) decrease with 
aging
Increased microglial uptake 
of Aβ42 
-  Activated microglia are 
found in the vicinity of Aβ 
plaques
-  An increased brain Abeta42 
load is found post-mortem
-  Microglia become 
dysfunctional with aging
Increased clearance of Aβ42 
from ISF to blood 
-  Expression of LRP (which 
promotes transport of Aβ 
from ISF to blood across 
the blood-brain barrier) by 
perivascular cells increased 
in reaction to Aβ42
-  Perivascular cells expressing 
LRP degenerated after 
uptake of Aβ
-  LRP expression is reduced 
in AD
-  No increase in plasma Aβ42 
is found
-  An increased brain Aβ42  
load is found post-mortem
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3. Is microglial uptake of Aβ42 increased?
An increased microglial uptake of Aβ42 could be hypothesized to lead to the decreased 
CSF Aβ42 concentration by leaving less Aβ42 available in the ISF for transport to the CSF. 
Activated microglia are found in the vicinity of compact Aβ plaques,69 however, the very 
presence of these plaques shows that microglial uptake of Aβ is insufficient to lead to a 
lower-than-normal concentration of Aβ in ISF. On the contrary, it has been suggested 
that with age, microglia become dysfunctional and less able to clear Aβ42.34,70,71 Thus, it 
is unlikely that microglial ability to degrade Aβ is increased in AD. 
4. Is Aβ42 clearance affected?
Changes in the clearance of Aβ from either ISF or CSF (the solid arrows in Figure 1) can 
influence the Aβ concentration. An increased transport of ISF or CSF, containing Aβ, to 
the lymphatics will not affect the Aβ concentration.
4.1. Is clearance of Aβ42 from ISF increased?
An increased clearance of Aβ42 from ISF to blood across the blood-brain barrier would 
leave a smaller amount of Aβ42 in the ISF that can be transported to the CSF and could 
thus explain the decreased CSF Aβ42 concentration. The primary transporter of Aβ 
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Table 1    Continued 
Hypothetical mechanism Supporting arguments Contradicting arguments
Hampered transport of Aβ42 
with ISF to CSF 
-  Dilated perivascular spaces 
may indicate obstruction of 
ISF flow
-  Dilated perivascular spaces 
are often seen in the elderly 
and their clinical relevance 
is unclear
-  Other proteins (including 
Aβ40) still reach the CSF
Perivascular deposition of 
Aβ42 
-  Aβ deposits are found 
perivascularly
-  Perivascular Abeta deposits 
contain mostly Aβ40
Parenchymal aggregation and 
deposition of Aβ42 
-  An increased brain Aβ42  
load is found post-mortem 
-  Aβ42 is more prone to 
aggregation than Aβ40
Increased clearance of Aβ42 
from CSF to the blood 
-  Uptake of Abeta from CSF 
decreased with aging
-  No increase in plasma Aβ42 
is found
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across the blood-brain barrier is LRP. Even though LRP favors clearance of Aβ40 over 
Aβ42, it can be hypothesized that in AD, clearance of Aβ42 is upregulated while clearance 
of Aβ40 remains the same. In support of this hypothesis, expression of LRP by perivascular 
cells was increased in response to Aβ42 in vitro, while Aβ40 had no such effect; however, 
uptake of Aβ resulted in degeneration of these perivascular cells.72 It has also been 
reported that LRP expression was reduced in AD, while RAGE expression (which 
transports Aβ from blood to brain) was increased.29 These changes do not support an 
increased clearance of Aβ42 from ISF over the blood-brain barrier and could actually 
lead to a reduced transport of Aβ42 out of the brain and an increased uptake of 
peripheral Aβ42 into the brain. 
 Another argument against an increased transport of Aβ42 across the blood-brain 
barrier is the lack of an increase in plasma Aβ42 concentration. Increased transport of 
Aβ42 to the blood should result in an increase in the plasma concentration of Aβ42 – 
assuming that the peripheral breakdown and elimination of Aβ42 are not increased in 
AD. Reports on the plasma Aβ42 concentration in AD patients are contradictory, but a 
clear increase has not been shown.73,74 Finally, enhanced clearance of Aβ42 from the ISF 
is incompatible with the increased Aβ load that is found in AD brains. In summary, it 
cannot be concluded that transport across the blood-brain barrier is increased. 
4.2. Is transport of Aβ42 from ISF to CSF hampered?
4.2.1. Hampered flow of ISF to CSF
ISF flows through the perivascular spaces, mixing with CSF in the subarachnoid 
compartment at the brain surface and at the ventricles. If Aβ42-containing ISF cannot 
reach the CSF or if Aβ42 is deposited before ISF reaches the CSF, the Aβ42 concentration 
in CSF will be decreased. Dilated perivascular spaces may be interpreted as a sign that 
ISF cannot, or has difficulty to, reach the CSF.75 However, dilated perivascular spaces are 
often seen in the elderly and are not AD-specific.76 Their clinical relevance is unclear. The 
fact that Aβ40 and other proteins can still reach the CSF in AD argues against an 
obstruction of transport between ISF and CSF. 
4.2.2. Perivascular deposition of Aβ
Signs that Aβ42 is deposited before it reaches the CSF are present: Aβ deposits are found 
in the walls of the cerebral vasculature and in the glia limitans in the subarachnoid 
compartment.43,77,78 The deposits in the cerebral vasculature consist mostly of Aβ40, and 
to a lesser extent of Aβ42.56 In clinically diagnosed cerebral amyloid angiopathy, a 
decreased CSF Aβ40 concentration was found.79 This suggests that perivascular Aβ 
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deposition can indeed lead to a decreased CSF Aβ concentration. However, cerebral 
amyloid angiopathy found in AD is mostly mild to moderate,55 and the amount of Aβ42 
that is deposited in the cerebral vasculature is presumably insufficient to be the sole 
explanation for the decreased CSF Aβ42 concentration. 
4.2.3. Parenchymal aggregation of Aβ
Aggregation of Aβ42 into insoluble deposits may be a reason why Aβ42 is decreased in 
CSF: less soluble Aβ42 is left for transport to the CSF, while the insoluble aggregates 
cannot be transported from ISF to the CSF. Aβ42 is much more prone to aggregation 
than Aβ40.56,80 Both diffuse and classic plaques contain Aβ42, but only the classic plaques, 
which are fewer in number, contain Aβ40.54 Thus, much more Aβ42 than Aβ40 is 
deposited in AD. Considering that Aβ40 is the most abundant Aβ peptide in CSF,81 the 
relative amount that is deposited in AD may be too little to induce a clear decrease in 
the CSF Aβ40 concentration. In contrast, the relative amount of Aβ42 that is deposited is 
much larger, which may explain why the CSF Aβ42 concentration is decreased.
4.3. Is CSF Aβ42 decreased because more Aβ42 is cleared from CSF?
Uptake of Aβ42 from the CSF was inferred from research in cell culture that used Aβ40 as 
a model compound for all Aβ species.50 Theoretically, this process could be upregulated 
in AD, resulting in more Aβ42 to be transported from the CSF into the blood. Since the 
CSF Aβ40 concentration is unaltered, this upregulation should then selectively affect 
Aβ42 and not Aβ40. Research to confirm this is currently lacking. In contrast, research in 
rats suggests that uptake of Aβ from the CSF decreases with aging.82 Furthermore, the 
increase in the plasma concentration of Aβ42 that would be expected if upregulated 
efflux was the case (and peripheral elimination of Aβ was unaltered), has not been 
shown convincingly.73,74 Therefore it seems unlikely that an increased clearance of Aβ42 
from the CSF is the cause of the decreased CSF Aβ42 concentration in AD. 
Perspective
We have reviewed a number of possible mechanisms that could theoretically explain 
the typical observation of a decreased CSF Aβ42 concentration in AD. It appears very 
difficult to understand the decrease in CSF Aβ42 found in AD. Based on simple but 
systematic reasoning, a number of theoretical mechanisms can be formulated, however, 
most of these do not concur with the premise that there is an increased Aβ load in the 
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AD brain, and that the decreased CSF Aβ42 is accompanied by an unaltered CSF Aβ40 
concentration. Furthermore, many of these theoretical mechanisms are contradicted by 
(often fragmented) findings from research. For example, a decreased production of 
Aβ42 has not been shown: production rates were comparable between controls and AD 
patients. Increased proteolytic breakdown of Aβ is unlikely, since available evidence 
suggests a decrease in proteolytic activity rather than an increase. An increased 
microglial uptake of Aβ42 is not supported, instead, a decrease in activity with aging is 
found. Increased clearance of Aβ42 from either ISF or CSF has not been reported; rather, 
decreases in clearance have been suggested. 
 What, in our opinion, remains as the most plausible cause of the decreased Aβ42 
concentration in CSF is Aβ42 aggregation. Aβ42 is known to aggregate easily and once 
aggregates have been formed, transport of these aggregates from the ISF to the CSF 
may be seriously impaired. Aβ40 has different properties and is not as prone to 
aggregation, which may explain why less Aβ40 is found deposited in the AD brain, and 
why CSF concentrations of Aβ40 are unaltered. 
 Until novel mechanistic insights with respect to the different steps in Aβ metabolism 
are obtained, this remains currently the most satisfying explanation for the observed Aβ 
changes in AD. Our systematic approach may have provided a framework against which 
the currently available knowledge from research can be laid out, as pieces of a puzzle. 
In this way, CSF Aβ42 can be much more than a diagnostic test with an empirical cut-off 
value for use in clinical settings. Better understanding of this biomarker may be the key 
to a better understanding of the disease. 
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Introduction
Although Alzheimer disease (AD) was discovered more than a century ago, several 
important aspects of its pathophysiology remain a mystery today. Its heterogeneous 
clinical presentation can make it difficult to differentiate AD from other types of 
dementia, especially in the early stages of the disease. This thesis aimed to investigate 
the use of cerebrospinal fluid (CSF) biomarkers as diagnostic tools in the differentiation 
between different types of dementia. Furthermore, we investigated whether CSF 
biomarkers support the current hypotheses on the pathophysiological cascade of AD. 
This chapter provides a summary of the findings presented in this thesis, followed by a 
general discussion.
Summary
The first part of this thesis focused on the use of CSF biomarkers in clinical practice for 
differential diagnostic purposes. We investigated the amyloid β42/amyloid β40 (Aβ42/
Aβ40) ratio in Chapter Two as a means to improve the accuracy of CSF Aβ42 in 
discriminating AD from other types of dementia. The concentration of CSF Aβ40 has 
been reported to remain unchanged in dementia and to be a measure of an individual’s 
total Aβ load. We hypothesized that relating Aβ42 to the Aβ40 concentration would 
provide a more accurate measure of changes in Aβ42. Indeed we found that the 
performance of the Aβ42/Aβ40 ratio was better than that of Aβ42 alone in discriminating 
AD from dementia with Lewy bodies (DLB), vascular dementia (VaD) and non-AD 
dementia. The Aβ42/Aβ40 ratio was similar in diagnostic value compared to Aβ42 alone 
in discriminating AD from frontotemporal dementia (FTD). However, the Aβ42/Aβ40 ratio 
did not add much to the frequently used combination of Aβ42, phosphorylated tau 
(p-tau) and total tau (t-tau): the latter combination was superior in differentiating AD 
from VaD and DLB, and equally good in discriminating AD from FTD or non-AD 
dementia. In the differentiation of AD from FTD and non-AD dementia, the Aβ42/Aβ40 
ratio may provide a more easily interpretable alternative to the combination of Aβ42, 
p-tau and t-tau.
 Unexpectedly, we found a decreased concentration of CSF Aβ40 in VaD and DLB. 
CSF Aβ40 concentrations for the different types of dementia have scarcely been reported 
separately before.1-3 The cause of the decreased CSF Aβ40 concentration remains to be 
elucidated. In DLB, the decrease may be related to an interaction with α-synuclein, the 
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main component of the Lewy bodies that accumulate intraneuronally in DLB: it was 
shown that persons with α-synuclein aggregates had a greater Aβ40 plaque level than 
persons without α-synuclein aggregates.4
 Thus, in Chapter Three, we hypothesized that the concentration of CSF α-synuclein 
would be decreased in DLB as a result of this α-synuclein accumulation, making CSF 
α-synuclein a possible biomarker for DLB. We compared the CSF α-synuclein 
concentration between groups of patients with different types of dementia. 
Unfortunately, no differences were found between DLB, AD, FTD and VaD; moreover, 
concentrations were unchanged compared to controls. We concluded that CSF 
α-synuclein cannot be advocated as a biomarker for DLB. Our findings were confirmed 
by others,5,6 however, contradictory findings followed ours as well7,8 and made us take a 
closer look at the properties of CSF α-synuclein. Interactions between Aβ and 
α-synuclein have been described in vitro.9,10 Sinusoidal fluctuations were found in CSF 
Aβ concentrations11 and our own research group confirmed these findings.12 Perhaps 
fluctuations in CSF α-synuclein are induced by its interaction with Aβ and offer an 
explanation for the contradicting reports on the value of α-synuclein as a biomarker for 
α-synucleinopathies. We studied this in Chapter Four. Six AD patients and six healthy 
volunteers received an indwelling intrathecal cathether from which CSF was drawn 
every hour. Approximately 33 samples per participant were available for analysis. 
However, we observed neither linear trends, nor sinusoidal fluctuations in the CSF 
α-synuclein concentrations. Furthermore, the interaction between α-synuclein and Aβ 
as observed in vitro was not reflected in a correlation in their CSF concentrations in this 
sample, nor in a sample of 164 memory clinic patients. 
 Our search for new biomarkers did not yield a marker that is ready to be implemented 
in clinical practice. Therefore, we decided to explore the application of CSF analysis at 
memory clinics and to investigate whether we were able to facilitate the use of the 
current CSF biomarkers Aβ42, p-tau and t-tau in clinical practice. Chapter Five described 
the frequency of CSF analysis use in Europe and in the Netherlands. We sent 
questionnaires to state-of-the-art memory research centres from the European 
Alzheimer’s Disease Consortium (EADC) and to all memory clinics in the Netherlands. 
CSF analysis was used in almost 60% of these memory clinics and – in the Netherlands 
– in 5% (median) of patients, mostly in patients suspected of mild dementia. 
Complications were rare and mild. The analysis sometimes resulted in a change of 
working diagnosis, according to almost 30% of memory clinics, which suggests that CSF 
analysis is perceived as sufficiently valid to change the diagnostic hypothesis. Reasons 
not to perform CSF analysis included a lack of clear recommendations in the guidelines. 
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Guidelines are also unclear on how to interpret the results of the three CSF biomarkers. 
For example, is an aberrant concentration of Aβ42 enough to support a diagnosis of AD, 
even if the concentrations of p-tau and t-tau are normal? In Chapter Six we introduced 
a prediction model in order to simplify the interpretation of CSF biomarker results in 
clinical practice. We are not the first to develop a model, however, previously described 
models did not provide sufficient discrimination between AD and non-AD dementia, or 
did not offer a formula that could be adopted by others.13,14 Our prediction model 
specifically addressed the question of how to differentiate between dementia due to 
AD and (presumptive) dementia due to another cause. It was developed on a sample of 
over 500 memory clinic patients and validated on an independent dataset containing 
almost 500 patients. We used the clinical diagnosis as reference standard. The final 
prediction model included sex, CSF Aβ42 and CSF p-tau and, based on these variables, 
estimated the probability that dementia in a memory clinic patient was due to AD. 
Adjustments for overfitting and a difference in AD prevalence between de datasets 
were made before validation. Inter-laboratory variation in CSF biomarker results was 
taken into account as well. The agreement between the probabilities of AD predicted 
by our model, and the observed actual diagnoses of AD was very good, as was the 
ability of our model to discriminate between AD and non-AD. A major advantage of this 
model is that it can be adjusted to other populations, allowing others to use it while 
retaining the information of over 1,000 patients.
The second part of this thesis investigated whether hypotheses on the pathophysiolog-
ical cascade of AD are supported by the results of CSF biomarker analysis. The 
hypothetical AD biomarker model proposed by Jack et al15 assumes that CSF and 
imaging biomarkers predate clinical symptoms by an unknown number of years and 
proposes a clear distinction between the moment that Aβ and tau become abnormal. 
Aβ is suggested to reach a plateau before clinical symptoms are apparent, while tau, as 
a marker of neurodegeneration, increases in abnormality during the early stages of the 
disease and into the dementia stage. In Chapter Seven we described a patient who 
presented with a mild memory disorder without interference with activities of daily 
living. The CSF biomarkers that were analysed at that moment were already clearly 
abnormal, Aβ42 as well as p-tau and t-tau. We followed this patient for nine years, during 
which he progressed to advanced AD dementia. A second lumbar puncture at that time 
showed that the CSF biomarkers were still clearly abnormal. These results, albeit from 
one person, suggest that either there is no delay between changes in Aβ and tau, or 
that the change in tau occurs already in the preclinical stage. This suggestion is 
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supported by findings from studies in MCI patients that show that both CSF Aβ42 and 
tau are already abnormal in those patients who progressed to AD at follow up.16
  We decided to further investigate the model by Jack et al. The model proposes a 
gradation of abnormality in the biomarkers that corresponds to the severity of AD 
neuropathology, which in turn corresponds to the severity of cognitive impairment. 
With this concept in mind, we investigated whether a correlation between CSF 
biomarkers and cognitive performance could be found (Chapter Eight). We 
hypothesized that abnormal concentrations of the CSF biomarkers are a sign of neuronal 
damage that should result in cognitive impairment. We examined 65 memory clinic 
patients with MCI, dementia due to AD or non-AD dementia, using the CAMCOG-R to 
assess multiple domains of cognitive functioning. We found that concentrations of CSF 
Aβ42, p-tau and t-tau had no clear relationship with cognitive functioning. Possibly, 
abnormal CSF biomarker concentrations are not a measure of neuronal damage, but 
merely serve as an indicator of AD pathology.
 Another pathophysiological hypothesis is the vascular hypothesis. It proposes that 
cerebrovascular disease leads to APP upregulation with Aβ deposition as a result,17-19 
while Aβ in itself may lead to cerebrovascular disease via its negative effects on cerebro-
vascular function and the architecture of the vascular wall.20-22 If this is the case, one 
would expect AD and cerebrovascular disease to go hand in hand: AD patients are 
expected to display signs of cerebrovascular disease, whereas patients with cerebrovas-
cular disease may not necessarily develop clinical AD but should at least display signs of 
Aβ deposition such as a decreased concentration of Aβ in CSF. We tested this theory in 
Chapter Nine. We classified 81 memory clinic patients as AD or non-AD based on the 
research criteria for AD. These criteria define AD (the disease, not the dementia per se) 
as an episodic memory disorder combined with at least one positive biomarker. We 
assessed cerebrovascular disease on MRI by visually rating white matter lesions and 
lacunar infarcts.23 Aβ42 and Aβ40 were analysed in CSF. We found that AD was not 
associated with cerebrovascular disease. The concentrations of CSF Aβ42 and Aβ40 were 
unrelated to the presence or severity of cerebrovascular disease as well. The relationship 
between vascular risk factors and cerebrovascular disease was not influenced by 
whether or not patients had AD, nor by their concentration of CSF Aβ42 or Aβ40. These 
results do not support the theory that cerebrovascular disease leads to AD pathology or 
vice versa. 
 In addition to its use as an indicator of disease, CSF Aβ42 has also been recommended 
as a biomarker to detect disease modification in drug trials.24,25 However, to be able to 
make predictions about what will happen with the CSF Aβ42 concentration when a 
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treatment is disease-modifying, it is important to first understand why the concentration 
is decreased in AD. The decreased CSF Aβ42 concentration in AD is often regarded as a 
consequence of Aβ42 deposition in the brain. However, Aβ40 is deposited as well, yet 
the CSF Aβ40 concentration is unaltered in AD. In Chapter Ten we systematically 
evaluated possible reasons for the decreased CSF Aβ42 concentration in AD. Aggregation 
of Aβ42 remained as the most likely cause, the aggregated state inhibiting Aβ42 from 
being transported from the interstitial fluid (ISF) to the CSF. The amount of Aβ40 that is 
deposited is far less than the amount of Aβ42, while the absolute concentration of Aβ40 
is much higher.26 Possibly, the amount of Aβ40 deposited relative to the absolute amount 
present is too small to induce a clear decrease in the CSF Aβ40 concentration. 
General discussion
This thesis described translational research with CSF biomarkers. Translational research 
can be defined as the process of applying discoveries generated during research in the 
laboratory and in preclinical studies to clinical studies in humans. Vice versa, findings 
from clinical studies can be used to direct preclinical research.27 In our work, new CSF 
biomarkers that were inspired by preclinical science were investigated in a clinical 
population, and clinical observations were used to test pathophysiological hypotheses. 
Our studies mostly yielded negative results, i.e. the preclinical assumptions could not be 
confirmed in clinical data. Two possible explanations for these negative results will be 
discussed here: the hypotheses were false, or the methodology used to test them was 
flawed, limiting the validity of the results. 
Hypotheses
In general, hypotheses are testable ideas derived from theories that are usually based 
on observations from explorative studies. In formulating these theories, several 
assumptions are – consciously or subconsciously – made (Figure 1). If a hypothesis is 
rejected by observations from research, it may indicate that one of the elements 
underlying the theory was incorrect. 
 As an example, let us consider the hypothesis we investigated in Chapter Three. In 
this chapter, we hypothesized that the CSF concentration of α-synuclein in synucle-
inopathies such as DLB would be decreased in comparison with controls and with 
patients with dementia without α-synuclein inclusions, such as AD, VaD and FTD. Our 
hypothesis was based on the theory that the pathophysiological changes in DLB 
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influence the α-synuclein concentration in the brain. Observations used to found this 
theory were: 1) the finding that Lewy bodies, found upon neuropathological 
examination in DLB patients, consist of α-synuclein28 and 2) research that showed that 
patients with Parkinson disease, in whom Lewy bodies are present as well, had 
significantly lower α-synuclein levels in their CSF than controls.29 Assumptions that 
underlay our theory were the idea that the observations made post-mortem would also 
be present durante vivam, the thought that findings in Parkinson disease could be 
extrapolated to DLB, as well as the suggestion that the CSF α-synuclein concentration 
reflects changes in the α-synuclein concentration in the brain. Had we extended our 
theory by assuming that α-synuclein accumulation in DLB was a result of overproduction 
of α-synuclein, we might have speculated that this overproduction would have masked 
a decrease in the CSF α-synuclein concentration, and thus we might have hypothesized 
that there was no difference in CSF α-synuclein concentrations between DLB and other 
dementias. Alternatively, we might have hypothesized an íncrease in the CSF α-synuclein 
concentration due to its accumulation in the brain in DLB, if we had not assumed 
that the decreased concentration that was found in Parkinson disease would be 
present in DLB as well. Different assumptions thus would have led to different theories 
and to different hypotheses. This underlines the importance of testing hypotheses. 
Furthermore, it indicates that being aware of the assumptions that are made may help 
to interpret negative results as well as provide areas for further research.
 We did not find support for our hypothesis that the CSF α-synuclein concentration 
is decreased in DLB. This may indicate that our theory was incorrect and therefore 
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that either the observations or the assumptions underlying the theory were incorrect. 
One may argue that observations from previous research cannot be incorrect since 
they are facts. Although semantically true, in reality observations need to be interpreted 
before they can be used, and previous research is hardly ever unambiguous. In addition, 
it appears that researchers are subjective in deciding which studies they cite: studies on 
biomarkers that report larger effect estimates for postulated associations are cited more 
often than meta-analyses that evaluate the same associations but that report smaller 
effect estimates.30 The ways previous observations are valued thus importantly affect 
the creation of theories. 
What do CSF biomarkers reflect?
Contrary to our assumption, it appears that the CSF α-synuclein concentration in DLB 
patients does not reflect the changes in α-synuclein in the brain – although alternative 
explanations for the lack of change are not ruled out, for example overproduction of 
α-synuclein masking a decrease in its CSF concentration. One way or the other, it leads 
to an interesting question: what exactly do CSF biomarkers reflect? The answer to this 
question is important since results from biomarker studies are used to make inferences 
about the pathophysiology of AD.15,25,31 
 The CSF biomarkers for AD are usually interpreted to reflect the presence of Aβ 
plaques and neurofibrillary tangles, but studies to confirm this are scarce and their 
results are contradicting. One study that reported a correlation between CSF Aβ42 and 
Aβ plaques and between CSF tau and neurofibrillary tangles32 was supported by 
moderate correlations found between ventricular CSF Aβ42 and Aβ plaques;33 between 
CSF p-tau231 and neurofibrillary tangles;34 and between CSF tau and neurofibrillary 
tangles.35 Other studies, however, found no correlation between CSF Aβ42, p-tau181 and 
t-tau and Aβ plaques or neurofibrillary tangles.36,37
 If we consider the CSF biomarkers for AD and our findings on CSF α-synuclein, we 
see that: 
•	 intraneuronal tau accumulation in AD is associated with an increase in CSF p-tau 
and t-tau;
•	 extraneuronal Aβ deposition in AD is associated with a decrease in CSF Aβ42; 
•	 intraneuronal α-synuclein accumulation in DLB is not associated with a change in 
CSF α-synuclein.
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It seems inconsistent that intraneuronal accumulation of α-synuclein would not lead to 
a change in its CSF concentration, while intraneuronal accumulation of tau would 
increase its CSF concentration. Furthermore, one may wonder why extraneuronal 
accumulation of Aβ would lead to a decrease in its CSF concentration, while 
intraneuronal accumulation of tau would lead to an increase in its CSF concentration. 
The suggestion that the increased tau concentration is the result of degenerating 
neurons spilling their tau content into the CSF is not in line with the suggestion that tau 
biomarkers are abnormal long before changes in brain structure become apparent.15  
 This ambiguity triggered us to review reasons for the decreased CSF Aβ42 
concentration in AD (Chapter Ten). From this study it became apparent that there are 
still several aspects of normal Aβ metabolism that are unclear and that prevent a 
thorough understanding of its mismetabolism in AD. For example, we are not certain 
whether Aβ can pass the pia mater or the arachnoid granulations, which is important 
because such a route of Aβ transportation in and out of the CSF could have a strong 
influence on the CSF Aβ concentration. We also do not know what amount of Aβ is 
degraded or what amount is transported from the ISF to the blood, to the lymphatics or 
the CSF. Without this kind of knowledge, it is difficult to understand what changes take 
place in AD. It is likely that CSF biomarker concentrations do not provide a straightfor-
ward reflection of the situation in the brain, but are the end result of a complicated 
interplay of production, degradation, transport, clearance and, in AD, aggregation and 
accumulation. The resulting discrepancy between the brain concentration of a protein 
and its concentration in the CSF may account for the fact that we were unable to 
observe a correlation between CSF α-synuclein and CSF Aβ, despite their interaction in 
vitro (Chapter Four). Furthermore, if the CSF biomarker concentrations are not a precise 
reflection of neuropathological changes in the brain, this may explain the lack of 
correlation between CSF biomarkers and cognitive functioning (Chapter Eight). 
Methodology
Diagnostic studies such as we performed in Chapter Two and Three may suffer from 
different sources of bias and variation that may affect the estimated accuracy of the test 
under study.38-41 For example, retrospective data collection and non-consecutive 
inclusion of patients were shown to lead to an overestimation of accuracy, whereas 
including only patients that were referred for the test under the study (rather than 
including them based on clinical symptoms) led to lower estimates.40 These sources of 
bias and variation may have affected our studies as well. We will discuss their presence 
and possible effect on our research results below.
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Population
Estimates of diagnostic accuracy may differ between populations.42 In translational 
research, testing a hypothesis in the population of interest – in our case, the memory 
clinic population – is the final step, since important differences often exist between the 
population of interest and the population that led to formulating the hypothesis. No 
one will dispute the differences between a transgenic mouse and an AD patient, 
however, differences also exist between selected research populations and the patient 
population generally seen at a memory clinic. Biomarker performance is easily 
overestimated if such performance is solely based on its ability to differentiate between 
AD patients and healthy controls: the inclusion of healthy controls likely decreases the 
number of false-positives and increases the specificity of the tested biomarker.39,40 
Moreover, the AD patients included in explorative studies usually fulfil strict inclusion 
criteria, e.g. they do not suffer from severe co-morbidities and concomitant medication 
use is restricted. Thus, these AD patients resemble only a small part of the memory clinic 
population, whereas truly healthy controls do not represent a part of this population at 
all since they never present themselves at a memory clinic. In clinical reality, the differ-
entiation is between AD and other causes of cognitive impairment such as other types 
of dementia, psychiatric disorders, psychosocial stress, or subjective memory complaints.
 The patients that we included in our studies were derived from the CSF database of 
the Alzheimer Centre of the Radboud University Nijmegen Medical Centre that contains 
clinical data as well as CSF of consecutive patients. Most patients in this database 
underwent lumbar puncture because there was a clinical indication, that is, if the clinical 
picture was unclear or atypical, and additional examinations were therefore desired. 
This means that we included a group of patients that may have been relatively difficult 
to diagnose clinically. These patients may differ from patients with a clear clinical picture 
that do not need such additional examinations; they may for instance have mixed 
pathologies more often. As a result, differences between the types of dementia may be 
less pronounced, which may have led to an underestimation of the performance of our 
biomarkers. However, such is clinical practice. In many patients, the clinical picture 
alone is not sufficient to make a diagnosis. One could argue that this selection of 
patients is exactly the population that should be included in biomarker studies: these 
are the patients for whom new biomarkers are most valuable, since it is already 
established that additional examinations are needed to arrive at a diagnosis. Our efforts 
to differentiate between these patients thus truly reflect the challenge of clinical practice. 
 The fact that our population includes more atypical patients and possibly 
overrepresents patients with mixed pathologies may have complicated the investigation 
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of pathophysiological hypotheses: associations may be less strong in atypical patients, 
or be obscured because more than one disease was present. We have attempted to 
minimize this effect by using biomarker-based diagnoses in our pathophysiological 
studies, reasoning that biomarkers are a more objective measure than clinical diagnosis. 
To prevent circular reasoning, we took care that we did not define our diagnoses based 
on the biomarker under study. 
Disease progression bias
Disease progression bias may occur if the diagnostic test under study is performed a 
long time before the reference standard, during which period the disease progresses:41 
the test under study may be negative while the reference standard, performed much 
later, is positive. As a result, the accuracy of the test under study is underestimated. In 
our CSF database, the lumbar puncture and the reference standard (see below) were 
part of the same diagnostic process, ruling out disease progression bias. In addition, in 
case of Aβ42, p-tau and t-tau, this bias is less relevant, since it was shown that CSF 
Aβ42, p-tau and t-tau are abnormal and stable in MCI patients who progressed to AD at 
follow up.16
Reference standard and verification bias
Partial verification bias occurs when only a selected sample of patients that underwent 
the test under study is verified by the reference standard.41 In our CSF database, the 
reference standard is the clinical diagnosis. For a small proportion of the patients, the 
clinical diagnosis was unclear, and therefore these patients were not included in our 
studies. If only patients with normal biomarker concentrations (i.e., negative test results) 
had had an unknown diagnosis, an overestimation of the sensitivity of the biomarker 
could have occurred, since patients with false-negative test results would go unnoticed. 
However, whether or not the diagnosis was known in our database was independent of 
the results of CSF analysis. Thus, the effect of this bias is probably minimal. 
 Differential verification bias occurs when part of the patients that underwent the 
test under study were verified by a different reference standard, and the different 
reference standards are treated as interchangeable.38,41 Our reference standard is the 
clinical diagnosis. This is not a single test, but the result of a diagnostic process that 
includes history taking, physical examination, neuropsychological assessment and 
often neuroimaging. This process may differ per patient, which may be regarded as 
differential verification bias: not every patient received exactly the same reference 
standard. This bias is however impossible to avoid in dementia research. Dementia 
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diagnoses are always composed of multiple assessments and never based on a single 
test with a clear cut-off; no perfect reference standard exists for dementia. The neuro-
pathological diagnosis is often considered the ultimate truth; however, this can be 
disputed. It turns out that neuropathological criteria have not been standardized and 
that inter-observer reliability is low when the clinical picture is unclear.43 In addition, 
efforts are currently undertaken to re(de)fine the neuropathological criteria for AD;44,45 
thus the standard that many consider as definite proof of AD is called into question. It 
has been suggested that neuropathology should instead be used as a biomarker, in 
addition to the clinical picture and other biomarkers.43,46 This way, the most reliable 
‘true’ AD diagnosis is derived from the integration of many sources of information, 
ideally complemented with data from follow up. 
 By using the clinical diagnosis as reference standard in our database, some mis-
classifications probably have occurred. Such misclassifications may have contaminated 
the different groups of dementia patients, thereby obscuring their differences. However, 
when we compared the AD, VaD, DLB and FTD patients included in our studies to the 
patients described in other studies, based on their mean concentrations of CSF Aβ42, 
p-tau and t-tau, they were similar. Likewise, the sensitivity and specificity of CSF Aβ42 for 
the discrimination of AD from other types of dementia as reported in Chapter Two was 
comparable to findings from other studies. Thus, it appears that our study population is 
not that different from the populations that have been investigated in other studies. It 
is of course not ruled out that these studies included the same selection of patients or 
suffered from the same misclassifications. A recent report, however, may support the 
validity of a clinical diagnosis. In this large cohort of patients followed over many years, 
the clinical diagnosis from an academic centre accurately predicted the ‘definite’ 
classification based on neuropathology post-mortem.47 The fact that our population 
was comparable to the literature makes us confident that we were able to discover any 
differences between groups and strong relations between disease characteristics that 
might have been present. 
Interpretation of the diagnostic tests
The interpretation of the test under study may be biased if it is influenced by knowledge 
of the results of the reference standard or knowledge of clinical data. In our studies, we 
have prevented this by using pre-defined cut-off values of the CSF biomarkers whenever 
possible. If the test under study is used to establish the reference standard, so-called 
incorporation bias will increase the agreement between the tests. Some incorporation 
bias probably has occurred in our database now CSF Aβ42, p-tau and tau are increasingly 
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used in memory clinics. In our diagnostic studies, however, the biomarkers under study 
were not used to establish the diagnosis. 
Indeterminable test results
Indeterminable test results are often omitted from the research analysis and this may 
lead to a biased assessment of test characteristics. In our database, CSF biomarker or 
α-synuclein concentrations were below the detection limit in a few cases. To prevent 
loss of information, the lowest detectable concentration was used in these cases. 
Having considered all these sources of bias, we may conclude that our studies are 
probably most affected by their retrospective nature, the imperfect reference standard, 
and, to some extent, by incorporation bias. When aiming to perform research in a 
population that is true to clinical practice, it is difficult to avoid these types of bias. 
However, these types of bias usually result in an overestimation of diagnostic 
accuracy.39,40 Considering that our studies were negative, avoiding these types of bias 
would probably not have changed our results. 
Clinical application
Even though we may not yet fully grasp the ins and outs of our CSF biomarkers, their 
role in clinical practice can be clearly defined. They can be used as a diagnostic tool in 
cases of diagnostic uncertainty. There is no need to perform a lumbar puncture in every 
patient attending a memory clinic – not for diagnostic purposes at least. The clinical 
picture, combined with neuropsychological assessment or neuroimaging is often clear 
enough to make a diagnosis. However, when dementia is suspected but the aetiology 
is unclear, analysis of CSF Aβ42 and p-tau may be a way to gain more certainty about 
whether or not AD is present, as shown with our prediction model. We have shown that 
clinicians are willing to use lumbar puncture as a diagnostic tool (Chapter Five) and with 
the development of our prediction model we have provided a way to further implement 
CSF biomarkers in clinical practice. The model has only been validated in the population 
suspected of dementia. It may be able to predict which MCI patients will convert to AD, 
but, true to translational research, this validation step should be awaited before we can 
conclude that it does. 
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Implications for future research
The next step in CSF biomarker research should be to gain a better understanding of 
the metabolism of these biomarkers and the changes therein in AD. This includes details 
about transport from ISF to CSF, flow to lymphatics and transport across the blood-brain 
barrier and blood-CSF barrier. The fact that the term blood-brain barrier is often used to 
indicate the blood-CSF barrier underlines the current lack of understanding of fluid 
circulation in the brain. Although not knowing these details does not prevent us from 
using the CSF biomarkers in clinical practice, better understanding of these biomarkers 
is an essential step to unravel AD pathophysiology and to develop and evaluate 
treatment. Especially CSF Aβ42 has been advocated as a marker to detect and monitor 
the biochemical effects of newly developed drugs for AD.24,25 However, so far most 
articles that report AD drug trials fail to formulate a hypothesis that a priori stipulates 
the expected change (in magnitude, duration and especially direction) in the CSF Aβ 
concentration if treatment is disease-modifying.48-54 Without specifying the expected 
outcome, it is difficult to claim a disease-modifying treatment. The development of 
successful treatment for AD will be greatly advanced through better knowledge of the 
underlying pathophysiology of AD and its biomarkers.
Conclusions
CSF biomarkers can predict the probability of AD in patients suspected of dementia and 
are a valuable diagnostic tool in clinical practice. Applying them to the population of 
interest is essential to translate research finding to clinical practice. By being aware of 
the assumptions that are made in this process, areas for further research were uncovered 
in this thesis. So far, CSF biomarker concentrations do not provide a straightforward 
reflection of the situation in the brain. Better understanding of their (mis)metabolism 
will provide the key to understanding AD. 
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Nederlandse samenvatting
Hoewel de ziekte van Alzheimer (AD) al meer dan een eeuw geleden voor het eerst 
beschreven werd, zijn veel aspecten van het ontstaan van deze ziekte nog onduidelijk. 
Het klinisch beeld is heterogeen; daardoor kan het moeilijk zijn om AD te onderscheiden 
van andere vormen van dementie, met name in de beginstadia van de ziekte. In dit 
proefschrift hebben we onderzocht of het bepalen van biomarkers in de liquor (CSF, 
cerebrospinal fluid) kan helpen bij het differentiëren tussen verschillende vormen van 
dementie. Daarnaast hebben we onderzocht of deze CSF biomarkers de huidige 
hypotheses over de pathofysiologie van AD ondersteunen. In dit hoofdstuk worden de 
bevindingen van dit onderzoek samengevat.
In Hoofdstuk Twee hebben we de CSF amyloid β42/amyloid β40 (Aβ42/Aβ40) ratio 
onderzocht. Aβ40 wordt gezien als een maat voor de totale hoeveelheid Aβ van een 
individu en volgens eerder onderzoek verandert de Aβ40 concentratie niet in patiënten 
met dementie. Wij verwachtten daarom dat we een preciezere weergave van de 
verandering in Aβ42 concentratie zouden krijgen wanneer we de Aβ42 concentratie 
zouden afzetten tegen de Aβ40 concentratie. Met deze preciezere maat zouden we 
beter moeten kunnen differentiëren tussen de verschillende vormen van dementie. De 
Aβ42/Aβ40 ratio was inderdaad beter dan alleen Aβ42 in het onderscheiden van AD en 
dementie met Lewy lichaampjes (DLB) of vasculaire dementie (VaD), en even goed in 
het differentiëren tussen AD en frontotemporale dementie (FTD). Echter, de Aβ42/Aβ40 
ratio voegde niet veel toe aan de veelvuldig gebruikte combinatie van Aβ42, 
gefosforyleerd tau (p-tau) en totaal tau (t-tau): deze laatste combinatie maakte in een 
aantal gevallen zelfs beter onderscheid tussen AD en andere vormen van dementie dan 
de Aβ42/Aβ40 ratio.
 Alfa-synucleine is het eiwit dat intraneuronaal neerslaat bij DLB. In Hoofdstuk Drie 
hebben we onderzocht of dit resulteert in een verlaagde CSF α-synucleine concentratie 
bij patiënten met DLB, vergeleken met patiënten met andere vormen van dementie. 
CSF α-synucleine zou in dat geval als biomarker voor DLB kunnen dienen. Helaas 
vonden we geen verschillen in CSF α-synucleine concentraties tussen patiënten met 
DLB, AD, FTD en VaD. Ook vergeleken met controle personen was de concentratie 
ongewijzigd. CSF α-synucleine kan dus niet worden gebruikt als biomarker voor DLB. 
Deze bevinding werd zowel bevestigd als tegengesproken in ander onderzoek. Om 
deze wisselende bevindingen beter te kunnen begrijpen, hebben we CSF α-synucleine 
nader onder de loep genomen in Hoofdstuk Vier. Er zijn in vitro interacties beschreven 
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tussen Aβ en α-synucleine, evenals sinusoïde schommelingen in CSF Aβ concentraties. 
Door een interactie tussen Aβ en α-synucleine zouden dergelijke schommelingen ook 
uitgelokt kunnen worden in α-synucleine concentraties. Om dit te onderzoeken hebben 
we bij zes AD patiënten en zes gezonde vrijwilligers herhaaldelijk CSF afgenomen, met 
tussenpozen van één uur. Per persoon waren ongeveer 33 samples beschikbaar voor 
analyse. In deze samples hebben we echter geen lineaire trends of sinusoïde 
schommelingen in CSF α-synucleine concentraties geobserveerd. Ook de interactie 
tussen Aβ en α-synucleine zoals beschreven in vitro werd niet teruggevonden: we 
vonden geen correlaties tussen CSF Aβ en α-synucleine in deze samples. 
 Om na te gaan hoe vaak CSF analyse wordt toegepast in de klinische praktijk, 
hebben we clinici op geheugenpoliklinieken in Nederland en in Europa ondervraagd 
door middel van een vragenlijst. De resultaten zijn beschreven in Hoofdstuk Vijf: CSF 
analyse werd in bijna 60% van de geheugenpoliklinieken toegepast, in 5% (mediaan) 
van de patiënten. Dit waren vooral patiënten die verdacht werden van een beginnende 
dementie. CSF analyse leidde er soms toe dat de werkdiagnose werd veranderd. Een 
reden om CSF analyse niet toe te passen was onder andere het ontbreken van duidelijke 
richtlijnen hiervoor. 
 De nationale en internationale richtlijnen over diagnostiek van dementie zijn ook 
onduidelijk over de interpretatie van de CSF biomarkers. Stel dat de concentratie Aβ42 
verlaagd is, maar de concentraties p-tau en t-tau zijn normaal, is er dan sprake van AD? 
Om de interpretatie van de CSF biomarkers te vergemakkelijken hebben we een 
predictiemodel ontwikkeld dat de waarschijnlijkheid berekent dat een geheugenpoli-
patiënt die verdacht wordt van dementie, AD heeft. Dit model wordt in Hoofdstuk Zes 
beschreven. Eerder gepubliceerde predictiemodellen maakten geen goed onderscheid 
tussen AD en andere vormen van dementie, of vermeldden geen formule die door 
anderen gebruikt kon worden. Ons model werd specifiek ontwikkeld voor geheugen-
polipatiënten die verdacht worden van dementie, omdat differentiëren tussen 
verschillende vormen van dementie vaak een uitdaging is in de klinische praktijk. 
Binnen deze populatie kon met behulp van geslacht, CSF Aβ42 en p-tau de waarschijn-
lijkheid berekend worden dat iemand AD heeft. Ons model maakte goed onderscheid 
tussen AD en non-AD en de voorspelling kwam goed overeen met de werkelijkheid. 
Een groot voordeel van ons model is dat het ook door andere geheugenpoliklinieken 
gebruikt kan worden na aanpassing aan de eigen populatie. 
In het tweede deel van dit proefschrift hebben we onderzocht of verschillende 
hypotheses over de pathofysiologie van AD ondersteund worden door de resultaten 
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van CSF biomarker analyses. Een vaak aangehaalde hypothese stelt dat Aβ biomarkers 
al maximaal afwijkend zijn voordat er klinisch symptomen optreden, terwijl tau 
biomarkers toenemend afwijkend worden tijdens de beginstadia van de ziekte. In 
Hoofdstuk Zeven beschrijven we een patiënt die zich presenteerde met een milde 
geheugenstoornis, zonder dat er sprake was van dementie. Zowel de concentraties van 
CSF Aβ42 als van p-tau en t-tau waren op dat moment duidelijk afwijkend. In de jaren 
hierna ging de patiënt achteruit, tot hij uiteindelijk een vergevorderde dementie had 
ontwikkeld. Negen jaar na de eerste LP werd een tweede verricht. De concentraties 
Aβ42, p-tau en t-tau waren vrijwel ongewijzigd. Deze casus suggereert – in tegenstelling 
tot de hypothese – dat er geen duidelijk tijdsverschil zit tussen het afwijkend worden 
van Aβ en tau; of dat tau biomarkers al veel eerder afwijkend worden, vóórdat klinisch 
symptomen optreden. 
 Om dit verder te onderzoeken hebben we in Hoofdstuk Acht de correlatie tussen 
CSF biomarkers en cognitie onderzocht. Volgens de hypothese zou er geen correlatie te 
verwachten zijn tussen CSF Aβ42 en cognitie omdat Aβ biomarkers al maximaal 
afwijkend zijn voordat cognitieve stoornissen optreden. Tau biomarkers echter zouden 
toenemend afwijkend worden tijdens het ziekteproces, en dus zou men kunnen 
verwachten dat een hogere concentratie CSF p-tau en t-tau correleren met een sterker 
gestoorde cognitie. In een groep van 65 geheugenpolipatiënten (AD en non-AD) 
vonden we echter geen correlaties tussen CSF biomarkers en cognitie. Een afwijkende 
concentratie van CSF biomarkers lijkt te signaleren dat het AD ziekteproces gaande is, 
maar geeft niet de ernst ervan weer.
 Een andere hypothese over de pathofysiologie van AD is de vasculaire hypothese. 
Deze hypothese kent twee richtingen: 1) cerebrovasculaire schade leidt via ischemie of 
microbloedingen tot Aβ depositie en 2) Aβ depositie leidt via effecten op de vaatwand 
tot cerebrovasculaire schade. Ongeacht de richting die men aanhangt, zou deze 
samenhang ertoe moeten leiden dat AD en cerebrovasculaire schade hand in hand 
gaan. In Hoofdstuk Negen hebben we 81 geheugenpolipatiënten onderzocht om 
deze hypothese te testen. We vonden dat het hebben van AD niet geassocieerd was 
met tekenen van cerebrovasculaire schade op MRI. Ook de concentratie CSF Aβ42 en 
Aβ40 correleerde niet met de mate van cerebrovasculaire schade. Daarnaast had het 
hebben van AD geen invloed op de bekende relatie tussen vasculaire risicofactoren en 
cerebrovasculaire schade. Onze resultaten ondersteunen de vasculaire hypothese dus 
niet. 
 In het laatste hoofdstuk van dit proefschrift, Hoofdstuk Tien, hebben we CSF Aβ42 
nader onder de loep genomen. De CSF Aβ42 concentratie wordt steeds vaker gebruikt 
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in therapeutische trials om disease modification – een beïnvloeding van het patho-
fysiologische proces van AD – aan te tonen. De oorzaak van de verlaagde CSF Aβ42 
concentratie bij AD is echter niet volledig opgehelderd. Uit een review van de 
beschikbare literatuur bleek dat aggregatie van Aβ42 de meest waarschijnlijke oorzaak 
was. Als gevolg van deze aggregatie kan Aβ42 niet meer vervoerd worden naar de CSF, 
resulterend in een verlaagde CSF Aβ42 concentratie. Ook bleek uit deze review dat er 
nog veel onduidelijkheid bestond over het transport van Aβ42 vanuit de interstitiële 
vloeistof in het brein naar de CSF, naar lymfe en naar het bloed. Het is niet duidelijk 
hoeveel Aβ42 via welke route vervoerd wordt, en of Aβ42 de verschillende barrières 
tussen deze compartimenten kan passeren. CSF Aβ42 kan niet worden ingezet als 
biomarker van disease modification bij AD totdat we hier meer van begrijpen.
Chapter twelve
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De wens om een origineel dankwoord te schrijven is net zomin origineel als het hebben 
van een onconventioneel promotietraject ongewoon is. Vanaf de eerste dag van mijn 
(uiteraard onconventionele) promotietraject heb ik nagedacht over mijn dankwoord, 
met als enige resultaat dat het waarschijnlijk verdacht veel lijkt op de dankwoorden van 
degenen die mij voor gingen. Het maakt ook eigenlijk niet uit. Het is mijn dankwoord en 
dat maakt het voor mij sowieso speciaal. Toch zou ik mezelf niet zijn als ik het er helemaal 
bij liet zitten, en daarom begin ik niet zoals gebruikelijk met het bedanken van het 
promotieteam, maar met de mensen zonder wie ik misschien wel helemaal niet aan dit 
traject begonnen was: Judith Wilmer, Carolien van der Linden en Geert van der Aa. 
Beste Judith, Carolien en Geert, bedankt voor de allerleukste eerste baan ooit, en 
bedankt dat jullie me hebben doen inzien dat mijn hart in de geriatrie ligt! Op momenten 
dat het even tegenzit, geven de herinneringen aan 4Oost me altijd weer nieuwe 
motivatie. 
En dan mijn promotieteam. Beste Marcel OR (‘Dat zijn de ballen die op tafel liggen’), je wist 
me altijd weer te verrassen met andere invalshoeken. Dat maakte het wel eens lastig om 
op één lijn te komen, maar het gaf tegelijkertijd ook aanleiding tot nieuwe 
gezichtspunten. Bedankt dat je me de mogelijkheid gaf om zelf invulling te geven aan 
mijn promotietraject: je was er als dat nodig was, en je was er niet als dat niet nodig was. 
Ik heb veel geleerd, niet alleen van onderzoek doen, maar ook van de wereld van het 
onderzoek doen. 
Beste Marcel V (‘We worden zeldzaam aan het lijntje gehouden’), een groot deel van onze 
communicatie verliep per e-mail, gewoon omdat dat zo lekker makkelijk was. Je 
reageerde snel en draaide er niet omheen: ‘Volgens mij wordt er in dit hele gesticht 
langs elkaar heen gepraat!!!!!!’. Je soms schaarse lettergreepgebruik werd gelukkig altijd 
gecompenseerd door een overmaat aan leestekens. En als ik het even niet begreep was 
je altijd bereid tot uitleg: ‘Nu gaat de wondere wereld van de biochemie open voor de 
clinicus! Ik bel je wel even.’ Bedankt voor die directheid; het maakt het leven een stuk 
makkelijker. Bedankt ook dat je me de gelegenheid gaf om een labstage te doen, zodat 
ik wat zou meekrijgen van de CSF analyses zelf, en dat je me, hoewel met een hoop 
gezucht en geprotesteer, toch altijd dat blad met die net iets hogere impactfactor nog 
liet proberen. 
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Beste Jurgen (‘Kippen hebben ook Alzheimer. Maar eieren niet.’), je raakte pas later betrokken 
bij mijn promotie en zorgde meteen voor structuur in de organisatie ervan – misschien 
wel het laatste wat je van jezelf verwacht had. Duidelijke afspraken over laatste auteurschap 
voorkwamen dat elk artikel en elke revisie eindeloos gepingpongd moesten worden, en 
dat voorkwam weer veel frustratie. Bedankt! Je deed me daarnaast inzien dat ik op 
sommige zaken en meningen geen enkele invloed had en dat ik m’n energie dus  beter 
voor andere dingen kon gebruiken. Bedankt dat ik in jouw plaats het geheugenpoli-MDO 
mocht voorzitten en dat je ook voor die tijd al toeliet dat ik de muis afpakte. 
Mijn manuscriptcommisie, prof. dr. Pieter Wesseling, prof. dr. Gerard Martens en prof. 
dr. Patrick Bossuyt wil ik hartelijk danken voor hun bereidheid om mijn manuscript te 
beoordelen.
Natuurlijk zijn er nog veel meer mensen betrokken geweest bij mijn promotietraject en 
de totstandkoming van mijn manuscript. Berry Kremer (‘Ik haal zelf wel koffie, ik ben een 
grote jongen’), bedankt voor de waardevolle bijdragen en het klinische perspectief in 
het begin van het traject. Magnus Sjögren (‘Boys need their tools and girls need tools as 
well’), thanks for lively discussions (and great aftershave!). Roy Kessels (‘Hij is een soort 
Willy Vandersteen’), ik doe mijn best om de term kortetermijngeheugen te vermijden; 
dankzij jou is cognitie een woord met betekenis geworden. De discussie over het nut 
van ‘prikken’ en ‘vragenlijstjes’ blijft leuk!
 
Wat is een promotietraject zonder collega-promovendi? Wat was het bijzonder om te 
werken op een afdeling waar begrippen als nieuwjaarsconceptie, fantoomorgasme en 
de ontploffende chihuahua drugshond tot gedeelde kennis behoorden (Appendix A).
Allereerst dank aan mijn kamergenoten op de 4e: Sarah (‘Ik ben eigenlijk niet geschikt om 
samen te werken maar het moet nou eenmaal’), Janneke (‘Het was er ook uit, voordat ik het 
zei’) en Cynthia (‘Je bent zo geel als je wilt zijn’). Dankzij jullie kreeg ik geen enkele kans om 
mijn koffiemisbruik te minderen! Concentratiedinsdag, vergaderdonderdag en vooral 
Eftelingvrijdag werden trouw in ere gehouden, en de kamerpauzes maakten de incidentele 
dramawoensdagen weer draaglijk. 
Maar natuurlijk ook dank aan the old gang, Mirrie (‘Pas op anders gooi ik je biertje over me 
heen!’), Arrie (‘Ik was de een-na eerste die wegging’), Els (‘Liever een badkamer dan een 
breezer’), Diane (‘Het is vermakelijk in zijn sneuheid’), Marieke (‘Brownie? Is dat een lekkere 
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neger?’), Olga (‘Ik zou geen even korte term kunnen bedenken die net zo lang is’) en Jaap 
(‘Mag ik binnenkomen in je nederige schulp?’): dank voor geweldige congressen, voor 
La Chouffe, de borrels, BBQs, en Martini die speciaal voor mij werd ingekocht – Bryan 
Adams’ summer of ’69 stelde weinig voor vergeleken met onze summer of ‘09! 
Daarnaast ook alle andere koffiepauzebezoekers bedankt, waaronder Mirjam (‘Wat je 
ook doet, doe het niet’), Franka (‘Mark Ruffalo, die komt echt m’n bed niet in’), Teun (‘Valt een 
boom niet als niemand het hoort’), Aisha (‘Voor een tikkie op de kop geprikt’), Anouk (‘De 
kerkdienst was wel veel met God’), Kim (‘Ik heb een heel delicaat kopje’), Lia (‘Voor veel doe ik 
alles’), René (‘Ik ben er ongetwijfeld van overtuigd’), Joep L. (‘Hoe oud ben je eigenlijk? Je 
hoort wat... En dan denk je ze zal wel jonger zijn’), Hans, Geke en Joep S.
Mijn collega’s van de wilde mok, Saskia (‘Wat je niet ziet bestaat niet’), Sondra, Margery en 
Bianca: we hebben het maar mooi gepresteerd om vier studies tegelijk draaiende te 
houden! Onze schema’s en overzichten stonden in schril contrast tot onze chaotische 
overlegmomenten (en etentjes!). Marianne en Jeanette, bedankt voor het meedenken 
over de ingewikkelde planning: gaat het om een NPO-K, een NPO-L of een NPO-R? 
Wordt het een 3T MRI, een ‘gewone’ of een Parelsnoer-MRI? Kunnen we de MRI al 
plannen vóór het NPO? Hoe ingewikkeld het ook was, hoeveel mailtjes er ook over heen 
gingen, ik voelde me altijd welkom op de poli. William (‘Ik zag een dame met een vriendelijk 
gebruinde huid’) en Anja, geweldig hoe jullie patiënten wisten te motiveren, maar ook 
altijd de tijd namen om even te informeren hoe het met mij ging. 
Een afdeling functioneert natuurlijk niet zonder secretariële ondersteuning. Gemma 
(‘Alle bouwvakkers zijn hetzelfde!’), Hanna en Nora, bedankt voor het geduld waarmee 
jullie me steeds opnieuw uitlegden hoe de fax werkte, waar ik A5-enveloppen met 
venster kon vinden en hoe ik declaratieformulieren moest invullen, en voor jullie hartelijke 
begroeting als ik weer even aan kom waaien!
Marijke Beenes, Inge van der Stelt, Nienke Timmers en Henk van het CDL, jullie hebben 
mij laten kennismaken met de niet-klinische kant van het onderzoek: de CSF analyse 
zelf, de transgene muizen en hun hersenen. Bedankt!
Ook mijn vrienden en familie wil ik bedanken: met jullie kon ik niet alleen mijn enthousiasme 
delen, maar ook de frustraties. Daarnaast boden jullie het onmisbare ingrediënt van elk 
promotietraject: afleiding. 
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Lieve Paula, dat jij mijn paranimf zou zijn stond eigenlijk in groep 8 al vast, lang voordat 
we wisten wat promoveren überhaupt betekende. Je kent me door en door en bij jou 
kan ik alles kwijt, inclusief de rare details! Bedankt dat je me altijd steunt, zo nodig met 
irrationele argumenten als de rationele op zijn (‘Wat heeft ze eigenlijk een gek hoofd’).
Lieve Emy, we zien elkaar chronisch te weinig, maar als het dan lukt, voelt het altijd net 
zo vertrouwd als ‘vroeger’, toen we nog vier minuten in plaats van 13 uur wandelen uit 
elkaar woonden. Jij was de enige die het waagde om keihard te lachen toen ik als eerste 
met kinderen te maken kreeg. Geweldig! Fijn dat je mijn paranimf wilt zijn. Lieve Naomi 
en Debbie, voor jullie geldt hetzelfde: afspreken is lastig, maar onze vriendschap is het 
zeker waard om sneeuwstormen, sein- en wisselstoringen, files en zelfgeïnduceerde 
opsluitingen te trotseren! 
Martine, jij introduceerde de afgedwongen ontspanning: onderzoek lijkt opeens heel 
ver weg als je in een bubbelbad van 36°C ligt! Hanneke, jouw enthousiasme voor koken 
zal ik wel nooit begrijpen, maar ik geniet van de maaltijden die je me voorzet! De 
meiden van het KWC, Simone, Sabine, Marieke, Marie-José, Cyrina, Cora, Arnélie, Anja: 
wat bijzonder dat we na al die jaren nog steeds zulke gezellige avonden hebben! 
Dr. Toonen, amice! en mede-grondlegger van de quoteslijst, waar zouden we zijn zonder 
Outlook? Bedankt voor de relativerende egotrips en regelmatige frietjes super!
My online friends, in anti-alphabetical order: Simon, Shreyas, Renato, Peter, Karin, Chris, 
Aurélie, thanks for the healthy injections of sarcasm! Peter, thanks for the many instant 
translations and corrections of contorted English sentences. It’s great to have online support 
when you spend a lot of time behind the computer in an effort to finish your thesis. 
Mijn familie, ooms en tantes, nichtjes en neven, ook al zien we elkaar soms tijden niet, er 
is altijd die band. Bedankt voor jullie warme belangstelling. Dat geldt natuurlijk ook voor 
mijn stoere oma (‘Zullen we gaan eten, dan hebben we dat maar weer gehad’). Ik zie heel 
wat overeenkomsten tussen ons! Lieve Frans en Adie, ik voel me altijd welkom bij jullie, 
bedankt!  Sander, zonder jou zou ik nog nooit van Plex of Dylan Moran gehoord hebben, 
Inception en The Big Lebowski nog nooit gezien hebben... jij laat me kennis maken met 
dingen buiten mijn eigen wereldje. Bedankt! 
Lieve mam, jij steunt me altijd, wat er ook gebeurt, of we het nou eens zijn of niet. 
Ik weet dat je trots op me bent; ik ben ook trots op jou!
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Tot slot, het meest onverwachte resultaat van mijn promotie: lieve Jurgen, my place in 
the sun, het was (en is) soms gecompliceerd, maar dat is het zo waard! Bedankt dat je me 
er steeds weer aan herinnert dat er meer in het leven is dan werk. Je relativeringsvermo-
gen – ‘anders ga je toch worsten verkopen bij de HEMA’ – heeft heel wat ingebeelde 
drempels verlaagd. Wat een heerlijk vooruitzicht om de rest van ons leven samen door 
te brengen!
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Het promotieteam
We nemen de knoop mee om door te hakken (MOR)
Hoe meer mensen je ontmoet, hoe meer contact  
je maakt (JC)
Dan moeten we nadrukkelijk om de tafel gaan  
zitten (MOR)
Alles is krom in het leven (JC)
Het zal vruchten opleveren (MOR)
We worden zeldzaam aan het lijntje gehouden (MV)
Het is een precaire dag aan het worden (MOR)
Als je het uitstelt, duurt het langer (JC)
Ze heeft wel wat zelfbesef (JC)
Dat zijn de ballen die op tafel liggen (MOR)
Nauseating behavior is the road to success (JC)
De promovenda
Iedere berg een Heidi
Je bent uniek in je saaiheid
Ik wil naar buiten, maar buiten wil mij niet
Hij zegt weinig dat onthouden moet worden
Je gaat helemaal op in de achtergrondmuziek
Daar word ik nog steeds niet juichend van wakker
We zien wel waar het ei landt
Je waardeert hem als zijnde iemand
Als jij piept dan trek ik 
Gaat het zo mee of wil je er een kusje op? 
Teleurstellend als ik ben, heb ik je gemaild 
Het houdt niet over aan zeeën van ruimte 
Niet alles wat lelijk is wordt een zwaan 
De kamergenoten
Er was minimale genegenheid (Sarah)
Ik krijg galbulten van je (Janneke)
Het is dat ik geen hersens heb om mee te  
gooien (Sarah)
M’n lach zit los (Marieke)
De frailty ligt hier voor het oprapen (Marieke)
En dan gaat-ie zitten denken in zijn eigen  
hoofd (Janneke)
Hij heeft echt een plaat voor z’n bord (Sarah)
Het was er ook uit, voordat ik het zei (Janneke)
Ik geloof in alles dat eetbaar is (Janneke)
Alle bij kwetsbare hulpverleners betrokken  
ouderen (Sarah)
Ik ben eigenlijk niet geschikt om samen te werken 
maar het moet nou eenmaal (Sarah)
Ik ben niet zo helder vandaag. Ik had gisteren m’n 
heldere dag (Janneke)
Dan zijn de apen echt gaar (Janneke)
Je kunt zeggen dat mensen gematigd neutraal 
reageerden. (Sarah) Dat is zeker CDA-taal (Janneke)
Ik was helemaal geïntegreerd in de  
medemens (Janneke)
Ze schrijft best goed Engels voor een gewoon  
iemand (Janneke)
Waarom luisteren als je ook zelf aan het woord  
kunt zijn? (Sarah)
Brownie? Is dat een lekkere neger? (Marieke)
Ik was tot tranen toe geamuseerd (Marieke)
Je bent zo geel als je wilt zijn (Cynthia)
Ik denk dat zij dat wel zo denkt (Cynthia)
Ik vind Hans wel een naam voor een schildpad.  
Ja, maar niet andersom (Sarah)
Waarom pas je het aan? Omdat je data het  
willen (Sarah)
Edwin is zo’n man die je niet moet laten  
bevallen (Sarah)
Omdat ik denk dat ik minder adequaat ben dan  
ik soms denk (Sarah)
De oud-kamergenoten
Ken ik u ergens van? Ja ik ben familie van  
iemand (Gerstella)
Ik word er gruwelijk simpel van (Gerstella)
Groen en geel is blauw (Els)
Ik jat liever dan dat ik brand sticht (Diane)
Ik was de een-na eerste die wegging (Arrie)
Het is vermakelijk in zijn sneuheid (Diane)
We gaan gewoon elkaars eigen gang (Arrie)
Het leven is één grote huwelijksreis (Bonnie)
Dat vind ik een gezamenlijke verzinning (Arrie)
Niet iedereen met een kind is lesbisch (Diane)
Niets bereiken is ook een eindpunt (Diane)
Wie twijfelt wordt overgeslagen (Mirrie)
Pas op anders gooi ik je biertje over me heen! (Mirrie) 
Jij hoeft alleen maar de trap op te rollen (Mirrie)
Het gras is groener bij de buren. Nou dan jatten  
we het toch? (Diane)
Er ligt een watermeloen en brood maar geen  
eten (Diane)
Schatje, je moet de beer niet verkopen... (Mirrie)
Ik heb zoveel Y daar kun je een taart van  
bakken (Diane)
Ik ben als een brok voor je gevallen
Ik snap nooit dat mensen mij bellen en dan nemen  
ze niet op (Arrie)
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Geen liefde vóór het huwelijk (Diane)
Een dag niet gezeken is een urineretentie 
Liever een badkamer dan een breezer (Els)
Jij zit onder jezelf (Els)
De collega’s van de 4e verdieping
Koppel me back baby! (Jaap)
Mag ik binnenkomen in je nederige schulp? (Jaap)
Van een koude curry thuiskomen (Jaap)
Hij heeft iets vaag alternatiefs (Olga)
Ik heb het warm aan m’n eigen achterkant (Olga)
Het is leuk dat-ie zo lang is. Als jongen (Olga)
Ik zou geen even korte term kunnen bedenken die  
net zo lang is (Olga)
Je ziet er goed uit, voor je eetgedrag (Olga)
Wat je niet ziet bestaat niet (Saskia)
Oh dus je hebt morgen last van gister (Teun)
Chronologisch ben ik ouder (Teun)
Nouhouhou, ik wil ook een standaardafwijking (Saskia)
Wat staan jullie spannend in de gang (Olga)
Valt een boom niet als niemand het hoort (Teun)
Was het maar week 8, dan was ik er volgende  
week niet meer (Saskia)
Die man is natuurlijk zwaar gepensioneerd (Olga)
De overige collega’s
Boys need their tools and girls need tools  
as well (Magnus)
Mensen die zonder autopsie overlijden (Drieske)
Humans or patients (Magnus)
Ik ben er ongetwijfeld van overtuigd (René)
Hoe oud ben je eigenlijk? Je hoort wat... En dan  
denk je ze zal wel jonger zijn (Joep L.)
Ik heb weinig uitspraken, ik drink alleen (Mike)
Van die halve semi-getrouwde vrouwen (Masha)
Mijn zus is soort van familie (Joep L.)
Elke wijn is mysterieus (Mirjam)
Ik zag een dame met een vriendelijk gebruinde  
huid (William)
Hij denkt dat-ie denkt zoals hulpverleners  
denken (Mirjam)
Voor een tikkie op de kop geprikt (Aisha)
Mark Ruffalo, die komt echt m’n bed niet in (Franka)
Wat je ook doet, doe het niet (Mirjam)
Achteraf was het helemaal niet zo erg maar ik dacht 
wel ik hoef hier geen kerel (Franka)
Voor veel doe ik alles (Lia)
Je moet er niet voor de diepgang heengaan 
(Anne over Afrika)
Ik kan alles horizontaal (Lia)
Hij is een soort Willy Vandersteen (Roy)
De kerkdienst was wel veel met God (Anouk)
Ik heb een heel delicaat kopje (Kim)
Het dossieronderzoek
Patiënte is vier maanden geleden twee keer op één 
volgende na elkaar gevallen. Op dit gebied is zij  
nu ruim vier maanden klachtenvrij.
Ik adviseerde patiënt in het bijzijn van zijn vrouw  
niet auto te rijden
Behoudens bradifrenie geen vocale afwijkingen
Na expiratie van het insulinoom
Patiënte is goed afleidbaar
Morbus Pieck met dementerend beeld
De opbrengst
Neusinsufficiëntie
Hypoanemie
De geriateur
Pradie cardie
Colonfractuur
Harde geriatrie 
Patiëntgerelateerde patiëntenzorg 
Dubbelzinnig printen 
Zinloos geschoven 
Pub mét (en Pub zonder) 
Fantoomorgasme
Placebothermostaat
Nieuwjaarsconceptie
Sportief grijs haar
Schurftkalender
Bad hair life
Extra-terosteriaal 
Aangeboren giraffe
Stickhorse 
Het gebleekte significantiesterretje
Teratoom met epilepsie
Breedsprakig looppatroon 
AIO: Ariër in opleiding 
Het ei opnieuw uitvinden 
Polyfiel en oligofoob
Voldoende positieve gedagzeggingen
Linksharig tuig
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